the hla dictionary 2008: a summary of hla-a, -b, -c, -drb1/3/4/5, and -dqb1 alleles
DESCRIPTION
The HLA dictionary 2008: a summary of HLA-A, -B, -C, -DRB1/3/4/5, and -DQB1 alleles and their association with serologically defined HLA-A, -B, -C, -DR, and -DQ antigensTRANSCRIPT
Tissue Antigens ISSN 0001-2815
The HLA dictionary 2008: a summary of HLA-A, -B, -C, -DRB1/3/4/5, and -DQB1 alleles and their association with serologicallydefined HLA-A, -B, -C, -DR, and -DQ antigensR. Holdsworth1,8,9, C. K. Hurley2,8,10, S. G. E. Marsh3,4,8,10, M. Lau5,8, H. J. Noreen6, J. H. Kempenich7,
M. Setterholm7,10 & M. Maiers7,10
1 Victorian Transplantation and Immunogenetics Service, Australian Red Cross Blood Service, Melbourne, Australia
2 Department of Oncology, Georgetown University Medical Center, Washington, DC, USA
3 Anthony Nolan Research Institute, Hampstead, London, UK
4 UCL Cancer Institute, Royal Free Campus, Hampstead, London, UK
5 UCLA Immunogenetics Center, Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, Los Angeles, CA, USA
6 Histocompatibility Laboratory, University of Minnesota Medical Center, Fairview, Minneapolis, MN, USA
7 National Marrow Donor Program, Minneapolis, MN, USA
8 WHO Nomenclature Committee for Factors of the HLA system
9 Australian Bone Marrow Donor Registry, NSW, Australia
10 Quality Assurance and IT Working Groups, World Marrow Donor Association, Leiden, The Netherlands
Key words
alleles; antigens; histocompatibility; HLA;
serological equivalents; serology
Correspondence
Rhonda Holdsworth, BSc
Victorian Transplantation and
Immunogenetics Service
Australian Red Cross Blood Service
PO Box 354
South Melbourne
Victoria 3205
Australia
Tel: 161 3 9694 0379
Fax: 161 3 9682 1630
e-mail: [email protected]
Received 27 October 2008; accepted 7
November 2008
doi: 10.1111/j.1399-0039.2008.01183.x
Abstract
The 2008 report of the human leukocyte antigen (HLA) data dictionary presents
serologic equivalents of HLA-A, -B, -C, -DRB1, -DRB3, -DRB4, -DRB5, and
-DQB1 alleles. The dictionary is an update of the one published in 2004. The data
summarize equivalents obtained by the World Health Organization Nomenclature
Committee for Factors of the HLA System, the International Cell Exchange,
UCLA, the National Marrow Donor Program, recent publications, and individual
laboratories. The 2008 edition includes information on 832 new alleles (685 class I
and 147 class II) and updated information on 766 previously listed alleles (577 class I
and 189 class II). The tables list the alleleswith remarks on the serologic patterns and
the equivalents. The serological equivalents are listed as expert assigned types, and
the data are useful for identifying potential stem cell donors who were typed by
either serology or DNA-based methods. The tables with HLA equivalents are
available as a searchable form on the IMGT/HLA database Web site (http://
www.ebi.ac.uk/imgt/hla/dictionary.html).
The 2008 edition of the human leukocyte antigen (HLA)
data dictionary is the fifth update; previous versions have
been published in 1997, 1999, 2001, and 2004 (1–4). The
HLA data dictionary is aimed at identifying the serological
types associated with each HLA-A, -B, -C, -DRB1, and
-DQB1 allelic product. The dictionary is a reference to help
with the identification of potential hematopoietic stem cell
(HSC) donors. The serologic equivalents of the DNA-
defined alleles can be used to identify potential donors listed
in unrelated donor registry databases and umbilical cord
banks who have been typed by serology. Although the
majority of laboratories useDNA-basedmethods for typing
today, there is a significant number of HLA assignments in
registries and banks that have been determined by serology-
based methods. For example, in the database of almost 7
million volunteers of the NationalMarrowDonor Program
ª 2009 John Wiley & Sons A/S � Tissue Antigens 73, 95–170 95
(NMDP) in the United States, the percent of serologic
assignments for volunteer donors is still significant, with
45% of the HLA-A and -B loci, 31% of the -C locus, 4% of
the -DRB1 locus, and 37% of the -DQB1 locus assignments
defined serologically. The availability of serologic equiv-
alents allows potentially matched volunteers typed by
serology to be matched to DNA-typed patients.
The number of newly identified HLA alleles grows each
year and since the 2004 publication, 832 new HLA alleles
have been added, including 235HLA-A, 310 -B, 140 -C, 116
-DRB1, 9 -DRB3/4/5, and 22 -DQB1 alleles. Information
has also been updated for 766 previously listed alleles
numbering 158 HLA-A, 303 -B, 116 -C, 133 -DRB1, 13 -
DRB3/4/5, and 43 -DQB1 alleles. This edition of the
dictionary includes all newly defined four-digit alleles
displayed in the IMGT/HLA database (5) to the end of
July 2007 in Tables 1–6.
Information for the 2008 edition of the dictionary has
been contributed from several sources. The World Health
Organization (WHO) serological assignment is taken from
the Nomenclature report 2004 (6) and from data submitted
to the WHO Nomenclature Committee for Factors of the
HLA System when a new allele is submitted for consider-
ation. The International Cell Exchange, UCLA program
provides a unique opportunity to obtain the serologic type
of rare and unusual alleles. Updated information for 335
alleles was provided by theCell Exchange for this dictionary
edition. Results are routinely submitted from laboratories
around the world. Half of the nearly 200 laboratories
actively participating in the Cell Exchange are outside the
United States, with laboratories in Canada, Europe, the
Middle East, Africa, Asia, Australia and New Zealand,
and South America. The serology typing data from this
program continue to enhance the dictionary information.
The NMDP data for 454 alleles have been updated with
serologic typing information. The 13 IHWS data have been
taken from the 2004 edition of the data dictionary. There
have been no further updates on these data. The artificial
neural network (NN) analysis (7) has been rerun to provide
valuable data on the most likely serological result for
a particular allele. The NN analysis now includes data for
alleles of the HLA-C and -DQB1 loci. In addition,
serological typing information has been submitted from
expert laboratories. The serology data from all sources have
been summarized by the authors in the second column of
Tables 1–6 as the expert assigned type.
WHO nomenclature: allele and serologicassignments
The 2008 edition of the dictionary contains all alleles from
the IMGT/HLA database in release 2.18.0 July 2007. Only
the four-digit numbering of alleles is listed in the tables
because the fifth and sixth digits (silent substitutions) are
not expected to alter the antigenic expression. Nonex-
pressed alleles with unique four-digit designations are in-
cluded for completeness. Nonexpressed alleles, which share
a four-digit designation with an expressed allele (e.g.
B*15010102N and B*15010101), have been excluded from
the tables.
The serologic assignment (third column of Tables 1–6) is
taken from the HLA Nomenclature report 2004 (6).
Serologic specificities of newly identified alleles are only
included when reported by the allele contributors as being
identical or very similar to the standard specificity
associated with the allele group (e.g. A1 associated with
A*01 alleles). Likewise, the contributor may report an allele
to be expressed as a serologically variant antigen. Such
information is included in the nomenclature report under
the heading ‘previous equivalents’ and is included here in
the ‘Comments’ column of Tables 1–6. In some cases, the
serological definition given in the WHO Nomenclature
Report and displayed in the third column has been derived
from the previous versions of the dictionary, as these data
were considered sufficiently compelling to be adopted as the
WHO value. Such instances of dictionary-derived WHO
values are indicated by a footnote in Tables 1–6.
International Cell Exchange, UCLA
The International Cell Exchange, UCLA provided data
showing serologic equivalents for 49 HLA-A, 128 -B, 35 -C,
88 -DRB1, 8 -DRB3, 3 -DRB4, 5 -DRB5, and 19 -DQB1
alleles. The latest HLA class I analysis has been updated
with the inclusion of data from 136 new samples, cells 1185–
1320, from healthy individuals, characterized between
February 2004 and November 2007. Each cell was typed
by an average number of 100 laboratories, ranging from
a low of 83 to a high of 118. The parallel typing for HLA-A,
-B, and -C alleles usingDNA-basedmethodswas performed
by an average of 46 laboratories, ranging from 43 to 51
reporting results for the monthly studies.
The HLA class II analysis was updated with the typing
information from 68 B lymphoblastoid cell lines (TER335-
402) from the same time period, February 2004 through
November 2007. Each cell was typed serologically by an
average number of 13 laboratories, ranging from a low of 8
to a high of 18. The parallel typing forHLA-DRB1, -DRB3,
-DRB4, -DRB5, and -DQB1alleles using DNA-based
methods was performed by an average of 80 laboratories,
ranging from a low of 66 to a high of 87.
HLA serologic equivalents have been analyzed in
heterozygous samples only if the other HLA allelic product
would not interfere with the serologic recognition. The
associated serologic specificities as reported by the partici-
pating laboratories are given with the lowest and highest
percentage recognition, shown in brackets in column 4 of
Tables 1–6.
HLA alleles and serologic types R. Holdsworth et al.
96 ª 2009 John Wiley & Sons A/S � Tissue Antigens 73, 95–170
Table
1HLA-A
allelesandtheirserologicdesignationsg
HLAallele
Expertassigned
WHO
assigned
InternationalC
ell
Exchange,UCLA
NMDP
IHW
S13data
NN
Assignedtype[%
]
Cells
tested
Assigned
type[%
]
Cells
tested
Assignment
Cells
tested
Assigned
type>0.55
Comments
A*0101
A1
A1
A1[98–100]
34a
A1[99]
5612
A1
113
Theallele
wasused
fortrainingofthe
NN–A1
A*01010102N
Notexpressed
Null
––
––
––
NT
A*0102
A1
A1
––
A1[95]
129
––
Training–A1
A*0103
A1
A1b
A1[99]
2A1[94]c
33
A1
5Training–A1
A*0104N
Notexpressed
Null
––
cd
1–
–NT
A*0106
A1
––
–A1[100]c
3–
–A1
A*0107
A1
A1
––
––
––
A1
A*0108
A1
A1
––
––
––
A1
Norm
alA
1
A*0109
A1
––
––
––
–A1
A*0110
A1
––
––
––
–A1
A*0111N
Notexpressed
Null
––
––
––
NT
A*0112
Undefined
––
––
––
–Notassignede
NN:A1
A*0113
A1
––
––
––
–A1
A*0114
A1
––
––
––
–A1
A*0115N
Notexpressed
Null
––
––
––
NT
A*0116N
Notexpressed
Null
––
––
––
NT
A*0117
A1
––
––
––
–A1
A*0118N
Notexpressed
Null
––
––
––
NT
A*0119
A1
A1
––
––
––
Notassignede
NN:A1
A*0120
A1
––
––
––
–A1
A*0121
A1
––
––
––
–A1
A*0122N
Notexpressed
Null
––
––
––
NT
A*0123
A1
––
––
––
–A1
A*0124
A1
––
––
––
–A1
A*0125
A1
––
––
––
–A1
A*0126
A1
––
––
––
–A1
A*0127N
Notexpressed
Null
––
––
––
NT
A*0201
A2
A2
A2[99–100]
117a
A2[98]
6315
A2
230
Training–A2
A*02010102L
Low
A2
Low
A2
––
––
––
IdenticaltoA*0201
Significantlyreduced
orlow
cellsurface
expression
A*0202
A2
A2
A2[100]a
7A2[81]
859
A2
8Training–A2
ihw13:variant
serum
pattern
A*0203
A203/A2
A203
A2[99–100]a
10
A2[64]
472
A203
12
A2
ihw13:very
short
A2
A*0204
A2
A2
––
A2[77]
28
––
A2
ª 2009 John Wiley & Sons A/S � Tissue Antigens 73, 95–170 97
R. Holdsworth et al. HLA alleles and serologic types
Table
1Continued
HLAallele
Expertassigned
WHO
assigned
InternationalC
ell
Exchange,UCLA
NMDP
IHW
S13data
NN
Assignedtype[%
]
Cells
tested
Assigned
type[%
]
Cells
tested
Assignment
Cells
tested
Assigned
type>0.55
Comments
A*0205
A2
A2
A2[100]
5A2[81]
462
A2
10
Training–A2
A*0206
A2
A2
A2[99–100]a
47
A2[68]
636
A2
24
Training–A2
A*0207
A2
A2
A2[100]a
15
A2[80]
135
A2
17
Training–A2
A*0208
A2
A2
––
A2[100]c
7–
–A2
A*0209
A2
A2
––
A2[100]c
10
––
A2
A*0210
A210/A2
A210
––
A2[100]c
10
––
A2
A*0211
A2
A2
A2[99]
1A2[74]
228
A2
17
A2
ihw13:shortA2
A*0212
A2
A2
––
A2[100]c
10
A2
1A2
A*0213
A2
A2
––
A2[100]c
17
––
A2
A*0214
A2
A2
––
A2[100]c
7–
–A2
A*0215N
Notexpressed
Null
––
c–
––
NT
A*0216
A2
A2
––
A2[81]c
16
––
A2
A*0217
A2
A2
––
A2[73]
51
A2
2A2
A*0218
A2
A2
––
A2[100]c
1–
–A2
A*0219
A2
––
–Blank[100]c
1–
–A2
A*0220
A2
A2
––
A2[100]c
26
––
A2
Norm
alA
2
A*0221
A2
A2
––
––
––
A2
A*0222
A2
A2
––
A2[100]c
21
––
A2
A*0224
A2
A2
––
A2[100]c
11
––
A2
A*0225
A2
A2
––
––
––
A2
A*0226
A2
––
–A2[100]c
3–
–A2
A*0227
A2
––
–A2[100]c
1–
–A2
A*0228
A2
––
–A2[100]c
1–
–A2
A*0229
A2
A2
––
A2[100]c
2–
–A2
A*0230
A2
––
–A2[100]c
7–
–A2
A*0231
A2
A2
––
––
––
A2
A*0232N
Notexpressed
Null
––
––
––
NT
A*0233
A2
––
–A2[100]c
3–
–A2
A*0234
A2
A2
––
––
––
A2
A*0235
A2
A2
––
A2[100]c
8A2
2A2
Norm
alA
2
A*0236
A2
––
–A2[100]c
1–
–A2
Norm
alA
2
A*0237
A2
––
––
––
–A2
A*0238
A2
––
–A2[67],blank[33]c
3–
–A2
Norm
alA
2
A*0239
A2
––
–A2[100]c
1–
–A2
A*0240
A2
––
––
––
–A2
A*0241
A2
A2
––
––
––
A2
A*0242
A2
A2
––
––
––
A2
98 ª 2009 John Wiley & Sons A/S � Tissue Antigens 73, 95–170
HLA alleles and serologic types R. Holdsworth et al.
Table
1Continued
HLAallele
Expertassigned
WHO
assigned
InternationalC
ell
Exchange,UCLA
NMDP
IHW
S13data
NN
Assignedtype[%
]
Cells
tested
Assigned
type[%
]
Cells
tested
Assignment
Cells
tested
Assigned
type>0.55
Comments
A*0243N
Notexpressed
Null
––
––
––
NT
A*0244
A2/blank
––
–Blank[100]c
6–
–A2
A*0245
A2
––
–A2[100]c
2–
–A2
A*0246
A2
A2
––
––
––
A2
A*0247
A2
––
––
––
–A2
A*0248
A2
––
––
––
–A2
A2x9,few
A231
24
sera
reactive
A*0249
A2
A2
––
––
A2
1A2
Norm
alA
2.TheHLA
clubce
llexch
ange:
ninelaboratories
perform
ingserology
A*0250
A2
A2
––
––
––
A2
A*0251
A2
––
––
––
–A2
A*0252
A2
––
––
––
–A2
A*0253N
Notexpressed
Null
––
––
––
NT
A*0254
A2
––
––
––
–A2
A*0255
A2/A28
––
––
––
–Notassignede
NN:A2,A28,A69
A*0256
A2
––
––
––
–A2
ShortA2
A*0257
A2
––
––
––
–A2
A*0258
A2
––
––
––
–A2
A*0259
A2
A2
––
––
––
A2
A*0260
A2
––
–A2[100]c
3–
–A2
A*0261
A2
––
––
––
–A2
A*0262
A2
––
––
––
–A2
A2variant;A2x69
variant
A*0263
A2
––
–A2[100]c
1–
–A2
A*0264
A2
––
–cd
1–
–A2
A*0265
A2/A19
A2/19
––
––
––
Notassignede
NN:A74
A*0266
A2
A2
––
A2[100]c
2–
–A2
A*0267
A2
A2
––
––
––
A2
A*0268
A2
A2
––
––
––
A2
A*0269
A2
––
––
––
–A2
A*0270
A2
A2
––
––
––
A2
A*0271
A2
A2
––
––
––
A2
A*0272
A2
A2
––
––
––
A2
A*0273
A2
A2
––
––
––
A2
A*0274
A2
A2
––
––
––
A2
ª 2009 John Wiley & Sons A/S � Tissue Antigens 73, 95–170 99
R. Holdsworth et al. HLA alleles and serologic types
Table
1Continued
HLAallele
Expertassigned
WHO
assigned
InternationalC
ell
Exchange,UCLA
NMDP
IHW
S13data
NN
Assignedtype[%
]
Cells
tested
Assigned
type[%
]
Cells
tested
Assignment
Cells
tested
Assigned
type>0.55
Comments
A*0275
A2
––
––
––
–A2
A*0276
A2
––
––
––
–A2
A*0277
A2
A2
––
––
––
A2
A*0278
Undefined
A2
––
––
––
Notassignede
NN:A69,A28
A*0279
A2
A2
––
––
––
A2
A*0280
A2
––
––
––
–A2
A*0281
A2
––
–A2[100]c
1–
–A2
A*0282N
Notexpressed
Null
––
––
––
NT
A*0283N
Notexpressed
Null
––
––
––
NT
A*0284
A2
––
––
––
–A2
A*0285
A2
––
–A2[100]c
1–
–A2
A*0286
A2
––
––
––
–A2
A*0287
A2
––
––
––
–A2
A*0288N
Notexpressed
Null
––
––
––
NT
A*0289
A2
A2
––
––
––
A2
A*0290
A2
A2
––
––
––
A2
A*0291
A2
––
––
––
–A2
A*0292
A2
––
––
––
–A2
A*0293
A2
––
––
––
–A2
A*0294N
Notexpressed
Null
––
––
––
NT
A*0295
A2
A2
––
––
––
A2
A*0296
A2
––
––
––
–A2
A*0297
A2
A2
––
––
––
A2
A*0299
A2
––
––
––
–A2
A*9201
A2
––
––
––
–A2
A*9202
A2
––
––
––
–A2
A*9203
A2
––
––
––
–A2
A*9204
A2
––
––
––
–A2
A*9205
A2
A2
––
––
––
A2
A*9206
A2
––
––
––
–A2
A*9207
A2
––
––
––
–A2
A*9208
A2
––
––
––
–A2
A*9209
A2
––
––
––
–A2
A*9210
A2
––
––
––
–A2
A*9211
A2
––
––
––
–A2
A*9212
A2
––
––
––
–A2
A*9213N
Notexpressed
Null
––
––
––
NT
100 ª 2009 John Wiley & Sons A/S � Tissue Antigens 73, 95–170
HLA alleles and serologic types R. Holdsworth et al.
Table
1Continued
HLAallele
Expertassigned
WHO
assigned
InternationalC
ell
Exchange,UCLA
NMDP
IHW
S13data
NN
Assignedtype[%
]
Cells
tested
Assigned
type[%
]
Cells
tested
Assignment
Cells
tested
Assigned
type>0.55
Comments
A*9214
A2
––
––
––
–A2
A*9215
A2
––
––
––
–A2
A*9216
A2
––
––
––
–A2
A*9217
A2
––
––
––
–A2
A*9218
A2
––
––
––
–A2
A*9219
A2
––
––
––
–A2
A*9220
A2
––
––
––
–A2
A*9221
A2
––
––
––
–A2
A*9222
A2
––
––
––
–A2
A*9223
A2
––
––
––
–A2
A*9224
A2
––
––
––
–A2
A*9225N
Notexpressed
Null
––
––
––
NT
A*9226
A2
––
––
––
–A2
A*0301
A3
A3
A3[98–100]a
44
A3[99]
3504
A3
106
Training–A3
A*03010102N
Notexpressed
Null
––
––
NT
A*0302
A3
A3
A3[99–100]
2A3[78]
342
A3
3Training–A3
A*0303N
Notexpressed
Null
––
––
––
NT
A*0304
A3
A3
––
cd
1–
–A3
A*0305
A3/blank
A3
––
Blank[100]c
5Blank
1A3
ihw13:onlyreactive
withsomeA31
11
andA31
191
34
sera;norm
alA
3
A*0306
A3/blank
––
––
–A3/blank
1A3
ihw13:very
shortA3
A*0307
A3
––
–A3[75]c
4–
–A3
A*0308
A3
––
–A3[100]c
4–
–A3
A*0309
A3
––
–cd
1A3
1A3
A*0310
A3/blank
––
––
––
–A3
A3sera
negative,only
A31
301
311
33
monoclonal
antibodie
positive
A*0311N
Notexpressed
Null
––
––
––
NT
A*0312
A3
––
––
––
–A3
A*0313
A3
––
––
––
–A3
A*0314
A3
––
––
––
–A3
A*0315
A3
––
––
––
–A3
A*0316
A3
––
––
––
–A3
A*0317
A3
––
––
––
–A3
ª 2009 John Wiley & Sons A/S � Tissue Antigens 73, 95–170 101
R. Holdsworth et al. HLA alleles and serologic types
Table
1Continued
HLAallele
Expertassigned
WHO
assigned
InternationalC
ell
Exchange,UCLA
NMDP
IHW
S13data
NN
Assignedtype[%
]
Cells
tested
Assigned
type[%
]
Cells
tested
Assignment
Cells
tested
Assigned
type>0.55
Comments
A*0318
Undefined
––
––
––
–A1
A*0319
A3
––
––
––
–A3
A*0320
A3
A3
––
––
––
A3
A*0321N
Notexpressed
Null
––
––
––
NT
A*0322
A3
––
––
––
–A3
A*0323
A3
––
––
––
–A3
A*0324
A3
A3
––
––
––
A3
A*0325
A3
––
––
––
–A3
A*0326
A3
––
––
––
–A3
A*0327
A3
––
––
––
–A3
A*0328
A3
––
––
––
–A3
A*0329
A3
––
––
––
–A3
A*0330
A3
––
––
––
–A3
A*1101
A11
A11
A11[99–100]a
77
A11[99]
2530
A11
118
Training–A11
A*1102
A11
A11
A11[99]
1A11[76]
42
A11
8A11
ihw13:shortA11
A*1103
A11
A11
––
A11[82]c
17
A11
1A11
A*1104
A11
A11
A11[63–69]
2A11[75],blank[25]c
8–
–A11
ShortA11;norm
al
A11
A*1105
A11
A11
––
A11[80]c
5–
–A11
ShortA11;3/31A11
sera
reactive
A*1106
A11
––
–A11[100]c
2–
–A11
A*1107
A11
A11
––
––
––
A11
Norm
alA
11
A*1108
A11
A11
––
––
––
A11
ShortA11
A*1109
A11
A11
––
A11[100]c
1–
–A11
A*1110
A11
A11
––
Blank[100]c
1–
–A10
A*1111
Undefined
––
––
––
–Notassignede
NN:A11
A*1112
A11
A11
––
A11[100]c
3–
–A11
Norm
alA
11
A*1113
A11
A11
––
––
––
A11
ShortA11
A*1114
A11
A11
––
––
––
A11
ShortA11,likeA11.2
A*1115
A11
A11
––
––
––
A11
A*1116
A11
––
––
––
–A11
A*1117
Undefined
––
––
––
–Notassignede
NN:A11
A*1118
Undefined
––
––
––
–Notassignede
NN:A11
A*1119
A11
A11
––
––
––
A11
A*1120
A11
––
––
––
–A11
A*1121N
Notexpressed
Null
––
––
––
NT
A*1122
A11
––
––
––
–A11
102 ª 2009 John Wiley & Sons A/S � Tissue Antigens 73, 95–170
HLA alleles and serologic types R. Holdsworth et al.
Table
1Continued
HLAallele
Expertassigned
WHO
assigned
InternationalC
ell
Exchange,UCLA
NMDP
IHW
S13data
NN
Assignedtype[%
]
Cells
tested
Assigned
type[%
]
Cells
tested
Assignment
Cells
tested
Assigned
type>0.55
Comments
A*1123
A11
––
––
––
–A11
A*1124
A11
––
––
––
–A11
A*1125
A11
A11
––
––
––
A11
A*1126
A11
––
––
––
–A11
A*1127
Undefined
––
––
––
–Notassignede
NN:A11,A1
A*1128
A11
––
–A11[100]c
1–
–A11
A*1129
A11
––
––
––
–A11
A*1130
A11
––
––
––
–A11
A*1131
A11
––
––
––
–A11
A*1132
A11
––
––
––
–A11
A*2301
A23
A23(9)
A23[95–100]a
29
A23[95],A24[1]
5119
A23
42
Training–A9,A23
A*2302
A23
––
–A23[100]c
5–
–A23
A*2303
A23
––
–A9[100]c
1–
–A23
A*2304
A23
A23(9)b
––
––
A23
1A23
ihw13:shortA23,
negativewithA91
80(1
1)sera
A*2305
A23
––
–A23[100]c
2–
–A23
A*2306
A23
––
––
––
–A23
A*2307N
Notexpressed
Null
––
––
––
NT
A*2308N
Notexpressed
Null
––
––
––
NT
A*2309
A23
––
––
––
–A23
A*2310
A23
––
––
––
–A23
A*2311N
Notexpressed
Null
––
––
––
NT
A*2312
A23
A23(9)
––
––
––
A23
A*2313
A23
––
––
––
–A23
A*2314
A23
––
––
––
–A23
A*2315
A23
––
––
––
–A23
A*2316
A23
––
––
––
–A23
A*2402
A24
A24(9)
A24[97–100]
99a
A24[97],A2403[1]
3098
A24
146
Training–A9,A24
A*24020102L
Low
A24
Low
A24(9)
A24[0–5]a
3–
–Blank
1IdenticaltoA*2402
Significantlyreduced
orlow
cellsurface
expression
A*2403
A2403/A24
A2403
A24[66–68],A2403
[29–31]a
10
A24[55],blank[20],
A9[4],A2403[1]
282
A24
5A24
ihw13:shortA24,
negativewithA91
80(1
1)sera
A*2404
A24
A24(9)
––
A24[62],blank[25],
A2403[13]c
8–
–A9
ª 2009 John Wiley & Sons A/S � Tissue Antigens 73, 95–170 103
R. Holdsworth et al. HLA alleles and serologic types
Table
1Continued
HLAallele
Expertassigned
WHO
assigned
InternationalC
ell
Exchange,UCLA
NMDP
IHW
S13data
NN
Assignedtype[%
]
Cells
tested
Assigned
type[%
]
Cells
tested
Assignment
Cells
tested
Assigned
type>0.55
Comments
A*2405
A9
A9
A23[67–70],A24
[14–19]a
2A24[45],A23[50]c
20
––
A24
A*2406
A24
A24(9)
––
A24[67],blank[33]c
3A24
5A24
A*2407
A24
A24(9)
A24[99–100]a
21
A24[59]
320
A24
17
Training–A9,A24
A*2408
A24
A24(9)
––
A24[47],blank[26]
30
––
A24
ShortA24,sim
ilarto
A2403
A*2409N
Notexpressed
Null
––
Blank[100]c
2–
–NT
A*2410
A2403/A24
A2403
––
A24[42],A9[9],blank
[16],A2403[3]
32
A24
1A24
A2403;ihw13:short
A24
A*2411N
Notexpressed
Null
Blanka
1Blank[100]c
2–
–NT
A*2413
A24
A24(9)
––
cd
1–
–A24
A*2414
A24
A24(9)
––
A24[82]c
11
––
A24
A*2415
A24
––
–c
––
–A24
A*2417
A24
A24(9)b
––
A24[82]c
11
A24
3A24
ihw13:shortA24
A*2418
A24/A3
A24(9)/A3
––
––
––
A9f
A2403x3;shortA24
withmostA3and
A9reactive;NN:
A24
A*2419
A9
A9
––
––
––
A24
Very
shortA9
A*2420
A24
A24(9)b
––
A24[100]c
9A24
1A24
A*2421
A24/A9
A24(9)
––
––
––
A24
A9variant;A24sera
negative
A*2422
A24
A9
––
A24[83]c
6A24
1A24
ihw13:shortA24,
negativewithA91
80(1
1)sera;A
2403
like
A*2423
A24
A2403
––
A24[100]c
11
––
A24
A2403
A*2424
A9
––
––
––
–A9f
NN:A23
A*2425
A24
––
–A24[100]c
13
––
A24
A*2426
A24
––
–A24[100]b
2–
–A24
A*2427
A24
A24(9)b
––
––
A24
1A24
ihw13:shortA24
A*2428
A9
A24(9)
––
A24[50],A9[50]c
2–
–Notassignede
NN:A9,A24,A2
A*2429
A24
––
–A24[100]c
1–
–A24
A*2430
A24
––
––
––
–A24
A*2431
A24
––
––
––
–A24
A*2432
A24
––
–A24[100]c
4–
–A24
A*2433
A2403/A24
A2403
A24[99–100]a
4A24[100]c
4A24
1A24
A2403
104 ª 2009 John Wiley & Sons A/S � Tissue Antigens 73, 95–170
HLA alleles and serologic types R. Holdsworth et al.
Table
1Continued
HLAallele
Expertassigned
WHO
assigned
InternationalC
ell
Exchange,UCLA
NMDP
IHW
S13data
NN
Assignedtype[%
]
Cells
tested
Assigned
type[%
]
Cells
tested
Assignment
Cells
tested
Assigned
type>0.55
Comments
A*2434
A24
––
––
––
–A24
A*2435
A24
––
––
––
–A24
A*2436N
Notexpressed
Null
––
––
––
NT
A*2437
A24
A24
A24[94–97]a
4A24[100]c
1–
–A24
A*2438
A24
––
––
––
–A24
A*2439
A24
––
––
––
–A24
A*2440N
Notexpressed
Null
––
––
––
NT
A*2441
A24
––
––
––
–A24
A*2442
A24
––
––
––
–A24
A*2443
A24
A24(9)
––
––
––
A24
A*2444
A9
––
––
––
–A9f
NN:A24
A*2445N
Notexpressed
Null
––
––
––
NT
A*2446
A24
––
––
––
–A24
A*2447
A24
––
––
––
–A24
A*2448N
Notexpressed
Null
––
––
––
NT
A*2449
A24
––
––
––
–A24
A*2450
A24
––
––
––
–A24
A*2451
A24
––
––
––
–A24
A*2452
A24
––
––
––
–A24
A*2453
A24
––
––
––
–A24
A*2454
A24
––
––
––
–A24
A*2455
A24
––
––
––
–A24
A*2456
A24
––
––
––
–A24
A*2457
A24
––
––
––
–A24
A*2458
A24
A24(9)
––
––
––
A24
A*2459
A24
––
––
––
–A24
A*2460N
Notexpressed
Null
––
––
––
NT
A*2461
A24
––
––
––
–A24
A*2462
A24
––
––
––
–A24
A*2463
A24
––
––
––
–A24
A*2464
A24
––
––
––
–A24
A*2465
A24
––
––
––
–A24
A*2466
A24
––
––
––
–A24
A*2467
A24
––
––
––
–A24
A*2468
A24
––
––
––
–A24
A*2469
A24
––
––
––
–A24
A*2470
A24
––
––
––
–A24
ª 2009 John Wiley & Sons A/S � Tissue Antigens 73, 95–170 105
R. Holdsworth et al. HLA alleles and serologic types
Table
1Continued
HLAallele
Expertassigned
WHO
assigned
InternationalC
ell
Exchange,UCLA
NMDP
IHW
S13data
NN
Assignedtype[%
]
Cells
tested
Assigned
type[%
]
Cells
tested
Assignment
Cells
tested
Assigned
type>0.55
Comments
A*2471
A24
––
––
––
–A24
A*2472
A24
––
––
––
–A24
A*2473
A24
––
––
––
–A24
A*2474
A24
––
––
––
–A24
A*2475
A24
––
––
––
–A24
A*2476
A24
A24(9)
––
––
––
A24
A*2477
A24
––
––
––
–A24
A*2478
A24
A24(9)
––
––
––
A24
A*2479
A24
––
––
––
–A24
A*2501
A25
A25(10)
A25[94–99]
6a
A25[95],A10[2]
1375
A25
18
Training–A10,A25
A*2502
A25
A25(10)b
––
A25[88]c
8A25
1A25
Norm
alA
25
A*2503
A25
––
–A25[100]c
2–
–A25
A*2504
A25
––
––
––
–A25
A*2505
A25
––
–A2[100]c
1A25
A*2506
A25
––
––
–A25
A*2601
A26
A26(10)
A26[95–97]a
27
A26[97],A10[2]
1730
A26
47
Training–A10,A26
A*2602
A26
A26(10)
A26[91–97]a
3A26[81]
31
A26
2Training–A10,A26
A*2603
A26
A26(10)
A26[92–98]a
11
A26[68],A10[8]
38
A26
5Training–A10,A26
ihw13:shortA26
A*2604
A26
A26(10)
––
A10[50],blank[50]c
2–
–A26
A*2605
A26
A26(10)
––
A26[90],A25[10]c
10
––
A26
A*2606
A26
A26(10)
––
A26[100]c
1–
–A26
A*2607
A26
A26(10)
––
A26[100]c
1–
–Notasssignede
NN:A43,A10,A26
A*2608
A26
A26(10)
––
A26[95]
65
A26
3A26
ihw13:shortA26,
sim
ilarto
A*2603;
norm
alA
26
A*2609
A26
A26(10)b
––
A26[33],A10[33],
A34[33]c
3A26
2A26
ihw13:shortA26
A*2610
A10
A10
––
––
––
A26
ShortA26,A10
variant
A*2611N
Notexpressed
Null
––
––
––
NT
A*2612
A26
––
–A26[75],A34[25]c
4–
–A26
A*2613
A26
––
–A26[100]c
3–
–A26
NN:A66
A*2614
A26
––
––
––
–A26
A*2615
A10
A10b
––
––
A10
2A26
ihw13:onlyfew
A10
sera
reactive,may
betypedasblank;A
blank
106 ª 2009 John Wiley & Sons A/S � Tissue Antigens 73, 95–170
HLA alleles and serologic types R. Holdsworth et al.
Table
1Continued
HLAallele
Expertassigned
WHO
assigned
InternationalC
ell
Exchange,UCLA
NMDP
IHW
S13data
NN
Assignedtype[%
]
Cells
tested
Assigned
type[%
]
Cells
tested
Assignment
Cells
tested
Assigned
type>0.55
Comments
A*2616
A26
––
–A26[100]c
1–
–A26
A*2617
A26
––
––
––
–A26
A*2618
A10
––
–Blank[100]c
1–
–A10f
NN:A26
A*2619
Undefined
––
––
––
–Notassignede
NN:A43,A10
A*2620
A26
––
––
––
–A26
A*2621
A26
––
––
––
–A26
A*2622
A26
A26(10)
––
––
––
A26
A*2623
A26
A26(10)
––
––
––
A26
A*2624
A26
––
––
––
–A26
A*2625N
Notexpressed
Null
––
––
––
NT
A*2626
A26
A10
––
––
––
A26
A*2627
A26
––
––
––
–A26
A*2628
A26
––
––
––
–A26
A*2629
A26
A26(10)
––
––
––
A26
A*2630
A26
––
––
––
–A26
A*2631
A26
––
––
––
–A26
A*2632
A26
––
––
––
–A26
A*2633
A26
––
––
––
–A26
A*2634
A26
––
––
––
–A26
A*2635
A26
––
––
––
–A26
A*2901
A29
A29(19)
A29[98]a
1A29[96]
115
A29
10
Training–A29
A*29010102N
Notexpressed
Null
––
––
––
NT
A*2902
A29
A29(19)
A29[98–100]a
17
A29[99]
1488
A29
28
Training–A29
A*2903
A29
––
–A29[100]c
4–
–A29
A*2904
A29
––
–A29[100]c
1–
–A29
A*2905
A29
––
––
––
–A29
A*2906
A29
––
––
––
–A29
A*2907
A29
––
––
––
–A29
A*2908N
Notexpressed
Null
––
––
––
NT
A*2909
A29
––
––
––
–A29
A*2910
A29
A29(19)
––
A29[100]c
2–
–A29
A*2911
A29
––
––
––
–A29
A*2912
A29
––
––
––
–A29
A*2913
Undefined
––
––
––
–Notassignede
NN:A32,A29
A*2914
Undefined
––
––
––
–Notassignede
NN:A29,A30
A*2915
A29
––
––
––
–A29
A*2916
A29
A29(19)
––
––
––
A29
ª 2009 John Wiley & Sons A/S � Tissue Antigens 73, 95–170 107
R. Holdsworth et al. HLA alleles and serologic types
Table
1Continued
HLAallele
Expertassigned
WHO
assigned
InternationalC
ell
Exchange,UCLA
NMDP
IHW
S13data
NN
Assignedtype[%
]
Cells
tested
Assigned
type[%
]
Cells
tested
Assignment
Cells
tested
Assigned
type>0.55
Comments
A*3001
A30
A30(19)
A30[97–100]a
25
A30[89],A31[3],
blank[3],A19[1]
2895
A30
28
Training–A30
A*3002
A30
A30(19)
A30[96–100]a
17
A30[93],A31[2],
A19[1]
2124
A30
25
Training–A30
A*3003
A30
A30(19)
––
A30[83],blank[17]c
6–
–A30
A*3004
A30
A30(19)
A30[97–98]a
2A30[94]
85
A30
7Training–A30
A*3006
A30
––
–cd
1–
–A30
A*3007
A30
––
–A30[100]c
2–
–A30
A*3008
A30
––
––
––
–A30
A*3009
A30
––
–A30[100]c
3A30
1A30
ihw13:very
short
A30,onlybroad
A19sera
reactive
A*3010
A30
––
–A30[100]c
10
––
A30
A*3011
A30
A30(19)
––
––
––
A30
A*3012
A30
––
––
––
–A30
A*3013
A30
––
––
––
–A30
A*3014L
A30
Low
A30(19)
––
––
––
A30
Significantlyreduced
orlow
cellsurface
expression
A*3015
A30
A30(19)
––
––
––
A30
A*3016
A30
––
––
––
–A30
A*3017
A30
A30(19)
––
––
––
A30
A*3018
A30
A30(19)
––
––
––
A30
A*3019
A30
––
––
––
–A30
A*3020
A30
––
––
––
–A30
A*3021
A30
––
––
––
–A30
A*3022
A30
––
––
––
–A30
A*3101
A31
A31(19)
A31[94–98]a
23
A31[90],A30[3],
A19[1]
3517
A31
58
Training–A31
A*3102
A31
A31(19)b
––
A31[100]c
17
––
A31
A*3103
A31
––
–A31[100]c
2–
–A31
A*3104
A31
A31(19)
––
––
––
A31
A*3105
A31
A31(19)
––
––
––
A31
A*3106
A31
––
––
––
–A31
A*3107
Undefined
––
––
––
–Notassignede
NN:A32,A23,A9
108 ª 2009 John Wiley & Sons A/S � Tissue Antigens 73, 95–170
HLA alleles and serologic types R. Holdsworth et al.
Table
1Continued
HLAallele
Expertassigned
WHO
assigned
InternationalC
ell
Exchange,UCLA
NMDP
IHW
S13data
NN
Assignedtype[%
]
Cells
tested
Assigned
type[%
]
Cells
tested
Assignment
Cells
tested
Assigned
type>0.55
Comments
A*3108
A31/A24
––
–A32[100]c
1–
–Notassignede
A31x24;previously
A*2416;NN:A23,
A9,A32
A*3109
A31
––
–A31[100]c
3–
–A31
Bw4motifpresent
A*3110
A31
A31(19)
––
––
––
Notassignede
NN:A32
A*3111
A31
––
––
––
–A31
A*3112
A31
A31(19)
––
––
––
A31
A*3113
A31
––
––
––
–A31
A*3114N
Notexpressed
Null
––
––
––
NT
A*3115
A31
––
––
––
–A31
A*3116
A31
––
––
––
–A31
A*3117
A31
––
––
––
–A31
A*3118
A31
––
––
––
–A31
A*3201
A32
A32(19)
A32[97–99]a
20
A32[94]
3441
A32
50
Training–A32
A*3202
A32
A32(19)
––
A32[100]c
3–
–Notassignede
NN:A32
A*3203
A32
––
–A32[67],blank[33]c
3–
–A32
A*3204
A32/A3
––
–A3[75],A19[13],
A32[13]c
8A‘3204’
1Notassignede
A3withmostA32
sera
reactive
(ihw13);NN:A32,
A3
A*3205
A32
––
––
––
–A32
A*3206
A32
––
––
––
–A32
A*3207
A32
––
–A32[100]c
1–
–A32
A*3208
A32
––
–A32[100]c
2–
–A32
A*3209
A32
––
––
––
–A32
A*3210
A32
––
––
––
–A32
A*3211Q
A32
––
––
––
–A32
Notexpectedto
be
expressed
A*3212
A32
––
––
––
–A32
A*3213
A32
––
–A32[100]c
1–
–A32
A*3214
A32
A32(19)
––
––
––
A32
A*3215
A32
––
––
––
–A32
A*3301
A33
A33(19)
A33[97–100]
10a
A33[87],A19[3],
blank[4]
687
A33
19
Training–A33
A*3303
A33
A33(19)
A33[95–100]a
36
A33[95],A34[1]
887
A33
27
Training–A33
A*3304
A33
––
–A33[50],blank[50]c
2–
–A33
A*3305
A33
A33(19)
––
A33[92]c
13
A33
1A33
ihw13:shortA33
ª 2009 John Wiley & Sons A/S � Tissue Antigens 73, 95–170 109
R. Holdsworth et al. HLA alleles and serologic types
Table
1Continued
HLAallele
Expertassigned
WHO
assigned
InternationalC
ell
Exchange,UCLA
NMDP
IHW
S13data
NN
Assignedtype[%
]
Cells
tested
Assigned
type[%
]
Cells
tested
Assignment
Cells
tested
Assigned
type>0.55
Comments
A*3306
A33
––
–cd
1–
–A33
A*3307
A33
––
––
––
–A33
A*3308
Undefined
A33(19)
––
––
––
Notassignede
NN:A31,A33
A*3309
Undefined
A19
––
––
––
Notassignede
NN:A31,A33
A*3310
A33
––
––
––
–A33
A*3311
A33
––
––
––
–A33
A*3312
A33
––
––
––
–A33
A*3313
Undefined
––
––
––
–Notassignede
NN:A33
A*3401
A34
A34(10)
A34[93–98]a
30
A34[67],A26[10],
A10[5],A66[4],
A33[2],blank[7]
269
A34
25
Training–A10,A34
ihw13:distinct
pattern
from
A*3402
A*3402
A34
A34(10)
A34[92–95]a
11
A34[89],A33[4],A26
[3],A10[2]
996
A34
11
Training–A10,A34
ihw13:distinct
pattern
from
A*3401
A*3403
A34
––
––
––
–A34
A*3404
A34
A34(10)
––
––
A34
2A34
ihw13:shortA34,
withsomeA11and
A19sera
reactive;
A34variantwith
someA10sera
reactive
A*3405
A34
––
––
––
–A34
A*3406
A10
––
––
–A10f
NN:A34
A*3407
A34
––
––
–A34
A*3408
A34
––
–A10[100]c
1A34
A*3601
A36
A36
A36[85–93],A1[5–8]a
5A36[68],A1[16],
blank[6]
807
A36
7Training–A36
A*3602
A36
––
––
––
–A36
A*3603
A36
A36
––
––
––
A36
A*3604
A36
A36b
––
––
A36
2A36
A*4301
A43
A43
––
A26[50],A10[13],
A34[13],A19[13],
blank[13]c
8–
–Training–A43
110 ª 2009 John Wiley & Sons A/S � Tissue Antigens 73, 95–170
HLA alleles and serologic types R. Holdsworth et al.
Table
1Continued
HLAallele
Expertassigned
WHO
assigned
InternationalC
ell
Exchange,UCLA
NMDP
IHW
S13data
NN
Assignedtype[%
]
Cells
tested
Assigned
type[%
]
Cells
tested
Assignment
Cells
tested
Assigned
type>0.55
Comments
A*6601
A66
A66(10)
A66[37–59],A‘6601’
[22–42],A26[15–
18],A10[2–7]a
14
A26[61],A66[20],
A34[8],A10[3],
A25[1]
799
A66
19
Training–A10,A66
ihw13:A‘6601’
pattern
–different
from
A‘6602’;
reactivewithA341
66sera
A*6602
A66
A66(10)
A‘6602’[35–65],
A66[15–42],A34
[7–18],A10[4]a
8A66[38],A34[27],
A10[10],A74[5],
A26[4]
205
A66
2A66
ihw13:A‘6602’,short
A66
A*6603
A10
A10
––
A66[32],A34[18],
A10[7],A26[7]
28
––
A10f
ShortA10;NN:A26
A*6604
A66
––
––
––
–A66
A*6605
A26
––
–A26[100]c
1–
–A26
A*6606
A66
A66(10)
––
––
––
A66
A*6801
A68
A68(28)
A68[53–68],A28
[31–45]a
34
A28[63],A68[27]
2736
A68
49
Training–A28,A68
A*6802
A68
A68(28)
A68[55–65],A28
[32–43]a
15
A28[72],A68[19],
A69[1]
2327
A68
18
Training–A28,A68
A*6803
A68
A68(28)b
A68[47–66],A28
[34–48]a
16
A28[63],A68[28]
202
A68
4A68
A*6804
A68
A68(28)
––
A28[75],A68[25]c
4–
–A68
A*6805
A68
A68(28)
––
A28[53],A68[29]
59
A28
1A68
ihw13:possiblyA68,
butcellalsoA2
positive
A*6806
A68
––
–A28[50],A68[50]c
2–
–A68
A*6807
A68
––
–Blank[100]c
1–
–A68
A*6808
A68
A68(28)
A68[38–45],A28[53]
2A28[100]c
2–
–A68
A*6809
A68
––
–A68[100]c
1–
–A68
A*6810
A68
A28b
––
Blank[50],A1[50]c
2A28
1A68
ihw13:possiblyA68,
butcellalsoA2
positive
A*6811N
Notexpressed
Null
––
––
––
NT
A*6812
A28
A28
––
A28[50],blank[50]c
6–
–A68
ShortA28
A*6813
A68
––
––
––
–A68
A*6814
A68
––
––
––
–A68
A*6815
A68
––
––
––
–A68
A*6816
A68
A68(28)
––
––
––
A68
ª 2009 John Wiley & Sons A/S � Tissue Antigens 73, 95–170 111
R. Holdsworth et al. HLA alleles and serologic types
Table
1Continued
HLAallele
Expertassigned
WHO
assigned
InternationalC
ell
Exchange,UCLA
NMDP
IHW
S13data
NN
Assignedtype[%
]
Cells
tested
Assigned
type[%
]
Cells
tested
Assignment
Cells
tested
Assigned
type>0.55
Comments
A*6817
A68
A28b
––
A28[100]c
1A28
1A68
ihw13:possiblyA68,
butcellalsoA2
positvie
A*6818N
Notexpressed
Null
––
––
––
NT
A*6819
A68
––
–A28[100]c
1–
–A68
A*6820
A68
––
––
––
–A68
A*6821
A68
––
––
––
–A68
A*6822
A68
––
––
––
–A68
A*6823
A68
––
–A68[100]c
1–
–A68
A*6824
A68
––
––
––
–A68
A*6825
A68
––
–A28[100]c
1–
–A68
A*6826
A68
A28
––
––
––
A68
A*6827
A68
––
––
––
–A68
A*6828
A68
––
––
––
–A68
A*6829
A68
––
––
––
–A68
A*6830
A68
––
––
––
–A68
A*6831
A68
––
––
––
–A68
A*6832
A68
––
––
––
–A68
A*6833
A68
A68(28)
––
––
––
A68
A*6834
A68
––
––
––
–A68
A*6835
A68
––
––
––
–A68
A*6836
A68
A68(28)
––
––
––
A28f
NN:A68
A*6837
A68
––
––
––
–A68
A*6838
A68
––
––
––
–A68
A*6839
A68
––
––
––
–A68
A*6840
A68
––
––
––
–A68
A*6901
A69
A69(28)
A69[40–70],A28
[33–49]a
3A28[56],A69[7],
A2[6],A68[3]
289
A69
6Training–A28,A69
A*7401
A74
A74(19)
A74[72–95]a
13
A74[40],A19[11],
blank[36]
115
A74
11
Training–A74
A*7402
A74
A74(19)
––
Blank[50],A74[17],
A33[17],A31[17]c
6–
–A74
A*7403
A74
A74(19)
A74[89–91]
5Blank[72],A74[17]
29
A74
4A74
A*7404
A74
––
–A74[100]c
1–
–A74
A*7405
A74
––
–Blank[100]c
1–
–A74
A*7406
A74
A74(19)
––
A74[100]c
1A74
1A74
A*7407
A74
A74(19)
––
––
––
A74
A*7408
A74
––
––
––
–A74
112 ª 2009 John Wiley & Sons A/S � Tissue Antigens 73, 95–170
HLA alleles and serologic types R. Holdsworth et al.
National Marrow Donor Program
Assignments made using the expectation
maximization algorithm
The 2008 data set includes only those typings from US
volunteer donors where both serologic and allele-level results
havebeen reported for theHLA-A, -B, -C, -DRB1, or -DQB1
loci. As in past versions of the dictionary, the expectation
maximization (EM) algorithm was used to obtain the cor-
relation between alleles and serologic assignments. Readers
are referred to previous versions of the dictionary that des-
cribe theuse of theEMalgorithmand thenuances of thedata.
In this version, data for alleles serologically typed in 20 or
more donors (cells tested) have not been updated and
remain the same as that shown in the 2004 dictionary (4).
For these alleles, we believe that adequate data have been
accumulated to define the serologic assignments.
A subset of theEMdata including the alleleswith counts of
less than 20 in the last dictionary version plus newly described
alleleswas analyzed.TheEMalgorithmprovides anunbiased
assignment of serologic specificities using information from
all cells carrying the allele in question. In addition, experts
reviewed the serologic assignments for all cells carrying an
allele in this category and assigned serologic specificities.
Uninformative cells were eliminated and known serologic
cross-reactivity was considered in the assignment. The
information from the EM algorithm and the results from
the review were compared and final serologic assignments
were made. The table shows the predicted serologic assign-
ments and the percent of informative individuals carrying
those assignments. The percentages listed in the table are
derived from the review of typings as described above; this
differs from previous years in which the percentages were
derived from the EM algorithm. This change will better
reflect the serologic assignment of these less frequent alleles.
In theEMalgorithm, percent assignments are skewed by cells
carrying a second more common allele with the same
serologic assignment. For example, cells carrying both
A*0201 and A*0208 frequently appear. The EM assignment
is influenced by the more common A*0201 allele resulting in
a lower percent assignment for A*0208 (78%). Expert review
eliminated these uninformative cells (i.e. carrying both
A*0201 and A*0208) resulting in an A2 assignment for
A*0208 of 100%.
The information for 454 alleles, including 122 HLA-A,
200 -B, 50 -C, 73 -DRB1, and 9 -DQB1, was reviewed and
updated. The reviewed and updated alleles are indicated by
a footnote in the tables. If an allele appears five times or less,
the serologic assignment(s) should be considered as only an
approximation of the serologic reactivity of the resultant
antigen. It should be noted that the number of individuals
carrying each allele shown in the tables might not be the
total number of volunteer donors carrying the allele in theTable
1Continued
HLAallele
Expertassigned
WHO
assigned
InternationalC
ell
Exchange,UCLA
NMDP
IHW
S13data
NN
Assignedtype[%
]
Cells
tested
Assigned
type[%
]
Cells
tested
Assignment
Cells
tested
Assigned
type>0.55
Comments
A*7409
A74
––
–A74[33],A33[33],
blank[33]c
3–
–A74
A*7410
Undefined
––
––
–Notassignede
NN:A74
A*7411
A74
––
–cd
1A74
A*7412N
Notexpressed
Null
––
––
NT
A*8001
A80
A80
A80[68–88],A36
[0–3]
11
Blank[77],A80[10],
A36[2],A1[1]
505
A80
9Training–A80
ihw13:d
ifficultto
type
nextto
A1orA24
NT,nottested;NN,neuraln
etw
ork;HLA,humanleukocyte
antigen;WHO,WorldHealthOrganization;NMDP,NationalM
arrow
DonorProgram.
aUpdatedInternationalC
ellExchange,UCLA.
bWHO
assignmentbasedondictionary
data.
cUpdatedNMDPdata.Insomecases,theinform
ationreportedinpreviousdictionarieshaschanged.C
ells
havebeenexcludedfrom
thisstudyinsomecasesbecausetheirHLAtypinghaschanged.
dTheallele
hasbeenidentifiedbutserologynotinform
ative.
eNotassigned;seecommentcolumnforpredictions>0.20.
fIfaprimary
specificityisprovidedbytheNN,otherspecificities>0.4
are
shownin
thecomments
column.
gRef13–28,61.
ª 2009 John Wiley & Sons A/S � Tissue Antigens 73, 95–170 113
R. Holdsworth et al. HLA alleles and serologic types
Table
2HLA-B
allelesandtheirserologicdesignationsg
HLAallele
Expert
assigned
WHO
assigned
InternationalC
ellExchange,UCLA
NMDP
IHWS13data
NN
Comments
Assignedtype[%
]Cells
tested
Assignedtype[%
]
Cells
tested
Assignment
Cells
tested
Assigned
type>0.55
B*0702
B7
B7
B7[98–100]a
32
B7[98]
10,841
B7
83
Training–B7
B*0703
B703/B7
B703
––
B7[94]b
17
B703,B7,blank
1B7
ShortB7,B71
42
sera
reactive,B71
22sera
negative
B*0704
B7
B7
––
B7[89]
44
B7
2Training–B7
B*0705
B7
B7
B7[91–97]a
4B7[95]
42
B7
6Training–B7
B*0706
B7
B7
B7[94–95]
4B7[96]
23
––
B7
B*0707
B7
B7
––
B7[93]b
15
––
B7
B*0708
B7
B7c
––
––
B7
1B7
ShortB7,negative
withB71
22sera,
sim
ilarto
B703
B*0709
B7
B7
B7[97–98]
2B7[100]b
8B7
2B7
B*0710
B7
B7c
––
B7[92]b
12
B7
2B7
B*0711
B7
B7
––
––
––
B7
B*0712
B7
B7c
––
B7[100]b
5–
–B7
B*0713
B7/blank
––
–Blank[100]b
3–
–B7
B*0714
B7
B7c
––
B7[100]b
10
B7
1B7
B*0715
B7
B7
––
B7[100]b
1–
–B7
B7variant,someBw6
sera
negative
B*0716
B7
B7
––
B7[50],B60[50]b
2–
–B7
ShortB7,few
B7sera
reactive,sim
ilarto
B703
B*0717
B7
B7
––
––
––
B7
B*0718
B7
––
––
––
–B7
B*0719
B7/42
––
–B42[100]b
1–
–B42
ShortB7
B*0720
B7/blank
––
––
––
–B7
ShortB7,B7sera
negative,B71
42
sera
reactive
B*0721
B7
––
–B7[100]b
1–
–B7
B*0722
B7
––
––
––
–B7
B*0723
B7
––
–bd
1–
–B7
B*0724
B7
B7
––
––
––
B7
B7weaklyexpressed,
reactivewithB71
27(1
40)sera
B*0725
B7
––
––
––
–B7
B*0726
B7
B7
––
B7[100]b
1–
–B7
Norm
alB
7
B*0727
Undefined
––
––
––
–Notassignede
NN:B7
B*0728
B7
––
––
––
–B7
114 ª 2009 John Wiley & Sons A/S � Tissue Antigens 73, 95–170
HLA alleles and serologic types R. Holdsworth et al.
Table
2Continued
HLAallele
Expert
assigned
WHO
assigned
InternationalC
ellExchange,UCLA
NMDP
IHWS13data
NN
Comments
Assignedtype[%
]Cells
tested
Assignedtype[%
]
Cells
tested
Assignment
Cells
tested
Assigned
type>0.55
B*0729
B7
––
––
––
–B7
B*0730
B7
B7
––
––
––
B7
B7variant
B*0731
B7/B42
B7/B42
––
––
––
B7
B7x42,shortB7
B*0732
B7/blank
––
––
––
–B7
Bblank
B*0733
B7
––
–B7[100]b
1–
–B7
B*0734
B7
––
––
––
–B7
B*0735
B7
––
––
––
–B7
B*0736
B7
––
–B7[100]b
1–
–B7
Bw4positive
B*0737
B7
––
––
––
–B7
B*0738
Undefined
––
––
––
–Notassignede
B*0739
B7
––
––
––
–B7
B*0740
B7
B7
––
––
––
B7
B*0741
B7
––
––
––
–B7
B*0742
B7
––
––
––
–B7
B*0743
B7
––
––
––
–B7
B*0744
B7
––
––
––
–B7
B*0745
B7
––
––
––
–B7
B*0746
B7
B7
––
––
––
B7
B*0747
B7
––
––
––
–B7
B*0748
B7
––
––
––
–B7
B*0749N
Notexpressed
Null
––
––
––
NT
B*0750
Undefined
––
––
––
–NT
NN:B7
B*0751
B7
––
––
––
–B7
B*0752
B7
––
––
––
–B7
B*0753
B7
––
––
––
–B7
B*0754
B7
––
––
––
–B7
B*0755
B7
––
––
––
–B7
B*0756
B7
––
––
––
–B7
B*0757
B7
B7
––
––
––
B7
B*0758
B7
B7
––
––
––
B7
B*0801
B8
B8
B8[100]a
9B8[99]
6518
B8
61
Training–B8
B*0802
B8
B8
––
bd
2B‘0802’
1Notassignede
B8Bw4;ihw13:B8
Bw4withextra
reactions;NN:B8
B*0803
B8
B8
––
B8[100]b
1–
–Notassignede
B8Bw4
B*0804
B8/blank
–B8[51–71],B59[6–7]
3B8[80],blank[20]b
5B8
1B8
BlankBw6;ihw13:
shortB8
B*0805
B8
––
–bd
1–
–B8
ª 2009 John Wiley & Sons A/S � Tissue Antigens 73, 95–170 115
R. Holdsworth et al. HLA alleles and serologic types
Table
2Continued
HLAallele
Expert
assigned
WHO
assigned
InternationalC
ellExchange,UCLA
NMDP
IHWS13data
NN
Comments
Assignedtype[%
]Cells
tested
Assignedtype[%
]
Cells
tested
Assignment
Cells
tested
Assigned
type>0.55
B*0806
B8
B8
––
B8[100]b
1–
–B8
B*0807
B8
B8
––
B8[100]b
1–
–B8
B*0808N
Notexpressed
Null
––
––
––
NT
B*0809
B8
B8
––
B8[100]b
11
B8
2B8
B*0810
B8
B8
––
––
––
B8
ShortB8
B*0811
B8
––
–B8[100]b
3–
–B8
B*0812
B8
––
–bd
1–
–B8
B*0813
B8
––
–B8[100]b
1–
–B8
B*0814
B8
––
––
––
–B8
B*0815
B8
B8
––
––
B8
1B8
B*0816
B8
B8
––
––
––
B8
B*0817
Undefined
––
––
––
–Notassignede
Bblank;NN:B8
B*0818
B8
B8
––
––
––
B8
B*0819N
Notexpressed
Null
––
––
––
NT
B*0820
B8
––
––
––
–B8
B*0821
B8
––
––
––
–B8
B*0822
B8
––
––
––
–B8
B*0823
B8
––
––
––
–B8
B*0824
B8
––
––
––
–B8
B*0825
B8
––
––
––
–B8
B*0826
B8
––
––
––
–B8
B*0827
B8
––
––
––
–B8
B*0828
B8
––
––
––
–B8
B*0829
B8
B8
––
––
––
B8
B*0830N
Notexpressed
Null
––
––
––
NT
B*0831
B8
––
––
––
–B8
B*0832
B8
––
––
––
–B8
B*0833
B8
––
––
––
–B8
B*1301
B13
B13
B13[95–99]a
4B13[97]
238
B13
9Training–B13
B*1302
B13
B13
B13[98–100]a
9B13[99]
1307
B13
17
Training–B13
B*1303
B49/B15
––
–B13[100]b
1–
–B13
B15x21–Bw4;B21
variantwithsome
B15sera
reactive
B*1304
B49/B15
B15/B21
B21[22–38],B49[15],
B15[7–17],B15x21
[0–15],B50[5–11],
B63[0–8],B77[4–7]
2–
–B‘1304’
1B13
B15x21–Bw4,sim
ilar
toB*1303;ihw13:
new
pattern,also
B49,B63andB77
reactivity
116 ª 2009 John Wiley & Sons A/S � Tissue Antigens 73, 95–170
HLA alleles and serologic types R. Holdsworth et al.
Table
2Continued
HLAallele
Expert
assigned
WHO
assigned
InternationalC
ellExchange,UCLA
NMDP
IHWS13data
NN
Comments
Assignedtype[%
]Cells
tested
Assignedtype[%
]
Cells
tested
Assignment
Cells
tested
Assigned
type>0.55
B*1306
B13
––
––
––
–B13
B*1307N
Notexpressed
Null
––
––
––
NT
B*1308
B13
––
––
––
–B13
B*1309
Undefined
––
––
––
–Notassignede
Bw6pos;NN:B13
B*1310
B13
––
–B13[100]b
2–
–Notassignede
NN:B13B15
B*1311
B13
––
–B13[100]b
1–
–B13
B*1312
B13
––
––
––
–B13
B*1313
B13
B13
––
––
B13
B*1314
B13
––
––
––
–B13
B*1315
B13
––
––
––
–B13
B*1316
B13
––
––
––
–B13
B*1317
B13
––
––
––
–B13
B*1318
B13
––
––
––
–B13
B*1319
B13
––
––
––
–B13
B*1320
B13
––
––
––
–B13
B*1401
B64
B64(14)
B14[49–58],B64
[32–43],B65
[2–10]a
8B14[72],B64[10],
B65[10]
1003
B64
11
Training–B14
B*1402
B65
B65(14)
B65[50–54],B14
[45–47],B64[1–3]a
9B14[71],B65[25],
B64[2]
2244
B65
22
Training–B14
B*1403
B14
B14c
––
B14[50],B65[35]
40
––
B14
B*1404
B14
––
–B14[67],B64[33]b
3–
–B14
B*1405
B14
––
–B14[40],blank[60]b
5B65
1B14
B*1406
B14
B14
––
B14[100]b
8–
–B14
B65
B*1407N
Notexpressed
Null
––
––
NT
B*1501
B62
B62(15)
B62[93–98]a
30
B62[96],B15[2]
1906
B62
64
Training–B15B62
B*15010102N
Notexpressed
Null
––
––
––
NT
B*1502
B75
B75(15)
B75[79–86],B15
[8–11],B62[5–12]
16
B75[62],B62[22],
B15[7]
1035
B75
18
Training–B15B75
B*1503
B72
B72(70)
B70[47–61],B72
[31–45]a
17
B70[61],B72[10],
B35[2],B62[1],
blank[11]
2569
B72
25
Training–B70B72
B*1504
B62
B62(15)
B62[90],B15[5],
B75[4]a
1B62[69],B15[10]
29
B62
1B62
B*1505
B62
B62(15)
B62[88]
1B62[64],B15[18]
22
B62
3B62
B*1506
B62
B62(15)
––
B62[81]b
13
––
B62
B*1507
B62
B62(15)
B62[93]
2B62[79]
101
B62
2Training–B15B62
ª 2009 John Wiley & Sons A/S � Tissue Antigens 73, 95–170 117
R. Holdsworth et al. HLA alleles and serologic types
Table
2Continued
HLAallele
Expert
assigned
WHO
assigned
InternationalC
ellExchange,UCLA
NMDP
IHWS13data
NN
Comments
Assignedtype[%
]Cells
tested
Assignedtype[%
]
Cells
tested
Assignment
Cells
tested
Assigned
type>0.55
B*1508
B75/B62
B75(15)
B75[30–48],B15
[19–35],B62
[6–19],B‘1508’
[11–14]
2B62[20],B15[18],
B75[18]
45
B75
3B15
B*1509
B70
B70
––
B70[53],blank[33]
65
B71
2Training–B70B71
B*1510
B71
B71(70)
B70[41–49],B71
[41–47]a
15
B70[49],B35[4],B72
[2],B71[2],B75[1],
B15[1],blank[13]
1204
B71
7Training–B70B71
B*1511
B75
B75(15)
B75[31–51],B15
[21–38],B46
[6–12],B‘1511’
[0–19]
3B62[27],B75[21],
B46[15],B15[15]
68
B75
4B15
B*1512
B76
B76(15)
B76[76–88],B45
[3–6]
5B76[29],B62[18],
B75[6],B15[29]b
17
B76
2Training–B15B76
B*1513
B77
B77(15)
B77[46–53],B63
[0–16]
2B77[21],B63[19],
B15[15],B75[12],
blank[13],B62[8],
B53[6]
116
B77
7Training–B15B77
B*1514
B76
B76(15)
B76[23],B45[20],
B15[20],B70[6],
B63[5]
1B45[80],B44[20]b
5B76
1B62
B*1515
B75/62
B62(15)
B75[43–57],B62
[31–42],B15
[8–15]a
10
B62[49],B75[28],
B15[13]
138
B75
1B15
ihw13:shortB75
B*1516
B63
B63(15)
B63[96–97]a
8B63[80],B57[3],
B15[3]
816
B63
3Training–B15B63
B*1517
B63
B63(15)
B63[92–96]
5B63[88],B15[3],
B57[1]
797
B63
11
Training–B15B63
B*1518
B71
B71(70)
B70[52–64],B71
[28–34]a
11
B70[51],blank[34],
B71[3]
552
B71
8Training–B70B71
B*1519
B76
B76(15)
B76[29],B15[19],
B45[11],B62[8],
B75[7]
1B70[50],B76[50]b
2–
–B76
B*1520
B62
B62(15)
B62[73],B15[18],
B75[5]
1B62[100]b
10
B62
1B62
ihw13:shortB62
B*1521
B75
B75(15)
B75[80–88],B15
[6–9],B62[3–10]
21
B75[55],B62[12],
B15[7]
132
B75
9Training–B15B75
118 ª 2009 John Wiley & Sons A/S � Tissue Antigens 73, 95–170
HLA alleles and serologic types R. Holdsworth et al.
Table
2Continued
HLAallele
Expert
assigned
WHO
assigned
InternationalC
ellExchange,UCLA
NMDP
IHWS13data
NN
Comments
Assignedtype[%
]Cells
tested
Assignedtype[%
]
Cells
tested
Assignment
Cells
tested
Assigned
type>0.55
B*1523
B70/B5/blank
–B‘1523’[17],B5
[14–15],B77
[7–11],B70[7–9],
B15[5–8]
2Blank[50],B70[17],
B51[17],B53[8]b
12
B‘1523’
2Notassignede
B5x70–Bw4,B5/53/
77variant;NM5;
ihw13:new
pattern,shortB71-
Bw4;NN:B70B71
B*1524
B62
B62(15)
B62[45–48],B‘1524’
[23–24],B15
[21–22],B77[4–6],
B63[2–3]
4B62[44],blank[22]
54
B62
8B15
B62Bw4
B*1525
B62
B62(15)
B62[86–94],B75
[2–10]a
10
B62[74],B75[8],
B15[7]
116
B62
1Training–B15B62
ihw13:shortB62,
shortB75
B*1526N
Notexpressed
Null
––
––
––
NT
B*1527
B62
B62(15)
B62[97]a
1B62[76],B15[7]
76
B62
2Training–B15B62
ihw13:shortB62,
shortB75
B*1528
B62
B62(15)c
––
B62[80],B15[20]b
5–
–B62
B*1529
B70
B15
B70[54–58],B15
[11–12],B71[7–10]
2Blank[71],B70[19]
21
B71
2B71
B*1530
B62
B62(15)c
B62[63–86],B75
[4–13],B15[12–19]
3B62[64],B15[17]
98
B62
3Training–B15B62
ihw13:shortB62,
shortB75
B*1531
B75
B75(15)
––
B75[38],B62[38]b
13
B75
1B75
ihw13:shortB75
B*1532
B62
B62(15)
––
B62[100]b
5–
–B62
B*1533
B62
B15
––
––
––
B62
B62
B*1534
B62
B62(15)c
––
B62[100]b
8–
–B62
Norm
alB
62
B*1535
B62
B62(15)c
B62[86–93],B75
[5–7]a
14
B62[79]
34
B62
5Training–B15B62
B*1536
Undefined
––
–B13[100]b
3–
–B15
Bw4positive,NN:
B77
B*1537
B70
B70c
B70[46],B71[11],
B78[9]
2Blank[54],B70[30]
24
––
B71
B*1538
B62
––
–B62[100]b
3–
–B62
B62variant,also
reactivewithB52
sera
B*1539
B62
B62(15)c
B62[92–98]
2B62[84],B15[13]b
38
B62
3B62
B*1540
B62/blank
––
–Blank[61],B70[10],
B62[8]
26
––
B62
ShortB62
B*1542
B15
––
––
––
–B62
ShortB15;reactive
withsomeB22sera
ª 2009 John Wiley & Sons A/S � Tissue Antigens 73, 95–170 119
R. Holdsworth et al. HLA alleles and serologic types
Table
2Continued
HLAallele
Expert
assigned
WHO
assigned
InternationalC
ellExchange,UCLA
NMDP
IHWS13data
NN
Comments
Assignedtype[%
]Cells
tested
Assignedtype[%
]
Cells
tested
Assignment
Cells
tested
Assigned
type>0.55
B*1543
B15
––
––
––
–B15f
Bw4positive,NN:
B62
B*1544
B75
––
––
––
–B75
B*1545
B62
B62(15)
––
B62[92]b
13
––
B62
B*1546
Undefined
B72(70)
––
B50[50],B72[25]b
4–
–Notassignede
NN:B15B62
B*1547
B70/blank
––
–Blank[57],B35[14]b
14
––
B72
B48,allB15sera
negative
B*1548
B62
B62(15)
––
B62[100]b
3–
–B62
B*1549
B72
––
––
––
–B72
B*1550
B62
––
––
––
–B62
B*1551
B70
B70
––
B35[100]b
1–
–B71
B*1552
Undefined
B15
––
Blank[67]b
3–
–B71
B15
B*1553
Undefined
––
––
––
–Notassignede
B*1554
B72
––
–B70[50],B72[50]b
2–
–B72
B*1555
B15
B15
––
––
––
B15f
B15Bw6;NN:B75
B*1556
B62
––
––
––
–B62
B*1557
B62
––
––
––
–B62
B*1558
B62
B62(15)
––
B62[100]b
3–
–B62
B15orB62
B*1560
B62
––
––
––
–B62
B*1561
B72
––
––
––
–B72
B*1562
Undefined
––
–B62[67]b
3–
–Notassignede
NN:B70B72
B*1563
B62
––
–B62[100]b
2–
–B62
B*1564
B71
––
––
––
–B71
B*1565
B62
––
–B62[100]b
2–
–B62
B*1566
B62
––
–B62[100]b
1–
–B62
B*1567
B63
––
––
––
–B63
Bw4positive
B*1568
Undefined
B35
––
––
––
Notassignede
NN:B70B72
B*1569
B72
––
––
––
–B72
B*1570
B62
B62(15)
––
––
B62
1B62
ihw13:shortB62,
shortB75
B*1571
B62
B62(15)
––
B62[83],B75[17]b
6–
–B62
B*1572
B71
––
––
––
–B71
B*1573
B62
B62(15)
––
B62[100]b
1–
–B62
B*1574
B72
––
––
––
–B72
B*1575
B62
––
–B62[100]b
1–
–B62
B*1576
Undefined
––
––
––
–Notassignede
NN:B15
B*1577
B62
––
––
––
–B62
B*1578
B62
B15
––
––
––
B62
120 ª 2009 John Wiley & Sons A/S � Tissue Antigens 73, 95–170
HLA alleles and serologic types R. Holdsworth et al.
Table
2Continued
HLAallele
Expert
assigned
WHO
assigned
InternationalC
ellExchange,UCLA
NMDP
IHWS13data
NN
Comments
Assignedtype[%
]Cells
tested
Assignedtype[%
]
Cells
tested
Assignment
Cells
tested
Assigned
type>0.55
B*1579N
Notexpressed
Null
––
––
––
NT
B*1580
B70
B70
––
––
––
B71
B70
B*1581
B62
––
––
––
–B62
B*1582
B62
B62(15)
––
––
––
B62
B621
A30/31
B*1583
B62
––
––
––
–B62
NN:B15
B*1584
B62
B62(15)
––
––
––
B62
B*1585
B62
––
––
––
–B62
B*1586
Undefined
––
––
––
–Notassignede
NN:B15,B62
B*1587
B15
––
––
––
–B15
B*1588
B75
––
––
––
–B75
B*1589
B77
––
––
––
–B77
B*1590
B71
––
––
––
–B71
B*1591
Undefined
––
––
––
–Notassignede
NN:B70,B72,B12
B*1592
B62
––
––
––
–B62
B*1593
B71
B71(70)
––
––
––
B71
B*1594N
Notexpressed
Null
––
––
––
NT
B*1595
B63
––
––
––
–B63
B*1596
B62
B62(15)
––
––
––
B62
B*1597
B62
––
––
––
–B62
B*1598
B72
––
––
––
–B72
B*1599
B71
––
––
––
–B71
B*9501
Undefined
––
––
––
–Notassignede
NN:B15,B46
B*9502
B62
B62(15)
––
––
––
B62
B*9503
B70
B70
––
––
––
B72
B*9504
B62
––
––
––
–B62
B*9505
B62
––
––
––
–B62
B*9506
Undefined
––
––
––
–Notassignede
NN:B15,B62
B*9507
B62
B62(15)
––
––
––
B62
B*9508
B71
B71(70)
––
––
––
B71
B*9509
B62
––
––
––
–B62
B*9510
B62
––
––
––
–B62
B*9511N
Notexpressed
Null
––
––
––
NT
B*9512
B75
B15
––
––
––
B75
B*9513
B62
––
––
––
–B62
B*9514
B70
B70
––
––
––
B71
B*9515
B70
––
––
––
–B70
B*9516
B62
––
––
––
–B62
B*9517
B62
––
––
––
–B62
ª 2009 John Wiley & Sons A/S � Tissue Antigens 73, 95–170 121
R. Holdsworth et al. HLA alleles and serologic types
Table
2Continued
HLAallele
Expert
assigned
WHO
assigned
InternationalC
ellExchange,UCLA
NMDP
IHWS13data
NN
Comments
Assignedtype[%
]Cells
tested
Assignedtype[%
]
Cells
tested
Assignment
Cells
tested
Assigned
type>0.55
B*9518
B62
––
––
––
–B62
B*9519
B71
––
––
––
–B71
B*9520
B62
––
––
––
–B62
B*9521
B75
––
––
––
–B75
B*9522
B62
––
––
––
–B62
B*9523
B72
––
––
––
–B72
B*9524
B71
––
––
––
–B71
B*9525
B62
––
––
––
–B62
B*9526
B62
––
––
––
–B62
B*9527
B72
––
––
––
–B72
B*9528
B62
––
––
––
–B62
B*9529
B62
––
––
––
–B62
B*9530
B62
––
––
––
–B62
B*9532
B72
––
––
––
–B72
B*1801
B18
B18
B18[97–100]a
12
B18[96]
1641
B18
53
Training–B18
B*1802
B18
B18
––
B18[90]
31
B18
3Training–B18
B*1803
B18
B18
––
B18[83],blank[17]
29
B18
1B18
B*1804
B18
B18c
––
B18[84],blank[11]b
19
B18
1Notassignede
NN:B18
B*1805
B18
B18
––
B18[83]b
6B18
1B18
ihw13:shortB18,
blank
B*1806
B18
B18
––
––
––
B18
B18variant,negative
withBw4andBw6
sera
B*1807
B18/blank
––
–Blank[100]b
1B18
1B18
ihw13:shortB18,
blank,B18spec
sera
negative
B*1808
B18
––
–B18[100]b
1–
–B18
B*1809
B18
B18
––
––
––
Notassignede
B18,Bw4;NN:B18,
B38
B*1810
B18
––
––
––
–B18
B*1811
B18
––
––
––
–B18
B*1812
B18
––
–B18[50],blank[50]b
2–
–B18
B*1813
B18
––
–B18[100]b
2–
–B18
B*1814
B18
––
–B18[100]b
2–
–B18
B*1815
B18
––
–B18[100]b
1–
–B18
B*1817N
Notexpressed
Null
––
––
––
NT
B*1818
B18
––
–B18[100]b
4–
–B18
B*1819
B18
––
––
––
–B18
122 ª 2009 John Wiley & Sons A/S � Tissue Antigens 73, 95–170
HLA alleles and serologic types R. Holdsworth et al.
Table
2Continued
HLAallele
Expert
assigned
WHO
assigned
InternationalC
ellExchange,UCLA
NMDP
IHWS13data
NN
Comments
Assignedtype[%
]Cells
tested
Assignedtype[%
]
Cells
tested
Assignment
Cells
tested
Assigned
type>0.55
B*1820
B18
––
––
––
–B18
B*1821
Undefined
––
––
––
–Notassignede
NN:B18
B*1822
B18
––
––
––
–B18
B*1823N
Notexpressed
Null
––
––
––
NT
B*1824
B18
––
––
––
–B18
B*1825
B18
––
––
––
–B18
B*1826
B18
––
––
––
–B18
B*2701
B27
B27
––
B27[100]b
12
––
B27
B*2702
B27
B27
B27[97]
1B27[87]
417
B27
9Training–B27
ihw13:shortB27
B*2703
B27
B27
B27[97]
1B27[88]
26
B27
5Training–B27
B*2704
B27
B27
B27[98]a
1B27[97]
31
B27
7B27
B*2705
B27
B27
B27[99–100]
6B27[99]
1194
B27
22
Training–B27
B*2706
B27
B27
B27[97–99]a
10
B27[97]
29
B27
6B27
Previouslyalso
namedB*2722
B*2707
B27
B27
––
B27[100]b
49
B27
5B27
B*2708
B2708/B27/B7
B2708
B2708[36–58],
B7[19–41],B27
[11–19]
3B27[31],B7[34],
blank[16],B2708
[9]b
32
B2708
1B27
B7variant,mostB27
sera
negative;
ihw13:alsoB73B7
blank
B*2709
B27
B27
B27[100]
1B27[100]b
15
––
B27
B*2710
B27
B27
––
B27[100]b
5–
–B27
B*2711
B27
B27
––
B27[100]b
2–
–Notassignede
B27variant,extra
reactivitywithB40
sera;NN:B27
B*2712
Undefined
B27
––
Blank[78],B60[9],
B27[4],B61[4]b
23
Blank
1Notassignede
BlankBw6;B27sera
negative,B71
27
(140)sera
positive;
ihw13:blank,B61
B27–Bw6;NN:B27
B*2713
B27
B27
––
––
––
B27
B*2714
B27
B27c
––
B27[100]b
14
––
B27
B*2715
B27
––
––
––
–B27
BlankBw4
B*2716
B27
––
––
––
–B27
ShortB27,someB40
sera
reactive
B*2717
B27
B27
––
––
––
B27
Norm
alB
27
B*2718
Undefined
––
–Blank[100]b
2–
–Notassignede
Bw6positive
B*2719
B27
B27
––
––
––
B27
Norm
alB
27
B*2720
B27
B27
––
––
––
B27
ª 2009 John Wiley & Sons A/S � Tissue Antigens 73, 95–170 123
R. Holdsworth et al. HLA alleles and serologic types
Table
2Continued
HLAallele
Expert
assigned
WHO
assigned
InternationalC
ellExchange,UCLA
NMDP
IHWS13data
NN
Comments
Assignedtype[%
]Cells
tested
Assignedtype[%
]
Cells
tested
Assignment
Cells
tested
Assigned
type>0.55
B*2721
B27
––
––
––
–B27
B*2723
Undefined
––
––
––
–Notassignede
BlankBw6,Bw4
negative/w
eak,
onlyreactivewith
few
B441
27sera
B*2724
B27
––
––
––
–B27
B*2725
B27
––
––
––
–B27
B*2726
B27
––
––
––
–B27
B*2727
B27
––
––
––
–B27
B*2728
B27
––
––
––
–B27
B*2729
B27
B27
––
––
––
Notassignede
NN:B27
B*2730
B27
B27
––
––
––
B27
B*2731
B27
––
––
––
–B27
B*2732
B27
––
––
––
–B27
B*2733
Undefined
––
––
––
–Notassignede
NN:B27,B40,B61
B*2734
B27
––
––
––
–B27
NN:B27
B*2735
B27
––
––
––
–B27
B*2736
B27
––
––
––
–B27
B*2737
B27
––
––
––
–B27
B*2738
B27
B27
––
––
––
B27
B*3501
B35
B35
B35[97–100]a
27
B35[98]
2023
B35
58
Training–B35
B*3502
B35
B35
B35[94–99]
3B35[72]
1013
B35
9Training–B35
B*3503
B35
B35
B35[95–100]
3B35[94]
1226
B35
22
Training–B35
B*3504
B35
B35
––
B35[100]
26
––
B35
B*3505
B35
B35
B35[98–99]
9B35[94]
231
B35
7Training–B35
B*3506
B35
B35
––
B35[100]b
13
––
B35
B*3507
B35
B35
––
––
––
B35
B*3508
B35
B35
B35[95–98]a
6B35[91]
345
B35
5Training–B35
B*3509
B35
B35
––
B35[100]b
3–
–B35
B*3510
B35
B35c
––
B35[77],B70[15]b
13
B35
1B35
ihw13:shortB35
B*3511
B35
B35
––
B35[88]b
16
––
B35
B*3512
B35
B35
B35[98–100]a
12
B35[78]
422
B35
2B35
B*3513
B35
B35
––
–b
––
B35
B*3514
B35
B35
B35[98]a
1B35[79]
29
––
B35
B*3515
B35
B35
––
Blank[50],B35[33]b
6–
–B35
ShortB35,B75CREG
sera
reactive
B*3516
B35
B35c
B35[63],B70[20]
2B35[33],blank[34]
41
B35
1B35
ihw13:shortB35
B*3517
B35
B35
B35[97–100]
9B35[93]
261
B35
2Training–B35
124 ª 2009 John Wiley & Sons A/S � Tissue Antigens 73, 95–170
HLA alleles and serologic types R. Holdsworth et al.
Table
2Continued
HLAallele
Expert
assigned
WHO
assigned
InternationalC
ellExchange,UCLA
NMDP
IHWS13data
NN
Comments
Assignedtype[%
]Cells
tested
Assignedtype[%
]
Cells
tested
Assignment
Cells
tested
Assigned
type>0.55
B*3518
B35
B35
––
B35[100]b
1–
–B35
B*3519
B35/blank
B35
––
B35[40],B70[20],
B77[20]b
5Blank
2B35
ihw13:new
pattern,
blank,very
short
B35
B*3520
B35
B35
––
B35[42],blank[13]
23
B35
5B35
B*3521
B35/B78
––
–B35[42],B78[33],
blank[25]b
12
B78
1B35
ihw13:B35/78variant
B*3522
B35
––
–B35[100]b
2–
–B35
B*3523
B35
B35c
B35[84–88]
4B35[92]b
13
B35
1B35
B*3524
B35
––
–B35[75],B78[25]b
8–
–B35
B*3525
B35
B35c
––
B35[33],blank[67]b
3B35
1B35
ihw13:shortB35
B*3526
B35
––
––
––
–B35
B*3527
B35
B35
––
B35[100]b
2–
–B35
B*3528
B35
––
–B35[50],blank[43]b
14
––
B35
B*3529
B35
B35
––
B35[100]b
2–
–B35
B*3530
B35
B35
––
B35[100]b
7–
–B35
Norm
alB
35
B*3531
B35
––
–Blank[67],B61[17],
B48[17]b
6B35
1B35
ihw13:shortB35;
reactivewithfew
B40andB35sera,
Korean
B*3532
B35
B35
––
B35[100]b
2–
–B35
B*3533
B35
––
––
––
–B35
B*3534
B35
––
–B35[100]b
1–
–B35
B*3535
B35
B35
––
––
––
B35
B*3536
B35
––
–B35[100]b
1–
–B35
B*3537
B35
––
–B35[100]b
1–
–B35
B*3538
B35
––
–bd
1–
–B35
B*3539
B35
––
––
––
–B35
B*3540N
Notexpressed
Null
––
––
––
NT
B*3541
B35
B35
––
B35[100]b
3–
–B35
B*3542
B35
B35
––
––
––
B35
Norm
alB
35
B*3543
B35
B35
B35[95–97]a
3B35[63],B70[12]
379
B35
2Notassignede
PreviouslyB*1522;
NN:B35
B*3544
Undefined
B35
––
––
––
Notassignede
PreviouslyB*1559
B*3545
B35
––
––
––
–B35
B*3546
B35
B35
––
––
––
B35
B*3547
B35
––
–B35[100]b
1–
–B35
B*3548
B35
––
––
––
–B35
ª 2009 John Wiley & Sons A/S � Tissue Antigens 73, 95–170 125
R. Holdsworth et al. HLA alleles and serologic types
Table
2Continued
HLAallele
Expert
assigned
WHO
assigned
InternationalC
ellExchange,UCLA
NMDP
IHWS13data
NN
Comments
Assignedtype[%
]Cells
tested
Assignedtype[%
]
Cells
tested
Assignment
Cells
tested
Assigned
type>0.55
B*3549
B35
––
–B35[100]b
1–
–B35
B*3550
B35
B35
––
––
––
B35
B*3551
B35
B35
––
––
––
B35
B*3552
B35
B35
––
––
––
B35
B*3553N
Notexpressed
Null
––
––
––
NT
B*3554
B35
––
––
––
–B35
B*3555
B35
B35
––
––
––
B35
B*3556
B35
––
––
––
–B35
B*3557
B35
B35
––
––
––
B35
B*3558
B35
––
––
––
–B35
B*3559
B35
––
––
––
–B35
B*3560
B35
B35
––
––
––
Notassignede
NN:B35
B*3561
B35
B35
––
––
––
B35
B*3562
B35
––
––
––
–B35
B*3563
Undefined
––
––
––
–Notassignede
NN:B40
B*3564
B35
––
––
––
–B35
B*3565Q
B35
––
––
––
–B35
Notexpectedto
be
expressed
B*3566
B35
––
–Blank[100]b
1–
–B35
B*3567
Undefined
––
––
––
–Notassignede
NN:B35
B*3568
B35
––
––
––
–B35
B*3569
B35
––
––
––
–B35
B*3570
B35
B35
––
––
––
B35
B*3571
B35
––
––
––
–B35
B*3572
B35
––
––
––
–B35
B*3573
B35
––
––
––
–B35
B*3574
B35
––
––
––
–B35
B*3575
B35
––
––
––
–B35
B*3576
B35/22
B35/22
––
––
––
B22f
NN:B56
B*3577
B35
––
––
––
–B35
B*3701
B37
B37
B37[98–100]a
6B37[93]
1721
B37
27
Training–B37
B*3702
B37/B27
––
–B27[33],blank[33],
B37[17],B47[17]b
6–
–Notassignede
B37x27orblank;few
B37andfew
B27
sera
reactive;NN:
B37
B*3703N
Notexpressed
Null
––
––
––
NT
126 ª 2009 John Wiley & Sons A/S � Tissue Antigens 73, 95–170
HLA alleles and serologic types R. Holdsworth et al.
Table
2Continued
HLAallele
Expert
assigned
WHO
assigned
InternationalC
ellExchange,UCLA
NMDP
IHWS13data
NN
Comments
Assignedtype[%
]Cells
tested
Assignedtype[%
]
Cells
tested
Assignment
Cells
tested
Assigned
type>0.55
B*3704
B37
B37c
––
B37[50],blank[50]b
2B37
1B37
B37variant,reactive
withfew
B37and
B18sera
B*3705
Blank
––
––
––
–Notassignede
BlankBw6,B37,and
Bw4sera
negative,
Korean;NN:B37
B*3706
B37
––
––
––
–B37
B*3707
Undefined
––
––
––
–Notassignede
B*3708
B37
B37
––
––
––
B37
B*3709
B37
B37
––
––
––
Notassignede
NN:B37
B*3710
B37
B37
––
––
––
B37
B*3711
Undefined
––
––
––
–Notassignede
NN:B37
B*3712
B37
––
––
––
–B37
B*3713
B37
––
––
––
–B37
B*3801
B38
B38(16)
B38[96–100]a
14
B38[94],B16[1],
B39[1]
2317
B38
43
Training–B16B38
B*3802
B38
B38(16)
B38[91–99]a
15
B38[87],B39[2],
B16[2]
788
B38
15
Training–B16B38
ihw13:differentfrom
B*3801
B*3803
B38
B16
––
Blank[100]b
1–
–Notassignede
B16Bw4,B38,and
B39sera
negative;
NN:B16B38
B*3804
B38
––
––
––
–B38
B*3805
B38
B38(16)
––
––
––
B38
Norm
alB
38
B*3806
B38
––
––
––
–B38
B*3807
B38
––
––
––
–B38
B*3808
B38
––
––
––
–B38
B*3809
B38
B16c
––
––
––
B38
B16–Bw4,oncell
VOATer299
B*3810
B38
––
––
––
–B38
B*3811
B38
––
––
––
–B38
B*3812
B38
B38(16)
––
––
––
B38
B*3813
B38
––
––
––
–B38
B*3814
B38
––
––
––
–B38
B*3815
B38
B38(16)
––
––
––
B38
B*3816
B38
––
––
––
–B38
B*3901
B3901/B39
B3901
B39[96–99]a
7B39[95]
476
B39
21
Training–B16B39
B*39010102L
Low
B39
Low
B39
––
––
IdenticaltoB*3901
ª 2009 John Wiley & Sons A/S � Tissue Antigens 73, 95–170 127
R. Holdsworth et al. HLA alleles and serologic types
Table
2Continued
HLAallele
Expert
assigned
WHO
assigned
InternationalC
ellExchange,UCLA
NMDP
IHWS13data
NN
Comments
Assignedtype[%
]Cells
tested
Assignedtype[%
]
Cells
tested
Assignment
Cells
tested
Assigned
type>0.55
B*3902
B3902/B39
B3902
B39[97–99]a
7B39[87]
96
B39
5Notassignede
ihw13:shortB39;N
N:
B16B39
B*3903
B39
B39(16)
––
B39[89]
19
B39
1B39
B*3904
B39
B39(16)
––
–b
––
B39
B*3905
B39
B39c
B39[89–92],B16
[4–7],B38[1–5]a
17
B39[82]
245
B39
4B39
B39variant,ST-16;
ihw13:B39and
B38sera
positive
B*3906
B39
B39(16)
B39[96–99]
6B39[94]
508
B39
8Training–B16B39
B*3907
B16
––
–Blank[100]b
1–
–B16
B*3908
B39
B39(16)
B39[86–91],B16
[3–5]
4B39[48],blank[41]
57
B39
1Notassignede
ihw13:B39andB38
sera
positive;NN:
B16
B*3909
B39
B39(16)
B39[96–99]
6B39[100]b
29
B39
2B39
B*3910
B39
B39(16)
B39[98]a
4B39[82],blank[16]
127
B39
5B39
B*3911
B39
B39(16)c
––
B39[79],blank[14]b
29
––
B39
B*3912
B39
B39(16)
––
B39[100]b
1B39
1B39
B*3913
B39
B39(16)
––
B39[40],blank[40]b
5–
–Notassignede
NN:B16,B39
B*3914
B39
––
–B39[100]b
4–
–B39
B*3915
B39
B39(16)c
––
B39[100]b
6B39
1B39
B*3916
B39
––
––
––
–B39
B*3917
B39
––
–B39[100]b
1–
–Notassignede
NN:B39,B16
B*3918
B39
––
––
––
–B39
B*3919
B39
B39(16)c
––
Blank[100]b
1B39
1B39
B*3920
B39
–B39[73],B16[16]a
1Blank[67],B38[33]b
3–
–B16f
NN:B38
B*3922
B39
––
–bd
1–
–B39
B*3923
B39
B39(16)
––
––
––
Notassignede
NN:B16,B39
B*3924
B39
B39(16)
––
B39[97]b
30
B39
1B39
Norm
alB
39
B*3925N
Notexpressed
Null
––
––
––
NT
B*3926
B39
––
––
––
–B39
B*3927
B39
B39(16)
––
––
––
B39
Norm
alB
39
B*3928
B39
––
––
––
–B39
B*3929
B39
––
––
––
–B39
B*3930
B39
––
––
––
–B39
B*3931
B39
––
–B39[100]b
2–
–B39
B*3932
B16
––
––
––
–B16f
NN:B39
B*3933
B39
––
––
––
–B39
B*3934
B39
B39(16)
––
––
––
B39
B*3935
B39
––
–B39[100]b
1–
–B39
128 ª 2009 John Wiley & Sons A/S � Tissue Antigens 73, 95–170
HLA alleles and serologic types R. Holdsworth et al.
Table
2Continued
HLAallele
Expert
assigned
WHO
assigned
InternationalC
ellExchange,UCLA
NMDP
IHWS13data
NN
Comments
Assignedtype[%
]Cells
tested
Assignedtype[%
]
Cells
tested
Assignment
Cells
tested
Assigned
type>0.55
B*3936
Undefined
––
––
––
–Notassignede
NN:B39,B16,B14
B*3937
B39
––
––
––
–B39
B*3938Q
B39
––
––
––
–B39
Notexpectedto
be
expressed
B*3939
B39
––
––
––
–B39
B*3940N
Notexpressed
Null
––
––
––
NT
B*3941
B39
B39(16)
––
––
––
B39
B*3942
B39
––
––
––
–B39
B*4001
B60
B60(40)
B60[96–98]a
37
B60[93],B40[4],
B61[2]
3854
B60
48
Training–B40B60
B*4002
B61
B61(40)
B61[75–95],B40
[3–19],B60[2–21]a
24
B61[80],B60[8],
B40[6]
1460
B61
33
Training–B40B61
B*4003
B61
B61(40)c
––
B61[62],B60[23]
31
B61
1B61
B*4004
B61
B61(40)c
––
B61[47],B60[12]
57
B61
3B61
B*4005
B4005/B50
B4005
B4005[41–57],B50
[28–36],B21[5–9]
3B50[34],B4005[12],
blank[23],B61[7],
B70[4],B21[4],
B60[4]
293
––
B61
BN21,B21variant
B*4006
B61
B61(40)
B61[87–90],B40[4],
B60[4–8]a
6B61[75],B60[5],
B40[5]
585
B61
17
Training–B40B61
B*4007
B60
B60(40)c
––
B60[100]b
12
––
B60
B‘Fu’
B*4008
B61/blank
–B61[20–27],B40
[20–30],B‘4008’
[9–10],B48[2–14]
3Blank[71],B61[12],
B40[9]
138
B61
2B61
B40x48variant,only
reactivewithsome
B401
48(1
7)
CREGsera
B*4009
B61
B61(40)
––
B61[60],B40[20]b
5B61
1B61
B*4010
B60
B60(40)
B60[75–93],B40
[14–15],B61[3–8],
B48[2–3]a
10
B60[43],B61[25],
B40[14],blank
[11]b
28
B60
2B60
ShortB60,B48like
B*4011
B61
B61(40)c
––
B61[71],B60[26]b
38
B61
2B61
B*4012
B60/B48
–B48[28–34],B70[7–
20],B40[11],B72
[10],B‘4012’[8],
B61[5]
3B48[37],B60[26],
blank[21],B40
[16]b
19
––
Notassignede
B48x70,some
reactivitywithB40
148andB151
70
CREGsera;NN:
B48
B*4013
Undefined
––
–Blank[100]b
1–
–Notassignede
B40Bw4;NN:B61
B40
B*4014
B60
B60(40)
––
B60[100]b
3–
–B40f
NN:B60
ª 2009 John Wiley & Sons A/S � Tissue Antigens 73, 95–170 129
R. Holdsworth et al. HLA alleles and serologic types
Table
2Continued
HLAallele
Expert
assigned
WHO
assigned
InternationalC
ellExchange,UCLA
NMDP
IHWS13data
NN
Comments
Assignedtype[%
]Cells
tested
Assignedtype[%
]
Cells
tested
Assignment
Cells
tested
Assigned
type>0.55
B*4015
Undefined
––
––
––
–Notassignede
NN:B41
B*4016
B61
B61(40)
––
B61[58],B60[25],
B40[17]b
12
––
Notassignede
NN:B40,B41
B*4018
B61
––
–B61[100]b
1–
–B61
B*4019
B61
––
––
–B‘4019’
1Notassignede
B40Bw4,B*4002
withBw4epitope;
ihw13:new
pattern
shortB61Bw4
positive;NN:B61,
B40
B*4020
B61
B61(40)c
––
B61[77],B60[8],
B40[8]b
13
B61
1B61
B*4021
B40/B15
––
––
––
–Notassignede
B40x15,reactivewith
B401
48,B
151
57
sera,notwithB40
113sera;N
N:B
15,
B48
B*4022N
Notexpressed
Null
––
––
––
NT
B*4023
B40
––
––
––
–B40f
NN:B60
B*4024
B61
––
––
––
–B61
B*4025
B40
––
––
––
–B60
ShortB40,few
B40
sera
reactive
B*4026
B21
B21
––
––
––
B40f
NN:B61
B*4027
B61
B61(40)
––
B61[68],B60[26]b
19
––
B61
Norm
alB
61
B*4028
Undefined
––
––
––
–Notassignede
NN:B40,B61
B*4029
B61
B61(40)
––
––
B61
1B61
B*4030
B60
––
––
–B60
1B60
ihw13:B61withfew
B60sera
pos
B*4031
B60
B60(40)
––
bd
1–
–B60
Norm
alB
60
B*4032
B40
––
–B60[50],B61[50]b
2–
–Notassignede
NN:B40,B41
B*4033
B60
––
––
––
–B60
B*4034
B60
B60(40)
––
––
––
B60
B*4035
B61
B61(40)
––
––
––
B61
ShortB40,B60sera
negative
B*4036
B60
––
––
––
–B60
B*4037
B61
––
–B61[100]b
1–
–B61
B*4038
B60
––
––
––
–B60
B*4039
B61/B41
B41
––
––
––
B61
130 ª 2009 John Wiley & Sons A/S � Tissue Antigens 73, 95–170
HLA alleles and serologic types R. Holdsworth et al.
Table
2Continued
HLAallele
Expert
assigned
WHO
assigned
InternationalC
ellExchange,UCLA
NMDP
IHWS13data
NN
Comments
Assignedtype[%
]Cells
tested
Assignedtype[%
]
Cells
tested
Assignment
Cells
tested
Assigned
type>0.55
B*4040
B61
––
–B61[100]b
1–
–B61
B*4042
B60
––
––
––
–B60
B*4043
B60
––
––
––
–B60
B*4044
B61
––
––
––
–B61
B*4045
B60
––
––
––
–B60
B*4046
B60
––
––
––
–B60
B*4047
B40
B40
––
––
––
Notassignede
B40Bw4;shortB60,
Bw4pos:NN:B40,
B60
B*4048
B60
B60(40)
––
––
––
B60
B*4049
B60
––
––
––
–B60
B*4050
B61
B61(40)
––
––
––
B61
B*4051
Undefined
––
––
––
–Notassignede
NN:B40
B*4052
B60
B60(40)
––
––
––
B60
B*4053
B61
B61(40)
––
––
––
B61
B*4054
B60
B60(40)
––
––
––
B60
B*4055
B60
––
––
––
–B60
B*4056
B61
B61(40)
––
––
––
B61
B*4057
B61
––
––
––
–B61
B*4058
B40
––
––
––
–B40
B*4059
B40
––
––
––
–B40f
NN:B60
B*4060
Undefined
––
––
––
–Notassignede
NN:B60,B40
B*4061
B60
––
––
––
–B60
B*4062
B60
––
––
––
–B60
B*4063
B60
––
––
––
–B60
B*4064
B61
B40
––
––
––
B61
B*4065
B60
––
––
––
–B60
B*4066
B60
––
––
––
–B60
B*4067
B60
––
––
––
–B60
B*4068
Undefined
––
––
––
–Notassignede
NN:B40,B61
B*4069
B60
––
––
––
–B60
B*4070
B61
B61(40)
––
––
––
B61
B*4071
B61
––
––
––
–B61
B*4072
B60
––
––
––
–B60
B*4073
B60
––
––
––
–B60
B*4074
B60
––
––
––
–B60
B*4075
B61
––
––
––
–B61
B*4076
B60
––
––
––
–B60
ª 2009 John Wiley & Sons A/S � Tissue Antigens 73, 95–170 131
R. Holdsworth et al. HLA alleles and serologic types
Table
2Continued
HLAallele
Expert
assigned
WHO
assigned
InternationalC
ellExchange,UCLA
NMDP
IHWS13data
NN
Comments
Assignedtype[%
]Cells
tested
Assignedtype[%
]
Cells
tested
Assignment
Cells
tested
Assigned
type>0.55
B*4077
B60
––
––
––
–B60
B*4101
B41
B41
B41[91–95]a
7B41[87]
543
B41
14
Training–B41
B*4102
B41
B41
B41[91–95]
9B41[87]
478
B41
16
Training–B41
B*4103
B41
B41
––
B41[92]b
13
––
B41
B*4104
B41
––
––
––
–B41
B*4105
B41
––
––
––
–B41
ShortB41,Bw6sera
negative
B*4106
B41
––
––
––
–B41
B*4107
B41
––
––
––
–B41
B*4108
B41
––
––
––
–B41
B*4201
B42
B42
B42[89–97]a
12
B42[93],B55[1],B7
[1]
1015
B42
9Training–B42
B*4202
B42
B42
B42[87–96],B67
[0–12]
6B42[95]
80
B42
2Training–B42
B*4204
B42
––
––
––
–B42
B*4205
B42
––
–Blank[100]b
1–
–B42
B*4206
B42
––
––
––
–B42
B*4207
Undefined
––
––
––
–Notassignede
NN:B42,B8
B*4208
B42
––
––
––
–B42
B*4209
B42
––
––
––
–B42
B*4402
B44
B44(12)
B44[99–100]
–B44[98]
6959
B44
55
Training–B12B44
B*44020102S
Seecomment
Soluble
––
––
––
IdenticaltoB*4402
Secretedmolecule
only(reference:62)
B*4403
B44
B44(12)
B44[97–100]a
30
B44[94]
2854
B44
65
Training–B12B44
B*4404
B44
B44(12)
––
B44[65]
42
B44
7B44
ihw13:shortB44
B*4405
B44
B44(12)
––
B44[92]
130
B44
1B44
B*4406
B44
B44(12)
––
B44[46],blank[31]b
13
B44
7Notassignede
ShortB44orblank;
ihw13:blank,short
B44;NN:B44,B12
B*4407
B44
B44(12)
––
B44[100]b
3–
–B44
B*4408
B44
B44(12)
––
B44[100]b
3B44
3B44
ShortB44;also
reactivewithB621
631
57sera,in
Welsh,butvery
rare;ihw13:new
pattern
132 ª 2009 John Wiley & Sons A/S � Tissue Antigens 73, 95–170
HLA alleles and serologic types R. Holdsworth et al.
Table
2Continued
HLAallele
Expert
assigned
WHO
assigned
InternationalC
ellExchange,UCLA
NMDP
IHWS13data
NN
Comments
Assignedtype[%
]Cells
tested
Assignedtype[%
]
Cells
tested
Assignment
Cells
tested
Assigned
type>0.55
B*4409
B45
B45(12)c
––
B45[92]b
12
B45
1B12
B44Bw6,willbe
typedasB45or
B12;m
ostB44-and
B45-specificsera
negative
B*4410
B44
B44(12)c
––
B44[70]
37
––
B12f
NN:B44
B*4411
B44
––
–B44[100]b
2–
–B44
B*4412
B44
B44(12)
––
––
––
B44
B*4413
B44
B44(12)
––
––
––
B44
B*4414
B44
B44(12)
––
––
––
B44
ShortB44
B*4415
B12
B12
––
––
––
B45
B45Bw4,willbe
typedasB44orB12
B*4416
B47/B44
B47
B47[52],B44[12]
1–
––
–B44
B44x47,reactivewith
mostB47andfew
B44/12sera
B*4417
B44
B44(12)
––
B44[100]b
1–
–B44
B*4418
B44
––
–B44[100]b
1–
–B12f
NN:B49
B*4419N
Notexpressed
Null
––
––
––
NT
B*4420
B44
––
–B44[100]b
1–
–B44
B*4421
B44
––
–B44[100]b
1B44
2B44
ihw13:blankorvery
shortB44
B*4422
B44
––
–B44[100]b
1–
–B44
B*4423N
Notexpressed
Null
––
––
Blank
1NT
B*4424
B44
––
––
––
–B44
B*4425
B44
––
–B44[100]b
1–
–B44
B*4426
B44
––
––
––
–B44
B*4427
B44
B44(12)
––
B44[100]b
30
––
B44
ShortB44
B*4428
B44
––
––
––
–B44
B*4429
B44
B44(12)c
––
B44[100]b
2–
–B44
Norm
alB
44
B*4430
B44
––
––
––
–B44
B*4431
B44
B44(12)
––
––
––
Notassignede
Alm
ostnorm
alB
44;
NN:B60,B40,B12
B*4432
B44
B44(12)
––
––
––
B44
ShortB44
B*4433
B44
––
––
––
–B44
B*4434
B44
––
––
––
–B44
B*4435
B44
––
––
––
–B44
Norm
alB
44
B*4436
B44
––
––
––
–B44
B*4437
B44
––
–bd
2–
–B44
ª 2009 John Wiley & Sons A/S � Tissue Antigens 73, 95–170 133
R. Holdsworth et al. HLA alleles and serologic types
Table
2Continued
HLAallele
Expert
assigned
WHO
assigned
InternationalC
ellExchange,UCLA
NMDP
IHWS13data
NN
Comments
Assignedtype[%
]Cells
tested
Assignedtype[%
]
Cells
tested
Assignment
Cells
tested
Assigned
type>0.55
B*4438
B44
––
––
––
–B44
B*4439
B44
––
––
––
–B44
B*4440
B44
B44(12)
––
––
––
B44
B*4441
B44
––
––
––
–B44
B*4442
Undefined
B21
––
––
––
B44
B*4443
B44
B44(12)
––
––
––
B44
B*4444
B44
––
––
––
–B44
B*4445
B44
––
––
––
–B44
B*4446
B12
––
––
––
–B12
B*4447
B44
––
––
––
–B44
B*4448
B44
––
––
––
–B44
B*4449
B44
––
––
––
–B44
B*4450
B44
––
––
––
–B44
B*4451
B44
––
––
––
–B44
B*4452N
Notexpressed
Null
––
––
––
NT
B*4453
B44
B44(12)
––
––
––
B44
B*4454
B44
B44(12)
––
––
––
B44
B*4501
B45
B45(12)
B45[96–99]
7B45[93],B12[1],
B44[1],B50[1]
2307
B45
16
Training–B12B45
B*4502
B45
––
–B45[100]b
3–
–B45
B*4503
B45
––
––
––
–B45
B*4504
B21
––
––
––
–B21f
NN:B50
B*4505
B45
––
––
––
–B45
B*4506
B45
––
–B45[100]b
1–
–B12f
NN:B45
B*4507
B45
––
––
–B45
B*4601
B46
B46
B46[91–97]a
17
B46[58],blank[27],
B62[1],B35[1]
1487
B46
30
Training–B46
B*4602
B46
B46
––
––
––
B46
B46variant,negative
withB461
75sera
B*4603
B46
B46
––
––
––
B46
B*4604
B46
B46
––
––
––
B46
B*4605
B46
B46
––
––
––
B46
B*4606
Undefined
––
––
––
–Notassignede
NN:B46,B81
B*4607N
Notexpressed
Null
––
––
––
NT
B*4608
B46
––
––
––
–B46
B*4609
B46
––
––
––
–B46
B*4610
B46
––
––
––
–B46
B*4611
B22
––
––
––
–B22
134 ª 2009 John Wiley & Sons A/S � Tissue Antigens 73, 95–170
HLA alleles and serologic types R. Holdsworth et al.
Table
2Continued
HLAallele
Expert
assigned
WHO
assigned
InternationalC
ellExchange,UCLA
NMDP
IHWS13data
NN
Comments
Assignedtype[%
]Cells
tested
Assignedtype[%
]
Cells
tested
Assignment
Cells
tested
Assigned
type>0.55
B*4701
B47
B47
B47[90–96]
3B47[50],B27[5],
blank[32]
311
B47
12
Training–B47
B*4702
B47
B47
––
B47[40],blank[40],
B60[20]b
5B61
1Notassignede
B47Bw6,B
471
131
27sera
negative,
B401
131
47sera
positive;NN:B47
B*4703
B47
B47
B47[70–77],B60
[4–9],B61[7–8],
B40[6–7]
2Blank[33],B47[17],
B13[17],B40[17],
B61[17]b
6B47
1B47
B47Bw4,B471
13
sera
negative,B40
113sera
positive
B*4704
Undefined
––
––
––
–Notassignede
NN:B47
B*4705
B17
––
––
––
–B47
B*4801
B48
B48
B48[90–100]a
26
B48[78],B60[6],
B61[2],B40[2]
610
B48
11
Training–B48
B*4802
B48/B70
B48
––
Blank[44],B35[16],
B70[13],B48[3]
39
B71
2Notassignede
B71like;ihw13:
pattern
identicalto
B*1510;NN:B35
B*4803
B48
B48c
B48[97]a
1B48[66],B60[13]
32
B48
1B48
B*4804
B48
B48
––
B48[50],B40[25]b
4–
–B48
Norm
alB
48
B*4805
B48
B48
––
––
––
Notassignede
NN:B48,B7
B*4806
Undefined
––
––
––
–Notassignede
NN:B48
B*4807
B48
B48
––
B60[42],B48[33],
B61[8]b
12
B48
2B48
B*4808
Undefined
––
––
––
–Notassignede
NN:B7,B48
B*4809
B48
B48
––
––
––
B48
B*4810
B48
B48
––
––
––
B48
B*4811
B48
––
––
––
–B48
B*4812
B48
––
––
––
–B48
B*4813
Undefined
––
––
––
–Notassignede
NN:B48,B61
B*4814
B48
––
––
––
–B48
B*4815
B48
––
––
––
–B48
B*4816
B48
––
––
––
–B48
B*4817
Undefined
B48/40
––
––
––
Notassignede
NN:B48
B*4818
B48
––
––
––
–B48
B*4901
B49
B49(21)
B49[94–98]a
6B49[94],B50[1],
B21[1]
3002
B49
22
Training–B21B49
B*4902
B49
B49(21)
––
B49[100]b
6–
–B49
Norm
alB
49
B*4903
B49
––
––
–B49
1Notassignede
ShortB49;NN:
B49,B21
ª 2009 John Wiley & Sons A/S � Tissue Antigens 73, 95–170 135
R. Holdsworth et al. HLA alleles and serologic types
Table
2Continued
HLAallele
Expert
assigned
WHO
assigned
InternationalC
ellExchange,UCLA
NMDP
IHWS13data
NN
Comments
Assignedtype[%
]Cells
tested
Assignedtype[%
]
Cells
tested
Assignment
Cells
tested
Assigned
type>0.55
B*4904
B49
––
––
––
–B49
B*4905
B49
B49(21)
––
––
––
B49
B*5001
B50
B50(21)
B50[92–97]a
12
B50[85],B21[3],
B49[2],B45[1]
1700
B50
20
Training–B21B50
B*5002
B45
B45(12)
B45[87–91],B50[7],
B44[5]a
2B45[96]
79
B45
3TrainingB12B45
B*5004
B50
B50(21)
––
B50[67]b
3–
–B50
B*5101
B51
B51(5)
B51[96–99]
40
B51[96],B5[2],
B52[1]
1899
B51
88
Training–B5B51
B*5102
B5102/B51
B5102
B51[38–57],B5102
[21–33],B53
[8–16],B5[4–7],
B52[3–7]
11
B51[73],B53[11],
B52[6],B5102[3],
B5[3]
218
B5102
5B51
ihw13:shortB51with
someB351
53
sera
reactive
B*5103
B5103/B51
B5103
––
B51[100]b
3–
–B51
B*5104
B51
B51(5)c
––
B51[75],B52[12],
B5[12]b
8B51
1B51
B*5105
B51
B51(5)
B51[45],B53[33],
B5[3],B52[3]
1B51[48],B53[24],
B52[16]
25
B51
3B51
ihw13:B5102,short
B51withsomeB35
153sera
reactive
B*5106
B51
B51(5)
B51[82–88],B53
[1–4],B52[0–4],
B5102[0–3]a
5B51[64],B53[12],
B52[7]
42
B51
5B51
B5,mostB51sera
negative;ihw13:
shortB51,distinct
pattern
B*5107
B51
B51(5)
––
B51[78],B52[9]
68
B51
3Training–B5B51
ihw13:shortB51,
distinctpattern
B*5108
B51
B51(5)
B51[96–99]a
3B51[77],B53[4]
154
B51
4Training–B5B51
B*5109
B51
B51(5)
––
B51[86]
43
––
Training–B5B51
B*5110
B51
––
–Blank[100]b
2B51
1B51
ihw13:B5102,short
B51withsomeB35
153sera
reactive
B*5111N
Notexpressed
Null
––
––
––
NT
B*5112
B51/blank
––
––
––
–B51
B‘blank’,possiblynot
expressed
B*5113
B51
–B51[95–98]a
2B51[100]b
7–
–B51
B*5114
B51
B51(5)c
––
B51[88],B5[12]b
17
B51
1B51
B*5115
Undefined
––
––
––
–Notassignede
NN:B59
B*5116
B51
B5
––
B51[100]b
1–
–B51
B*5117
B51
B51(5)
––
––
––
B51
136 ª 2009 John Wiley & Sons A/S � Tissue Antigens 73, 95–170
HLA alleles and serologic types R. Holdsworth et al.
Table
2Continued
HLAallele
Expert
assigned
WHO
assigned
InternationalC
ellExchange,UCLA
NMDP
IHWS13data
NN
Comments
Assignedtype[%
]Cells
tested
Assignedtype[%
]
Cells
tested
Assignment
Cells
tested
Assigned
type>0.55
B*5118
B51
B51(5)
––
––
––
B51
B*5119
B51
––
––
––
–B51
B*5120
B51
––
––
––
–B51
B*5121
B51
––
–B51[100]b
1–
–B51
B*5122
B51
––
–B51[100]b
2–
–B51
B*5123
B51
––
–d
2–
–B51
B*5124
B51
B51(5)
––
––
B51
1B51
B*5126
B51
––
––
––
–B51
B*5127N
Notexpressed
Null
––
––
––
NT
B*5128
B51
B51(5)
––
––
B51
1B51
B*5129
B51
B51(5)
––
B51[100]b
1–
–B51
B*5130
B51
––
––
––
–B51
B*5131
B51
B51(5)
––
d1
––
B51
B*5132
B51
––
––
––
–B51
B*5133
B51
––
––
––
–B51
B*5134
B51
––
––
––
–B51
B*5135
B51
B51(5)
––
––
––
B51
B*5136
B51
––
––
––
–B51
B*5137
B51
––
––
––
–B51
B*5138
B51
––
––
––
–B51
B*5139
B51
––
––
––
–B51
B*5140
B51
––
––
––
–B51
B*5141N
Notexpressed
Null
––
––
––
NT
B*5142
Undefined
B44(12)
––
––
––
Notassignede
NN:B44,B12,B53
B*5143
B51
B51(5)
––
––
––
B51
B*5144N
Notexpressed
Null
––
––
––
NT
B*5145
Undefined
––
––
––
–Notassignede
NN:B5,B51
B*5146
B51
B51(5)
––
––
––
B51
B*5147
B51
––
––
––
–B51
B*5148
B51
––
––
––
–B51
B*5149
B51
––
––
––
–B51
B*5201
B52
B52(5)
B52[93–95]
13
B52[82],B51[7],
B5[2],B53[1]
2823
B52
32
Training–B5B52
B*5202
B52
––
–B52[100]b
2–
–B52B15
B*5203
B52
––
–B52[100]b
1–
–B52
B*5204
B52
B52(5)
B52[76],B5[11]
1–
––
–B52
Norm
alB
52
B*5205
B52
––
––
––
–B52
B*5206
B52
––
––
––
–B52
ª 2009 John Wiley & Sons A/S � Tissue Antigens 73, 95–170 137
R. Holdsworth et al. HLA alleles and serologic types
Table
2Continued
HLAallele
Expert
assigned
WHO
assigned
InternationalC
ellExchange,UCLA
NMDP
IHWS13data
NN
Comments
Assignedtype[%
]Cells
tested
Assignedtype[%
]
Cells
tested
Assignment
Cells
tested
Assigned
type>0.55
B*5207
B52
B52(5)
––
––
––
B52
B*5208
B52
B52(5)
––
––
––
B52
B*5209
B52
––
––
––
–B52
B*5210
B52
––
––
––
–B52
B*5211
B52
––
––
––
–B52
B*5301
B53
B53
B53[91–94]a
25
B53[86],B35[5],
B51[1]
3054
B53
20
Training–B53
B*5302
B53
––
–B53[83]b
6–
–B53
B*5303
B53/B35
––
–B35[100]b
2–
–Notassignede
NN:B35,B53
B*5304
B53
––
–B53[100]b
2–
–B53
LongB53,someB5
sera
reactive
B*5305
B53
––
–B53[100]b
3–
–B53
B*5306
B53/B51
––
––
–B51
1B53
B53x51,longB53,
extrareactivitywith
someB51sera
B*5307
B53
B53
––
––
––
Notassignede
B53x37,reactivewith
someB37CREG
sera;NN:B51,B5
B*5308
B53
––
––
––
–B53
B*5309
B53
––
––
––
–B53
B*5310
B53
––
–B53[100]b
1–
–B53
B*5311
B53
B53
––
––
––
B53
B*5312
B53
––
––
––
–B53
B*5313
B53
––
––
––
–B53
B*5401
B54
B54(22)
B54[88–94]a
8B54[67],B55[10],
B22[3],B56[2],
blank[9]
631
B54
20
Training–B22B54
B*5402
B54
B54(22)
––
––
––
B54
B*5403
B22
––
––
––
–B54B56
B*5404
B54
––
––
––
–B54
B*5405N
Notexpressed
Null
––
––
––
NT
B*5406
Undefined
––
––
––
–Notassignede
NN:B22
B*5407
B54
––
––
––
–B54
B*5408N
Notexpressed
Null
––
––
––
NT
B*5409
Undefined
––
––
––
–Notassignede
NN:B54,B22
B*5410
B54
––
––
––
–B54
B*5411
B54
B54(22)
––
––
––
B54
B*5412
Undefined
––
––
––
–Notassignede
NN:B54,B22
138 ª 2009 John Wiley & Sons A/S � Tissue Antigens 73, 95–170
HLA alleles and serologic types R. Holdsworth et al.
Table
2Continued
HLAallele
Expert
assigned
WHO
assigned
InternationalC
ellExchange,UCLA
NMDP
IHWS13data
NN
Comments
Assignedtype[%
]Cells
tested
Assignedtype[%
]
Cells
tested
Assignment
Cells
tested
Assigned
type>0.55
B*5413
B54
––
––
––
–B54
B*5501
B55
B55(22)
B55[89–97]
4B55[92],B22[5]
453
B55
21
Training–B22B55
B*5502
B55
B55(22)
B55[89–96]a
6B55[84],B54[3],
B22[2]
309
B55
11
Training–B22B55
B*5503
B55
B55(22)c
––
B55[100]b
1–
–B55
B55x67,someBw6
sera
negative
B*5504
B55
B55(22)
––
B55[80],B56[7],
B22[7]b
15
––
B22
B*5505
B55
B22
––
B22[100]b
1–
–B55
B*5507
B54
B54(22)
––
B55[25],B54[25],
B56[25],blank
[25]b
4–
–B22f
NN:B54
B*5508
B56
B56(22)
––
––
B56
2B56
B*5509
B22
B22
––
––
––
B55
ShortB22,B7CREG
sera
positive,
negativewithB55
andB56sera
B*5510
B55
B55(22)
––
B55[100]b
1–
–B22
B*5511
B55
––
––
––
–B55
B*5512
B55
B22
––
––
––
B55
B*5513
B55
––
–B55[100]b
1–
–B55
B55v
B*5514
Undefined
––
––
––
–Notassignede
NN:B22,B55
B*5515
B55
B55(22)
––
––
––
B55
B*5516
B55
B22
––
––
––
B55
B*5517
B55
––
––
––
–B55
B*5518
Undefined
––
––
––
–Notassignede
B*5519
B55
––
––
––
–B55
B*5520
B22
––
––
––
–B22f
NN:B55
B*5521
B55
––
––
––
–B55
B*5522
B22
B55(22)
––
––
––
B22f
NN:B56
B*5523
B55
––
–B55[100]b
1–
–B55
B*5524
B55
––
––
––
–B55
B*5525
B55
––
––
––
–B55
B*5526
B55
––
––
––
–B55
B*5527
B55
––
––
––
–B55
B*5601
B56
B56(22)
B56[94–96]
5B56[72],B22[5],B55
[3],blank[8]
671
B56
23
Training–B22B56
ª 2009 John Wiley & Sons A/S � Tissue Antigens 73, 95–170 139
R. Holdsworth et al. HLA alleles and serologic types
Table
2Continued
HLAallele
Expert
assigned
WHO
assigned
InternationalC
ellExchange,UCLA
NMDP
IHWS13data
NN
Comments
Assignedtype[%
]Cells
tested
Assignedtype[%
]
Cells
tested
Assignment
Cells
tested
Assigned
type>0.55
B*5602
B56
B56(22)
––
B56[63],B55[12],
blank[25]b
8B56
6Training–B22B56
B*5603
B22/15
B22
––
B56[65],B22[6],
blank[12]b
17
B56
1Notassignede
B22variant,B55,B56
sera
negative,B15
1461
70sera
reactive;in
Asians
B*5604
B56
B56(22)
B56[88–93],B22
[1–5]a
4B56[82],B54[4],B22
[4],blank[11]b
28
B56
1B56
ShortB56s,some
B56andB22sera
negative
B*5605
B56
B56(22)
––
Blank[100]b
1B56
4B22
ShortB56
B*5606
B78
B78
––
––
––
B22
B78variant,some
B35andB15CREG
sera
positive,all
B22sera
negative
B*5607
B56
B56(22)
––
––
B56
1Notassignede
B56Bw4,someB7
sera
positive;
ihw13:B56Bw4;
NN:B56,B22
B*5608
B56
––
––
––
–B56
B*5609
B56
––
––
––
–B56
B*5610
B55
B55(22)
––
––
––
B55
ShortB22,reactive
withB541
55sera,
negativewithB55
17sera
B*5611
B56
B56(22)
––
––
––
B56
ShortB56
B*5612
B22
B55(22)
––
––
––
B22
B*5613
B56
B56(22)
––
––
––
B56
B*5614
B56
––
––
––
–B56
B*5615
B56
B56(22)
––
––
––
B56
B*5616
B56
––
––
––
–B56
B*5617
B56
––
–Blank[100]b
1–
–B56
B*5618
Undefined
––
––
––
–Notassignede
NN:B22
B*5619N
Notexpressed
Null
––
––
––
NT
B*5620
B56
B56(22)
––
––
––
B56
B*5701
B57
B57(17)
B57[87–98],B58
[1–7],B17[1–6]a
12
B57[92],B17[5],
B58[2]
3670
B57
28
Training–B17B57
B*5702
B57
B57(17)
B57[95–96]a
8B57[78],B17[8]
65
B57
4Training–B17B57
ihw13:shortB57
140 ª 2009 John Wiley & Sons A/S � Tissue Antigens 73, 95–170
HLA alleles and serologic types R. Holdsworth et al.
Table
2Continued
HLAallele
Expert
assigned
WHO
assigned
InternationalC
ellExchange,UCLA
NMDP
IHWS13data
NN
Comments
Assignedtype[%
]Cells
tested
Assignedtype[%
]
Cells
tested
Assignment
Cells
tested
Assigned
type>0.55
B*5703
B57
B57(17)
B57[96–98]a
5B57[85],B17[6],
B58[6]
412
B57
7Training–B17B57
B*5704
B57
B57(17)
––
B57[67],B17[7]
32
B57
1B57
ihw13:shortB57
B*5705
B57
––
–B57[100]b
3–
–B57
B*5706
B57
––
––
––
–B57
B*5707
B57
––
––
––
–B57
B*5708
B57
B57(17)
––
––
––
B57
Bw4sera
negative,
onlystrongly
reactivewithB151
57sera
B*5709
B57
––
––
––
–B57
B*5710
B57
––
––
––
–B57
B*5711
B57
––
––
––
–B57
B*5712
B57
––
–B57[100]b
1–
–B57
B*5713
B57
––
––
––
–B57
B*5801
B58
B58(17)
B58[90–100]a
25
B58[79],B57[8],
B17[4]
2096
B58
28
Training–B17B58
B*5802
B58
B58(17)
B58[82–93]a
2B58[72],B57[12],
B17[3]
837
B58
10
Training–B17B58
B*5804
B58
––
–B58[100]b
1–
–B58
B*5805
B58
––
––
––
–B58
B*5806
B58
––
–B58[100]b
1–
–B58
B*5807
B58
––
––
––
–B58
B*5808
B17/B5
B17
––
––
––
B5
B17andsomeB5
sera
reactive;NN:
B17
B*5809
B17
––
––
––
–B58
B57
B*5810N
Notexpressed
Null
––
––
––
NT
B*5811
B58
––
––
––
–B58
B*5812
B58
––
––
––
–B58
B*5813
B58
––
––
––
–B58
B*5814
B58
––
––
––
–B58
B*5815
B58
––
––
––
–B58
B*5901
B59
B59
B59[92–95]a
9B59[45],blank[41]
123
B59
6Training–B59
B*5902
B59
B59
––
––
––
B59
B*6701
B67
B67
B67[86–90],B39
[5–11]a
6B39[43],B67[32],
B55[8],blank[11]
81
B67
5Training–B67
ihw13:pattern
includedin
B22
B*6702
Undefined
––
–B39[100]b
1–
–Notassignede
NN:B67
ª 2009 John Wiley & Sons A/S � Tissue Antigens 73, 95–170 141
R. Holdsworth et al. HLA alleles and serologic types
Table
2Continued
HLAallele
Expert
assigned
WHO
assigned
InternationalC
ellExchange,UCLA
NMDP
IHWS13data
NN
Comments
Assignedtype[%
]Cells
tested
Assignedtype[%
]
Cells
tested
Assignment
Cells
tested
Assigned
type>0.55
B*7301
B73
B73
B73[81–87]
4Blank[69],B73[22]
106
B73
3Training–B73
ihw13:pattern
sim
ilar
toB2708
B*7801
B78
B78
B78[83–90],B35
[1–9],B51[1–6]
5B78[41],B35[15],
B51[10],B70[4],
blank[19]
210
B78
1Training–B78
B*7802
B78
B78
––
B78[25],B35[25],
B51[25]b
4–
–B78
B*7803
B78
––
––
––
–B78
B*7804
B35
––
–B35[100]b
5–
–Notassignede
NNB35
B*7805
Undefined
––
––
––
–Notassignede
NNB52
B*8101
B81
B81
B81[81–90],B7
[10–18],B48[0–3]a
12
B7[76],B81[8]
657
B81
7Training–B81
B*8102
B81
B81
B81[89–90],B7[10],
B48[0–3],B60
[2–3]a
2–
––
–B81
B*8201
B82
B82
B‘8201’[28],B22[9]
1Blank[68],B45[4],
B70[4],B‘82’[3],
B65[3]
146
B‘82’
4B56
B22x45,reactivewith
someB45andB22
sera;ihw13:
pattern
alm
ost
includedin
B55
B*8202
B82
–B82[23],B81[19],
B‘8201’[11],B56
[5],B22[3],B42[3]a
1B45[33],blank[67]b
3B‘82’
1B56
B*8301
Undefined
––
–B45[100]b
1–
–Notassignede
NT,nottested;NN,neuraln
etw
ork;HLA,humanleukocyte
antigen;WHO,WorldHealthOrganization;NMDP,NationalM
arrow
DonorProgram.
aUpdatedInternationalC
ellExchange,UCLA.
bUpdatedNMDPdata.Insomecasestheinform
ationreportedinpreviousdictionarieshaschanged.C
ells
havebeenexcludedfrom
thisstudyinsomecasesbecausetheirHLAtypinghaschanged.
cWHO
assignmentbasedondictionary
data.
dTheallele
hasbeenidentifiedbutserologynotinform
ative.
eNotassigned;seecommentcolumnforpredictions>0.20.
fIfaprimary
specificityisprovidedbytheNN,otherspecificities>0.4
are
shownin
thecomments
column.
gRef13–16,29–57,62.
142 ª 2009 John Wiley & Sons A/S � Tissue Antigens 73, 95–170
HLA alleles and serologic types R. Holdsworth et al.
Table
3HLA-C
allelesandtheirserologicdesignationsg
HLAallele
Expert
assigned
WHO
assigned
InternationalCellExchange,U
CLA
NMDP
IHW
S13data
NN
Comments
Assignedtype[%
]
Cells
tested
Assignedtype[%
]
Cells
tested
Assignment
Cells
tested
Assigned
type>0.55
Cw*0102
Cw1
Cw1
Cw1[55–75]a
76
Cw1[92]
260
Cw1
104
Training–Cw1
Cw*0103
Cw1
Cw1
––
Cw1[100]b
1–
–Cw1
Cw*0104
Cw1
––
––
––
–Cw1
Cw*0105
Cw1
––
––
––
–Cw1
Cw*0106
Cw1
––
––
––
–Cw1
Cw*0107
Cw1/blank
––
–Cw1[100]b
1–
–Cw1
Cw
blank,theHLA
clubcell
exchange:nine
laboratories
perform
ing
serology
Cw*0108
Cw1
––
––
––
–Cw1
Cw*0109
Cw1
Cw1
––
––
––
Cw1
ShortCw1
Cw*0110
Cw1
––
––
––
–Cw1
Cw*0111
Cw1
––
––
––
–Cw1
Cw*0112
Cw1
––
––
––
–Cw1
Cw*0113
Cw1
––
––
––
–Cw1
Cw*0114
Cw1
––
––
––
–Cw1
Cw*0115
Cw1
––
––
––
–Cw1
Cw*0116
Cw1
––
––
––
–Cw1
Cw*0117
Cw1
––
––
––
–Cw1
Cw*0118
Cw1
––
––
––
–Cw1
Cw*0119
Cw1
––
––
––
–Cw1
Cw*0202
Cw2
Cw2
Cw2[62–76]a
27
Cw2[91]
382
Cw2
67
Training–Cw2
Cw*0203
Cw2
––
–Cw2[100]b
1–
–Cw2
Cw*0204
Cw2
––
––
––
–Cw2
Cw*0205
Cw2
––
––
––
–Cw2
Cw*0206
Cw2
––
––
––
–Cw2
Cw*0207
Cw2
––
––
––
–Cw2
Cw*0208
Cw2
Cw2
––
––
––
Cw2
Cw*0209
Cw2
––
––
––
–Cw2
Cw*0210
Cw2
Cw2
––
Cw2[75]b
4Cw2
Cw*0211
Cw2
––
––
––
–Cw2
Cw*0212
Cw2
––
––
––
–Cw2
Cw*0213
Cw2
––
––
––
–Cw2
Cw*0214
Cw2
––
––
––
–Cw2
Cw*0215
Cw2
––
––
––
–Cw2
Cw*0216
Cw2
––
––
––
–Cw2
Cw*0217
Cw2
––
––
––
–Cw2
ª 2009 John Wiley & Sons A/S � Tissue Antigens 73, 95–170 143
R. Holdsworth et al. HLA alleles and serologic types
Table
3Continued
HLAallele
Expert
assigned
WHO
assigned
InternationalCellExchange,U
CLA
NMDP
IHW
S13data
NN
Comments
Assignedtype[%
]
Cells
tested
Assignedtype[%
]
Cells
tested
Assignment
Cells
tested
Assigned
type>0.55
Cw*0218
Cw2
––
––
––
–Cw2
Cw*0302
Cw10
Cw10(w
3)
Cw3[45–67],Cw10
[6–13]a
13
Cw3[69],Cw10[5]
41
Cw10
11
Cw10
Cw*0303
Cw9
Cw9(w
3)
Cw3[55–68],Cw9
[8–15]a
38
Cw3[80],Cw9[6]
446
Cw9
75
Training–Cw3Cw9
Cw*0304
Cw10
Cw10(w
3)
Cw3[52–69],Cw9
[0–11],Cw10
[3–12]a
62
Cw3[92],Cw10[3],
Cw9[1]
603
Cw10
51
Training–Cw3Cw10
Cw*0305
Cw3
–Cw3[48],Cw10[7]a
1Cw3[83],blank[17]b
12
––
Cw10
Cw*0306
Cw10
Cw10(w
3)c
Cw3[52],Cw10[6]
1Cw3[75],blank[25]b
16
Cw10
1Cw10
ihw13:shortpattern
Cw*0307
Cw3
Cw3
––
Cw3[100]b
1–
–Cw10
Cw*0308
Cw10
––
––
––
–Cw10
Cw*0309
Cw10
Cw3c
Cw3[44–59],Cw10
[3–6]
3Cw3[100]b
1–
–Cw10
Cw*0310
Cw3
Cw3
––
Cw3[100]b
1–
–Cw10
Cw*0311
Cw9
Cw3
––
––
––
Cw9
Cw*0312
Cw9
––
––
––
–Cw9
Cw*0313
Cw9
––
––
––
–Cw9
Cw*0314
Cw10
––
––
––
–Cw10
Cw*0315
Undefined
––
––
––
–Notassignedd
NN:Cw3,Cw10
Cw*0316
Blank
––
––
––
–Cw3
Cw3,w9,w10sera
negative;NN:
Cw10
Cw*0317
Cw10
––
––
Cw10
Cw*0318
Cw9
––
–Cw3[100]b
1Cw9
Cw*0319
Cw3
Cw3
––
––
––
Cw10
Cw*0320N
Notexpressed
Null
––
––
––
NT
Cw*0321
Cw9
––
––
––
–Cw9
Cw*0322Q
Undefined
––
––
––
–Cw9
Notexpectedto
be
expressed
Cw*0323
Cw10
––
––
––
–Cw10
Cw*0324
Cw10
Cw3
––
––
––
Cw10
Cw*0325
Cw10
––
––
––
–Cw10
Cw*0326
Cw10
Cw10(w
3)
––
––
––
Cw10
Cw*0327
Cw10
––
––
––
–Cw10
Cw*0328
Cw10
Cw10(w
3)
––
––
––
Cw10
Cw*0329
Cw10
––
––
––
–Cw10
Cw*0330
Cw9
––
––
––
–Cw9
144 ª 2009 John Wiley & Sons A/S � Tissue Antigens 73, 95–170
HLA alleles and serologic types R. Holdsworth et al.
Table
3Continued
HLAallele
Expert
assigned
WHO
assigned
InternationalCellExchange,U
CLA
NMDP
IHW
S13data
NN
Comments
Assignedtype[%
]
Cells
tested
Assignedtype[%
]
Cells
tested
Assignment
Cells
tested
Assigned
type>0.55
Cw*0331
Cw9
––
––
––
–Cw9
Cw*0332
Cw10
––
––
––
–Cw10
Cw*0333
Cw10
––
––
––
–Cw10
Cw*0334
Cw10
––
––
––
–Cw10
Cw*0335
Cw10
––
––
––
–Cw10
Cw*0336
Cw10
––
––
––
–Cw10
Cw*0337
Cw10
––
––
––
–Cw10
Cw*0338
Cw10
––
––
––
–Cw10
Cw*0339
Cw9
Cw3
––
––
––
Cw9
Cw*0340
Cw10
Cw3
––
––
––
Cw10
Cw*0341
Cw10
––
––
––
–Cw10
Cw*0401
Cw4
Cw4
Cw4[54–76]a
107
Cw4[98]
736
Cw4
114
Training–Cw4
Cw*0403
Cw4/Cw6
–Cw4[16–33],Cw6
[7–26],C‘403’
[3–8]a
35
Blank[100]b
7Cw4
11
Notassignedd
NN:Cw4;Cw4/6
variant;ihw13:C
w6
orblank,onlyCw4
16sera
reactive
Cw*0404
Cw4
––
–Cw4[75],blank[25]b
4Blank
1Cw4
Cw*0405
Cw4
––
–Cw4[100]b
2–
–Cw4
Cw*0406
Cw4/Cw6
–Cw6[27–33],Cw4
[20–25],C‘403’
[2–3]a
4–
––
–Notassignedd
NN:Cw4
Cw*0407
Cw4
Cw4c
––
Cw4[100]b
1Cw4
1Cw4
Cw*0408
Cw4
––
–be
1–
–Cw4
Cw*0409N
Notexpressed
Null
–1
Blank[100]b
2–
–NT
Cw*0410
Cw4
Cw4
––
Cw4[100]b
1–
–Cw4
Norm
alC
w4
Cw*0411
Undefined
––
––
––
–Notassignedd
NN:Cw4
Cw*0412
Cw4
––
––
––
–Cw4
Cw*0413
Cw4
––
––
––
–Cw4
Cw*0414
Cw4
––
––
––
–Cw4
Cw*0415
Cw4
––
––
––
–Cw4
Cw*0416
Cw4
––
––
––
–Cw4
Cw*0417
Cw4
––
––
––
–Cw4
Cw*0418
Cw4
––
––
––
–Cw4
Cw*0419
Cw4
––
––
––
–Cw4
Cw*0420
Cw4
Cw4
––
––
––
Cw4
Cw*0421
Cw4
––
––
––
–Cw4
Cw*0423
Cw4
––
––
––
–Cw4
Cw*0424
Cw4
––
––
––
–Cw4
Cw*0425
Cw4
––
––
––
–Cw4
ª 2009 John Wiley & Sons A/S � Tissue Antigens 73, 95–170 145
R. Holdsworth et al. HLA alleles and serologic types
Table
3Continued
HLAallele
Expert
assigned
WHO
assigned
InternationalCellExchange,U
CLA
NMDP
IHW
S13data
NN
Comments
Assignedtype[%
]
Cells
tested
Assignedtype[%
]
Cells
tested
Assignment
Cells
tested
Assigned
type>0.55
Cw*0426
Cw4
––
––
––
–Cw4
Cw*0427
Cw4
––
––
––
–Cw4
Cw*0501
Cw5
Cw5
Cw5[50–63]a
13
Cw5[83],blank[15]
579
Cw5
69
Training–Cw5
Cw*0502
Cw5
Cw5
––
Cw5[100]b
2–
–Cw5
Cw*0503
Cw5
––
––
––
–Cw5
Cw*0504
Cw5
––
––
––
–Cw5
Cw*0505
Cw5
––
–Blank[100]b
1–
–Cw5
Cw*0506
Cw5
––
––
––
–Cw5
Cw*0507N
Notexpressed
Null
––
––
––
NT
Cw*0508
Cw5
––
––
––
–Cw5
Cw*0509
Cw5
––
–Cw5[100]b
1–
–Cw5
Cw*0510
Cw5
––
––
––
–Cw5
Cw*0511
Cw5
––
––
––
–Cw5
Cw*0512
Cw5
––
––
––
–Cw5
Cw*0513
Cw5
––
––
––
–Cw5
Cw*0514
Cw5
––
––
––
–Cw5
Cw*0515
Cw5
––
––
––
–Cw5
Cw*0516
Cw5
––
––
––
–Cw5
Cw*0517
Cw5
––
––
––
–Cw5
Cw*0602
Cw6
Cw6
Cw6[51–71]a
44
Cw6[74],Cw4[1],
blank[12]
665
Cw6
104
Training–Cw6
Cw*0603
Cw6
––
–Cw6[100]b
1–
–Cw6
Cw*0604
Cw6
––
–Cw6[100]b
2–
–Cw6
Cw*0605
Cw6
Cw6
––
––
––
Cw6
Cw*0606
Cw6
––
––
––
–Cw6
Cw*0607
Cw6
––
–Blank[100]b
1–
–Cw6
Cw*0608
Cw6
––
––
––
–Cw6
Cw*0609
Cw6
––
––
––
–Cw6
Cw*0610
Cw6
––
––
––
–Cw6
Cw*0611
Undefined
––
––
––
–Notassignedd
NN:Cw6
Cw*0612
Cw6
––
––
––
–Cw6
Cw*0613
Cw6
––
––
––
–Cw6
Cw*0614
Cw6
––
––
––
–Cw6
Cw*0615
Cw6
––
––
––
–Cw6
Cw*0616N
Notexpressed
Null
––
––
––
NT
Cw*0701
Cw7
Cw7
Cw7[52–73]a
36
Cw7[74],blank[20]
304
Cw7
129
Training–Cw7
Cw*0702
Cw7
Cw7
Cw7[51–73]a
110
Cw7[68],blank[14]
976
Cw7
144
Training–Cw7
Cw*0703
Cw7
––
–b
––
–Cw7
146 ª 2009 John Wiley & Sons A/S � Tissue Antigens 73, 95–170
HLA alleles and serologic types R. Holdsworth et al.
Table
3Continued
HLAallele
Expert
assigned
WHO
assigned
InternationalCellExchange,U
CLA
NMDP
IHW
S13data
NN
Comments
Assignedtype[%
]
Cells
tested
Assignedtype[%
]
Cells
tested
Assignment
Cells
tested
Assigned
type>0.55
Cw*0704
Cw7
Cw7
Cw7[59–72]
14
Cw7[64],blank[24]
54
Cw7
30
Cw7
Cw*0705
Cw7
Cw7c
––
––
Cw7
2Cw7
Cw*0706
Cw7
Cw7
Cw7[62–76]
4Cw7[67],blank[33]b
3–
–Cw7
Cw*0707
Cw7
––
–Blank[100]b
1–
–Cw7
Cw*0708
Cw7
––
–Cw7[100]b
1–
–Cw7
Cw*0709
Cw7
––
–Cw7[100]b
1–
–Cw7
Cw*0710
Cw7
––
–Cw7[100]b
1–
–Cw7
Cw*0711
Cw7
––
––
––
–Cw7
Cw*0712
Cw7
Cw7
––
––
––
Cw7
Cw*0713
Cw7
––
––
––
–Cw7
Cw*0714
Cw7
Cw7
––
––
––
Cw7
Cw*0715
Cw7
––
––
––
–Cw7
Cw*0716
Cw7
Cw7
––
Blank[100]b
1–
–Cw7
Cw*0717
Cw7
–Cw7[61%
]allele
typedoutside
primary
cellrange
1–
––
–Cw7
Cw*0718
Cw7
–Cw7[73]a
1Cw7[67],blank[33]b
3–
–Cw7
Cw*0719
Cw7
––
––
––
–Cw7
Cw*0720
Cw7
––
––
––
–Cw7
Cw*0721
Cw7
––
––
––
–Cw7
Cw*0722
Cw7
––
––
––
–Cw7
Cw*0723
Cw7
––
––
––
–Cw7
Cw*0724
Cw7
––
––
––
–Cw7
Cw*0725
Cw7
––
––
––
–Cw7
Cw*0726
Cw7
––
––
––
–Cw7
Cw*0727
Cw7
––
–be
1–
–Cw7
Cw*0728
Cw7
––
––
––
–Cw7
Cw*0729
Cw7
––
––
––
–Cw7
Cw*0730
Cw7
Cw7
––
––
––
Cw7
Cw*0731
Cw7
––
––
––
–Cw7
Cw*0732N
Notexpressed
Null
––
––
––
NT
Cw*0733N
Notexpressed
Null
––
––
––
NT
Cw*0734
Cw7
––
––
––
–Cw7
Cw*0735
Cw7
––
––
––
–Cw7
Cw*0736
Cw7
Cw7
––
––
––
Cw7
Cw*0737
Cw7
Cw7
––
––
––
Cw7
Cw*0738
Cw7
Cw7
––
––
––
Cw7
Cw*0739
Cw7
––
––
––
–Cw7
ª 2009 John Wiley & Sons A/S � Tissue Antigens 73, 95–170 147
R. Holdsworth et al. HLA alleles and serologic types
Table
3Continued
HLAallele
Expert
assigned
WHO
assigned
InternationalCellExchange,U
CLA
NMDP
IHW
S13data
NN
Comments
Assignedtype[%
]
Cells
tested
Assignedtype[%
]
Cells
tested
Assignment
Cells
tested
Assigned
type>0.55
Cw*0740
Cw7
Cw7
––
––
––
Cw7
Cw*0741
Undefined
––
––
––
–Cw8
Cw*0742
Cw7
––
––
––
–Cw7
Cw*0743
Cw7
––
––
––
–Cw7
Cw*0744
Cw7
Cw7
––
––
––
Cw7
Cw*0745
Cw7
Cw7
––
––
––
Cw7
Cw*0746
Cw7
––
––
––
–Cw7
Cw*0747
Cw7
––
––
––
–Cw7
Cw*0748
Cw7
––
––
––
–Cw7
Cw*0749
Cw7
Cw7
––
––
––
Cw7
Cw*0801
Cw8
Cw8
Cw8[40–66]a
62
Cw8[41],blank[34]
31
Cw8
40
Cw8
ihw13:pattern
differentfrom
Cw*0802
Cw*0802
Cw8
Cw8
Cw8[55–66]a
21
Cw8[67],blank[29]
234
Cw8
30
Training–Cw8
Cw*0803
Cw8
Cw8
Cw8[8–16]a
4Blank[100]b
3Blank
2Cw8
Cw*0804
Cw8
Cw8c
Cw8[43–57]a
4Cw8[100]b
2–
–Cw8
Cw*0805
Cw8
––
––
––
–Cw8
Cw*0806
Cw8
––
––
––
–Cw8
Cw*0807
Cw8
––
––
––
–Cw8
Cw*0808
Cw8
––
––
––
–Cw8
Cw*0809
Cw8
––
––
––
–Notassignedd
NN:Cw8,Cw7
Cw*0810
Undefined
––
––
––
–Cw5
Cw*0811
Undefined
––
––
––
–Notassignedd
NN:Cw8,Cw7
Cw*0812
Cw8
––
––
––
–Cw8
Cw*0813
Cw8
––
––
––
–Cw8
Cw*0814
Cw8
––
––
––
–Cw8
Cw*1202
Undefined
–Blank,noCw
antigen
reportedbymore
than5%
ofthe
laboratories
11a
Blank[94]
85
Blank
27
Notassignedd
ihw13:reactivewith
broadCw
reagents
Cw*1203
Undefined
–Blank
30a
Blank[59],Cw7[4]
238
Blank
75
Notassignedd
ihw13:reactivewith
broadCw
reagents
Cw*1204
Blank
–Blank
4a
Blank[100]b
3–
–Cw6
Cw*1205
Undefined
––
––
––
–Notassignedd
NN:Cw2,Cw6
Cw*1206
Undefined
––
––
––
–Notassignedd
Cw*1207
Undefined
––
––
––
–Notassignedd
NN:Cw6
Cw*1208
Undefined
––
––
––
–Notassignedd
Cw*1209
Undefined
––
––
––
–Notassignedd
NN:Cw2,Cw6
148 ª 2009 John Wiley & Sons A/S � Tissue Antigens 73, 95–170
HLA alleles and serologic types R. Holdsworth et al.
Table
3Continued
HLAallele
Expert
assigned
WHO
assigned
InternationalCellExchange,U
CLA
NMDP
IHW
S13data
NN
Comments
Assignedtype[%
]
Cells
tested
Assignedtype[%
]
Cells
tested
Assignment
Cells
tested
Assigned
type>0.55
Cw*1210
Undefined
––
––
––
–Notassignedd
Cw*1211
Undefined
––
––
––
–Notassignedd
Cw*1212
Undefined
––
––
––
–Notassignedd
Cw*1213
Undefined
––
––
––
–Notassignedd
Cw*1214
Cw7
––
––
––
–Cw7
Cw*1215
Undefined
––
––
––
–Notassignedd
Cw*1216
Undefined
––
––
––
–Notassignedd
NN:Cw7
Cw*1217
Undefined
––
––
––
–Notassignedd
Cw*1218
Undefined
––
––
––
–Notassignedd
NN:Cw7
Cw*1219
Undefined
––
––
––
–Notassignedd
Cw*1220
Undefined
––
––
––
–Notassignedd
Cw*1221
Undefined
––
––
––
–Notassignedd
NN:Cw2,Cw5
Cw*1402
Cw1/blank
–Blank,noCw
antigen
reportedbymore
than5%
ofthe
laboratories
19a
Blank[93]
93
Cw1
36
Cw1
ihw13:shortCw1
Cw*1403
Cw1/blank
–Blank,noCw
antigen
reportedbymore
than5%
ofthe
laboratories
5a
Blank[100]b
11
Cw1
10
Notassignedd
ihw13:shortCw1;
NN:Cw1
Cw*1404
Undefined
––
–Blank[100]b
1–
–Notassignedd
NN:Cw4,Cw1
Cw*1405
Cw1
––
–Blank[100]b
1–
–Cw1
Cw*1406
Undefined
––
––
––
–Notassignedd
NN:Cw1
Cw*1407N
Notexpressed
Null
––
––
––
NT
Cw*1408
Cw1
––
––
––
–Cw1
Cw*1502
Undefined
–Blank
31a
Blank[90]
107
Blank
56
Notassignedd
NN:C
w10,C
w3,C
w2
Cw*1503
Undefined
––
–Blank[100]b
2–
–Notassignedd
NN:C
w10,C
w3,C
w2
Cw*1504
Undefined
––
–Blank[100]b
2Blank
2Notassignedd
NN:Cw3,Cw2
Cw*1505
Undefined
–Blanka
11a
Blank[62],Cw7[24],
Cw2[10]b
29
Blank
5Notassignedd
NN:Cw10,Cw3,
Cw2,Cw5
Cw*1506
Undefined
––
–Blank[100]b
1–
–Notassignedd
NN:C
w10,C
w3,C
w2
Cw*1507
Cw3
––
––
––
–Cw3f
NN:Cw10
Cw*1508
Undefined
––
––
––
–Notassignedd
NN:Cw10,Cw3,
Cw2,Cw5
Cw*1509
Undefined
–Blank
1Blank[100]b
8–
–Notassignedd
NN:Cw3,Cw2
Cw*1510
Undefined
––
––
––
–Notassignedd
Cw*1511
Undefined
––
–Blank[100]b
1–
–Notassignedd
NN:C
w2,C
w3,C
w10
Cw*1512
Undefined
––
––
––
–Notassignedd
NN:Cw3,Cw9,Cw2
ª 2009 John Wiley & Sons A/S � Tissue Antigens 73, 95–170 149
R. Holdsworth et al. HLA alleles and serologic types
Table
3Continued
HLAallele
Expert
assigned
WHO
assigned
InternationalCellExchange,U
CLA
NMDP
IHW
S13data
NN
Comments
Assignedtype[%
]
Cells
tested
Assignedtype[%
]
Cells
tested
Assignment
Cells
tested
Assigned
type>0.55
Cw*1513
Undefined
––
–Blank[100]b
1–
–Notassignedd
NN:C
w10,C
w3,C
w2
Cw*1514
Undefined
––
––
––
–Notassignedd
Cw*1515
Undefined
––
––
––
–Notassignedd
NN:C
w10,C
w3,C
w2
Cw*1516
Undefined
––
––
––
–Notassignedd
NN:Cw10,Cw3
Cw*1517
Undefined
––
––
––
–Notassignedd
NN:C
w10,C
w3,C
w2
Cw*1518
Undefined
––
––
––
–Notassignedd
NN:C
w10,C
w3,C
w2
Cw*1519
Undefined
––
––
––
–Notassignedd
NN:Cw3,Cw2
Cw*1520
Undefined
––
––
––
–Notassignedd
NN:Cw3,Cw2
Cw*1521
Cw3
––
––
––
–Cw3f
NN:Cw10
Cw*1601
Undefined
–Cw7[2–23]a
36
Blank[94]
276
Blank
57
Notassignedd
Cw*1602
Undefined
–Blanka
3Blank[97]
22
Blank
5Notassignedd
NN:Cw2,Cw6
Cw*1604
Undefined
––
–Blank[100]b
10
Blank
2Notassignedd
NN:Cw1
Cw*1606
Undefined
––
––
––
–Notassignedd
NN:Cw7
Cw*1607
Undefined
––
––
––
–Notassignedd
NN:Cw7
Cw*1608
Undefined
––
––
––
–Notassignedd
Cw*1609
Undefined
––
––
––
–Notassignedd
NN:Cw2,Cw6
Cw*1701
Cw7/blank
–C‘17’[27–43],Cw7
[6–22]a
25
Blank[82],Cw7[18]b
28
––
Notassignedd
Cw*1702
Undefined
––
––
––
–Notassignedd
Cw*1703
Cw7/blank
–C‘17’[31–44],Cw7
[10–20]a
3Blank[100]b
8–
–Notassignedd
Cw*1704
Undefined
––
––
––
–Notassignedd
Cw*1801
Cw6/blank
–Cw6[30–42]a
3Cw4[40],Cw6[40],
Cw7[20]b
5–
–Notassignedd
NN:Cw6,Cw4
Cw*1802
Cw6/blank
–Cw6[32–49],Cw4
[2–6]a
8Cw6[100]b
1–
–Notassignedd
NN:Cw6,Cw4
Cw*1803
Undefined
––
––
––
–Notassignedd
NN:Cw6,Cw4
NT,nottested;NN,neuraln
etw
ork;HLA,humanleukocyte
antigen;WHO,WorldHealthOrganization;NMDP,NationalM
arrow
DonorProgram.
aUpdatedInternationalC
ellExchange,UCLA.
bUpdatedNMDPdata.Insomecases,theinform
ationreportedinpreviousdictionarieshaschanged.C
ells
havebeenexcludedfrom
thisstudyinsomecasesbecausetheirHLAtypinghaschanged.
cWHO
assignmentbasedondictionary
data.
dNotassigned;seecommentcolumnforpredictions>0.20.
eTheallele
hasbeenidentifiedbutserologynotinform
ative.
fIfaprimary
specificityisprovidedbytheNN,otherspecificities>0.4
are
shownin
thecomments
column.
gRef14,58,59.
150 ª 2009 John Wiley & Sons A/S � Tissue Antigens 73, 95–170
HLA alleles and serologic types R. Holdsworth et al.
Table
4HLA-DRB1allelesandtheirserologicdesignations
HLAallele
Expertassigned
WHO
assigned
InternationalC
ellExchange,UCLA
NMDP
NN
Comments
Assignedtype[%
]Cells
tested
Assignedtype[%
]Cells
tested
Assignedtype>0.55
DRB1*0101
DR1
DR1
DR1[95–100]a
21
DR1[97]
6317
Training–DR1
DRB1*0102
DR1
DR1
DR1[86–95]
2DR1[95]
2035
Training–DR1
DRB1*0103
DR103/DR1
DR103
DR103[75–80],
DR1[9–17]a
5DR1[56],DR103
[12],blank[18]
1186
Training–DR1
DR103
DRB1*0104
DR1
DR1
––
––
DR1
DRB1*0105
DR1
––
–DR1[100]b
2DR1
DRB1*0106
DR1
––
––
–DR1
DRB1*0107
DR1
DR1
––
––
DR1
DRB1*0108
DR1
––
––
–DR1
DRB1*0109
DR1
DR1
––
––
DR1
DRB1*0110
DR1
––
––
–DR1
DRB1*0111
DR1
––
––
–DR1
DRB1*0112
DR1
––
––
–DR1
DRB1*0113
DR1
DR1
––
––
Notassignedc
NN:DR1
DRB1*0114
DR1
––
––
–DR1
DRB1*0115
DR1
––
––
–DR1
DRB1*0116
DR1
––
––
–DR1
DRB1*0301
DR17
DR17(3)
DR17[33–70],
DR3[20–50],
DR18[0–11]a
36
DR17[64],DR3
[33]
9698
Training–DR3
DR17
DRB1*0302
DR18
DR18(3)
DR18[62–67],
DR3[27–35]
10
DR18[66],DR3
[24],DR17[3]
317
Training–DR3
DR18
DRB1*0303
DR18
DR18(3)
––
DR18[50],DR17
[50]b
4DR18
DRB1*0304
DR17
DR17(3)
DR17[50],DR3
[44–50]a
3DR3[57],DR17
[29]b
7DR17
DRB1*0305
DR3
DR3
––
––
DR17
DRB1*0306
DR3
DR3
––
––
DR17
DRB1*0307
DR3
DR3d
––
DR3[100]b
1DR17
DRB1*0308
DR3
––
––
–DR17
DRB1*0309
DR3
––
––
–DR17
DRB1*0310
DR3
DR17(3)d
––
DR3[100]b
1DR17
DRB1*0311
DR3
DR17(3)d
––
DR3[100]b
1DR17
DRB1*0312
DR3
DR3
––
––
DR17
DRB1*0313
DR3
––
––
–DR17
DRB1*0314
DR3
DR3
––
––
DR17
DRB1*0315
DR17
DR3
DR3[38–40],
DR17[20–25],
DR18[0–10]a
2–
–DR17
DRB1*0316
DR3
––
––
–DR17
ª 2009 John Wiley & Sons A/S � Tissue Antigens 73, 95–170 151
R. Holdsworth et al. HLA alleles and serologic types
Table
4Continued
HLAallele
Expertassigned
WHO
assigned
InternationalC
ellExchange,UCLA
NMDP
NN
Comments
Assignedtype[%
]Cells
tested
Assignedtype[%
]Cells
tested
Assignedtype>0.55
DRB1*0317
DR3
––
–DR17[100]b
1DR3
DRB1*0318
DR3
––
––
–DR17
DRB1*0319
DR3
––
––
–DR17
DRB1*0320
DR3
––
––
–DR17
DRB1*0321
DR3
––
––
–DR17
DRB1*0322
DR3
––
––
–DR17
DRB1*0323
DR3
DR3
––
––
DR17
DRB1*0324
DR3
––
––
–DR17
DRB1*0325
DR3
––
––
–DR17
DRB1*0326
DR3
––
––
–DR17
DRB1*0327
DR3
––
––
–DR18
DRB1*0328
DR3
––
––
–DR17
DRB1*0329
DR3
––
––
–DR18
DRB1*0330
DR3
––
––
–DR17
DRB1*0331
DR3
––
––
–DR17
DRB1*0332
DR3
––
––
–DR17
DRB1*0333
DR3
––
––
–DR17
DRB1*0335
DR3
––
––
–DR18
DRB1*0401
DR4
DR4
DR4[100]a
13
DR4[98]
5118
Training–DR4
DRB1*0402
DR4
DR4
DR4[84–100]
4DR4[92]
1029
Training–DR4
DRB1*0403
DR4
DR4
DR4[97–100]a
9DR4[92]
748
Training–DR4
DRB1*0404
DR4
DR4
DR4[95–100]a
20
DR4[89]
2164
Training–DR4
DRB1*0405
DR4
DR4
DR4[94–100]a
13
DR4[91]
505
Training–DR4
DRB1*0406
DR4
DR4
DR4[89–100]
3DR4[89]
83
DR4
DRB1*0407
DR4
DR4
DR4[97–100]a
7DR4[86]
846
Training–DR4
DRB1*0408
DR4
DR4
DR4[100]a
1DR4[86]
258
DR4
DRB1*0409
DR4
DR4
––
DR4[100]b
11
DR4
DRB1*0410
DR4
DR4
DR4[100]
3DR4[84]
29
DR4
DRB1*0411
DR4
DR4
DR4[94–100]a
3DR4[93]
76
DR4
DRB1*0412
DR4
––
–DR4[100]b
1DR4
DRB1*0413
DR4
DR4
––
DR4[100]b
3DR4
DRB1*0414
DR4
DR4
––
DR4[100]b
1DR4
DRB1*0415
DR4
DR4
DR4[84–100],
DR11[20]a
4DR4[67]b
3DR4
DR4x11
DRB1*0416
DR4
DR4
DR4[100]
2DR4[100]b
1DR4
DRB1*0417
DR4
DR4
––
be
1DR4
DRB1*0418
DR4
––
––
–DR4
DRB1*0419
DR4
DR4
––
––
DR4
DRB1*0420
DR4
DR4
––
DR4[100]b
1DR4
152 ª 2009 John Wiley & Sons A/S � Tissue Antigens 73, 95–170
HLA alleles and serologic types R. Holdsworth et al.
Table
4Continued
HLAallele
Expertassigned
WHO
assigned
InternationalC
ellExchange,UCLA
NMDP
NN
Comments
Assignedtype[%
]Cells
tested
Assignedtype[%
]Cells
tested
Assignedtype>0.55
DRB1*0421
DR4
DR4
––
DR4[100]b
1DR4
DRB1*0422
DR4/DR3
DR4
––
––
DR4
DR4x3
DRB1*0423
DR4
DR4
––
––
DR4
DRB1*0424
DR4
DR4
––
––
DR4
DRB1*0425
DR4
DR4
––
––
DR4
ShortDR4
DRB1*0426
DR4
DR4
DR4[100]
3DR4[100]b
1DR4
DRB1*0427
DR4
––
––
–DR4
DRB1*0428
DR4
DR4
––
––
DR4
DRB1*0429
DR4
DR4
––
––
DR4
DRB1*0430
DR4
––
––
–DR4
DRB1*0431
DR4
DR4
DR4[100]a
2be
1DR4
DRB1*0432
DR4
DR4d
DR4[94–100]a
2–
–DR4
DRB1*0433
DR4
––
–DR4[100]b
1DR4
DRB1*0434
DR4
––
––
–DR4
DRB1*0435
DR4
––
–DR4[100]b
1DR4
DRB1*0436
DR4
––
––
–DR4
DRB1*0437
DR4
––
––
–DR4
DRB1*0438
DR4
––
––
–DR4
DRB1*0439
DR4
––
––
–DR4
DRB1*0440
DR4
––
––
–DR4
DRB1*0441
DR4
––
––
–DR4
DRB1*0442
DR4
DR4
––
––
DR4
DRB1*0443
DR4
––
––
–DR4
DRB1*0444
DR4
––
––
–DR4
DRB1*0445
DR4
––
––
–DR4
DRB1*0446
DR4
––
––
–DR4
DRB1*0447
DR4
––
––
–DR4
DRB1*0448
DR4
––
––
–DR4
DRB1*0449
DR4
––
––
–DR4
DRB1*0450
DR4
––
––
–DR4
DRB1*0451
DR4
––
––
–DR4
DRB1*0452
DR4
––
––
–DR4
DRB1*0453
DR4
––
––
–DR4
DRB1*0454
DR4
––
––
–DR4
DRB1*0455
DR4
––
––
–DR4
DRB1*0456
DR4
––
––
–DR4
DRB1*0457
DR4
––
––
–DR4
DRB1*0458
DR4
––
––
–DR4
DRB1*0459
DR4
––
––
–DR4
ª 2009 John Wiley & Sons A/S � Tissue Antigens 73, 95–170 153
R. Holdsworth et al. HLA alleles and serologic types
Table
4Continued
HLAallele
Expertassigned
WHO
assigned
InternationalC
ellExchange,UCLA
NMDP
NN
Comments
Assignedtype[%
]Cells
tested
Assignedtype[%
]Cells
tested
Assignedtype>0.55
DRB1*0460
DR4
––
––
–DR4
DRB1*0461
DR4
––
––
–DR4
DRB1*0462
DR4
––
––
–DR4
DRB1*0463
DR4
––
––
–DR4
DRB1*0464
DR4
DR4
––
––
DR4
DRB1*0701
DR7
DR7
DR7[93–100]a
43
DR7[99]
7390
Training–DR7
DRB1*0703
DR7
DR7
––
––
DR7
DRB1*0704
DR7
DR7
DR7[100]
2–
–DR7
DRB1*0705
DR7
––
––
–DR7
DRB1*0706
DR7
––
––
–DR7
DRB1*0707
DR7
––
––
–DR7
DRB1*0708
DR7
––
––
–DR7
DRB1*0709
DR7
DR7
––
––
DR7
DRB1*0710N
Notexpressed
Null
––
––
NT
DRB1*0711
DR7
––
––
–DR7
DRB1*0712
DR7
––
––
–DR7
DRB1*0713
DR7
––
––
–DR7
DRB1*0714
DR7
––
––
–DR7
DRB1*0801
DR8
DR8
DR8[91–100]a
7DR8[95]
1076
Training–DR8
DRB1*0802
DR8
DR8
DR8[100]a
4DR8[96]
265
Training–DR8
DRB1*0803
DR8
DR8
DR8[96–100]
12
DR8[88],DR12[3]
230
Training–DR8
DRB1*0804
DR8
DR8
DR8[88–100]a
9DR8[93]
186
Training–DR8
DRB1*0805
DR8
DR8
––
DR8[83]b
6DR8
DRB1*0806
DR8
DR8
DR8[96–100]
4DR8[95]b
21
DR8
DRB1*0807
DR8
DR8
DR8[89]
1DR8[100]b
3DR8
DRB1*0808
DR8
––
––
–DR8
DRB1*0809
DR8
DR8
––
DR8[100]b
2DR8
DR8variant
DRB1*0810
DR8
DR8
DR8[94–100]a
2DR8[67],DR12
[22]b
9DR8
DRB1*0811
DR8
DR8
DR8[89–94]a
2DR8[100]b
10
DR8
DRB1*0812
DR8
DR8
––
––
DR8
DRB1*0813
DR8
DR8
––
––
DR8
DRB1*0814
DR8
DR8
DR8[74–78]a
2–
–DR8
DRB1*0815
DR8
––
––
–DR8
DRB1*0816
DR8
DR8
DR8[85]a
1–
–DR8
DRB1*0817
DR8
DR8
––
––
DR8
DRB1*0818
DR8
DR8
––
DR8[100]b
2DR8
DRB1*0819
DR8
––
––
–DR8
DRB1*0820
undefined
––
––
–Notassignedc
NN:DR8
154 ª 2009 John Wiley & Sons A/S � Tissue Antigens 73, 95–170
HLA alleles and serologic types R. Holdsworth et al.
Table
4Continued
HLAallele
Expertassigned
WHO
assigned
InternationalC
ellExchange,UCLA
NMDP
NN
Comments
Assignedtype[%
]Cells
tested
Assignedtype[%
]Cells
tested
Assignedtype>0.55
DRB1*0821
DR8
––
––
–DR8
DRB1*0822
DR8
––
––
–DR8
DRB1*0823
DR8
––
––
–DR8
DRB1*0824
DR8
––
––
–DR8
DRB1*0825
DR8
––
––
–DR8
DRB1*0826
DR8
––
––
–DR8
DRB1*0827
DR8
––
––
–DR8
DRB1*0828
DR8
––
––
–DR8
DRB1*0829
DR8
––
––
–DR8
DRB1*0830
DR8
––
––
–DR8
DRB1*0831
DR8/DR11
DR11(5)
––
––
Notassignedc
NN:DR8,DR11
DRB1*0832
Undefined
––
––
–Notassignedc
NN:DR8,DR12
DRB1*0901
DR9
DR9
DR9[89–100]
19
DR9[95]
1058
Training–DR9
DRB1*0902
DR9
––
––
–DR9
DRB1*0903
DR9
––
––
–DR9
DRB1*0904
DR9
––
––
–DR9
DRB1*0905
DR9
DR9
––
––
DR9
DRB1*0906
DR9
––
––
–DR9
DRB1*1001
DR10
DR10
DR10[87–100]a
14
DR10[90],DR1
[4],blank[2]
894
Training–DR10
DRB1*1101
DR11
DR11(5)
DR11[88–100]a
15
DR11[92],DR5[5]
3474
Training–DR11
DRB1*1102
DR11
DR11(5)
DR11[89–100]
6DR11[89],DR5[3]
430
Training–DR11
DRB1*1103
DR11
DR11(5)
DR11[84–100]
2DR11[89],DR5[4]
397
Training–DR11
DRB1*1104
DR11
DR11(5)
DR11[87–100]a
13
DR11[87],DR5[4]
2119
Training–DR11
DRB1*1105
DR11
DR11(5)
DR11[90–100]a
2DR11[100]b
3DR11
DRB1*1106
DR11
DR11(5)
––
DR5[79],DR11
[21]b
14
DR11
DRB1*1107
DR11
DR11(5)d
––
DR11[100]b
3Notassignedc
DR11x3;NN:
DR17,DR3,DR11
DRB1*1108
DR11
DR11(5)
DR11[91–100]a
3be
1DR11
DRB1*1109
DR11
DR11(5)
DR11[100]
1DR11[75],DR5
[25]b
4Training–DR11
DRB1*1110
DR11
––
–DR11[100]b
2DR11
DRB1*1111
DR11
DR11(5)
DR11[87–90],
DR13[7–8],
DR5[4–5]
3DR11[90],DR5
[10]b
10
DR11
DR11x13
DRB1*1112
DR11
––
–DR11[100]b
5DR11
DRB1*1113
DR11
DR11(5)
DR11[93]a
2DR11[86]b
7DR11
DR11x14
DRB1*1114
DR11
DR11(5)
DR11[94–100]a
3DR11[100]b
2DR11
ª 2009 John Wiley & Sons A/S � Tissue Antigens 73, 95–170 155
R. Holdsworth et al. HLA alleles and serologic types
Table
4Continued
HLAallele
Expertassigned
WHO
assigned
InternationalC
ellExchange,UCLA
NMDP
NN
Comments
Assignedtype[%
]Cells
tested
Assignedtype[%
]Cells
tested
Assignedtype>0.55
DRB1*1115
DR11
––
–DR11[50],DR6
[50]b
2DR11
DRB1*1116
DR11/DR13
DR11(5)/DR13
(6)d
––
DR11[100]b
1DR11
DR11x13;DR11
(70),DR13(30)
DRB1*1117
DR14
––
––
–DR14f
NN:DR6
DRB1*1118
DR11
––
–be
1DR11
DRB1*1119
DR11
DR11(5)
DR11[100]
4be
1DR11
DRB1*1120
DR11
DR11(5)
––
––
DR11
DR11x13
DRB1*1121
DR11
DR11(5)
DR11[88–97],
DR13[12]a
2–
–DR11
DRB1*1122
Undefined
––
––
–Notassignedc
NN:DR11
DRB1*1123
DR11
DR11(5)
––
––
DR11
DRB1*1124
DR11
––
––
–DR11
DRB1*1125
DR11
DR11(5)
––
––
DR11
DRB1*1126
DR11
DR11(5)
––
––
DR11
DRB1*1127
DR11
DR11(5)
––
––
DR11
DRB1*1128
DR11
––
––
–DR11
DRB1*1129
DR11
DR11(5)
DR11[100]
2–
–DR11
DRB1*1130
DR11
––
––
–DR11
DRB1*1131
DR11
––
––
–DR11
DRB1*1132
DR11
––
––
–DR11
DRB1*1133
DR11
––
––
–DR11
DRB1*1134
DR11
––
––
–DR11
DRB1*1135
DR11
––
––
–DR11
DRB1*1136
DR11
––
––
–DR11
DRB1*1137
DR11
DR11(5)
––
––
DR11
DRB1*1138
DR11
––
––
–DR11
DRB1*1139
DR11
––
––
–DR11
DRB1*1140
DR11
––
––
–DR11
DRB1*1141
DR11
––
––
–DR11
DRB1*1142
DR11
––
––
–DR11
DRB1*1143
DR11
––
––
–DR11
DRB1*1144
DR11
––
––
–DR11
DRB1*1145
DR11
––
––
–DR11
DRB1*1146
DR11
––
––
–DR11
DRB1*1147
DR11
––
––
–DR11
DRB1*1148
DR11
––
––
–DR11
DRB1*1149
DR11
––
––
–DR11
DRB1*1150
DR11
––
––
–DR11
156 ª 2009 John Wiley & Sons A/S � Tissue Antigens 73, 95–170
HLA alleles and serologic types R. Holdsworth et al.
Table
4Continued
HLAallele
Expertassigned
WHO
assigned
InternationalC
ellExchange,UCLA
NMDP
NN
Comments
Assignedtype[%
]Cells
tested
Assignedtype[%
]Cells
tested
Assignedtype>0.55
DRB1*1151
DR11
––
––
–DR11
DRB1*1152
DR11
DR11(5)
––
––
DR14
DRB1*1153
DR11
––
––
–DR11
DRB1*1154
DR11
––
––
–DR11
DRB1*1155
DR11
––
––
–DR11
DRB1*1156
DR11
––
––
–DR11
DRB1*1157
DR11
––
––
–DR11
DRB1*1158
DR11
––
––
–DR11
DRB1*1159
DR11
––
––
–DR11
DRB1*1160
DR11
––
––
–DR11
DRB1*1161
DR11
––
––
–DR11
DRB1*1162
DR11
––
––
–DR11
DRB1*1201
DR12
DR12(5)
DR12[85–100],
DR13[5–12]
9DR12[83],DR5
[4],DR8[2],
DR11[2]
893
Training–DR12
DRB1*1202
DR12
DR12(5)
DR12[91–100]
17
DR12[89]
162
Training–DR12
DRB1*1203
DR12
DR12(5)
––
DR12[100]b
4DR12
DRB1*1204
DR12
––
––
–DR12
DR12x11
DRB1*1205
DR12
DR12(5)
––
––
DR12
DRB1*1206
DR12
DR12(5)
––
DR12[100]b
3DR12
DRB1*1207
DR12
––
––
–DR12
DRB1*1208
DR12
––
––
–DR12
DRB1*1209
DR12
––
––
–DR12
DRB1*1210
DR12
––
––
–DR12
DRB1*1211
DR12
––
––
–DR12
DRB1*1212
DR12
––
––
–DR12
DRB1*1213
DR12
––
––
–DR12
DRB1*1214
DR12
––
––
–DR12
DRB1*1215
DR12
––
––
–DR12
DRB1*1301
DR13
DR13(6)
DR13[90–100],
DR6[0–7]a
17
DR13[81],DR6
[14],DR14[1]
3788
Training–DR6DR13
DRB1*1302
DR13
DR13(6)
DR13[81–97],
DR6[7–11]a
17
DR13[74],DR6
[17],DR14[2]
3081
Training–DR6DR13
DRB1*1303
DR13
DR13(6)
DR13[50–93],
DR6[4–21],
DR‘1303’
[0–11],DR14
[0–17],DR3
[0–8]
11
DR13[69],DR6
[10],DR12[3],
DR11[3],DR5
[2],DR14[2]
948
Training–DR6DR13
ª 2009 John Wiley & Sons A/S � Tissue Antigens 73, 95–170 157
R. Holdsworth et al. HLA alleles and serologic types
Table
4Continued
HLAallele
Expertassigned
WHO
assigned
InternationalC
ellExchange,UCLA
NMDP
NN
Comments
Assignedtype[%
]Cells
tested
Assignedtype[%
]Cells
tested
Assignedtype>0.55
DRB1*1304
DR13
DR13(6)
––
DR13[87]
127
DR13
DRB1*1305
DR13
DR13(6)
DR13[48–62],
DR11[11–34],
DR6[5–20],
DR14[3–8]
3DR13[54],DR6
[12],DR11[7],
DR12[6],DR5
[4]
305
DR6
DRB1*1306
DR13
DR13(6)
DR13[95]
1DR13[88],DR6
[12]b
8DR13
DRB1*1307
DR13
DR13(6)
––
DR13[100]b
1Notassignedc
NN:DR11,DR6
DRB1*1308
DR13
DR13(6)
DR13[84],DR6[5]
1DR13[100]b
5DR13
DRB1*1309
DR13
––
–DR13[100]b
1DR6f
NN:DR13
DRB1*1310
DR13
DR13(6)
DR13[80–95],
DR6[7–15],
DR14[0–10]a
5DR13[100]b
4DR13
DRB1*1311
DR13
DR13(6)
DR13[72–90],
DR11[0–28],
DR14[0–10],
DR6[0–6]a
2DR6[50],blank
[50]b
2DR11
DRB1*1312
DR13
DR13(6)d
––
DR13[50],DR6
[13],DR12[13],
DR11[13]b
8DR13
DR13x12
DRB1*1313
DR13
DR13(6)d
DR13[83],DR6
[13]
1–
–DR6
DR52negative;
NN:DR13,DR8
DRB1*1314
DR13
DR13(6)
DR13[69–77],
DR11[0–15],
DR14[0–9],
DR6[0–5]a
3DR11[50],blank
[50]b
2DR11
DRB1*1315
DR13
––
––
–DR13
DRB1*1316
DR13
DR13(6)
––
––
DR13
DRB1*1317
DR13
DR13(6)
DR13[53],DR8
[41],DR11[6]a
1–
–Notassignedc
DR13x8;NN:DR8
DRB1*1318
DR13
DR13(6)
––
––
Notassignedc
NN:DR6,DR11
DRB1*1319
DR13
DR13(6)d
––
––
DR13
NN:DR14
DRB1*1320
DR13
DR13(6)
DR13[87–95],
DR6[0–5]a
2–
–DR13
DRB1*1321
DR13/DR11
––
–DR13[50],blank
[50]b
2DR11
DRB1*1322
DR13
DR13(6)d
––
DR13[100]b
1DR13f
NN:DR6
DRB1*1323
DR13
––
––
–DR13
NN:DR6
DRB1*1324
DR11
––
––
–DR11
158 ª 2009 John Wiley & Sons A/S � Tissue Antigens 73, 95–170
HLA alleles and serologic types R. Holdsworth et al.
Table
4Continued
HLAallele
Expertassigned
WHO
assigned
InternationalC
ellExchange,UCLA
NMDP
NN
Comments
Assignedtype[%
]Cells
tested
Assignedtype[%
]Cells
tested
Assignedtype>0.55
DRB1*1325
DR11
––
––
–DR11
DRB1*1326
DR14
––
––
–DR14
DRblankDR52
positive
DRB1*1327
DR13
DR13(6)
––
––
DR13
DRB1*1328
DR13
––
––
–DR13
DRB1*1329
DR13
DR13(6)d
DR13[72–90],
DR6[0–9]a
2–
–DR13
DRB1*1330
Undefined
––
––
–Notassignedc
NN:DR13,DR6,
DR11
DRB1*1331
DR13
–DR13[80],DR14
[10]a
1–
–DR13
DRB1*1332
DR13
––
––
–DR13
DRB1*1333
DR13
––
––
–DR13
DRB1*1334
DR13
––
––
–DR13
DRB1*1335
DR13
––
––
–DR13
DRB1*1336
DR13
DR13(6)
DR13[91–100],
DR6[0–5],
DR14[0–4]a
3DR6[100]b
1DR13
DRB1*1337
DR13
––
––
–DR13
DRB1*1338
DR13
––
––
–DR13
DRB1*1339
DR13
––
––
–DR13
DRB1*1340
DR13
––
––
–DR13
DRB1*1341
DR13
––
––
–DR13
DRB1*1342
DR6
DR13(6)
––
––
DR6
DRB1*1343
DR13
––
––
–DR13
DRB1*1344
Undefined
––
––
–Notassignedc
NN:DR11
DRB1*1345
DR13
––
––
–DR13
DRB1*1346
DR11
––
––
–DR11
DRB1*1347
Undefined
––
––
–Notassignedc
NN:DR8
DRB1*1348
DR13
––
––
–DR13
DRB1*1349
DR6
––
––
–DR6
DRB1*1350
DR11
––
––
–DR11
DRB1*1351
DR13
––
––
–DR13
DRB1*1352
DR13
DR13(6)
––
––
DR13
DRB1*1353
DR13
––
––
–DR13
DRB1*1354
DR14
DR14(6)
––
––
Notassignedc
NN:DR11
DRB1*1355
Undefined
––
––
–Notassignedc
NN:DR8,DR6
DRB1*1356
DR6
––
––
–DR6
NN:DR13
DRB1*1357
DR13
DR13(6)
––
––
DR13
ª 2009 John Wiley & Sons A/S � Tissue Antigens 73, 95–170 159
R. Holdsworth et al. HLA alleles and serologic types
Table
4Continued
HLAallele
Expertassigned
WHO
assigned
InternationalC
ellExchange,UCLA
NMDP
NN
Comments
Assignedtype[%
]Cells
tested
Assignedtype[%
]Cells
tested
Assignedtype>0.55
DRB1*1358
DR13
––
––
–DR13
DRB1*1359
DR13
––
––
–DR13
DRB1*1360
DR6
––
––
–DR6
DRB5*02
associated(60)
DRB1*1361
DR13
––
––
–DR13
DRB1*1362
DR11
––
––
–DR11
DRB1*1363
DR13
––
––
–DR13
DRB1*1364
DR13
––
––
–DR13
DRB1*1365
DR13
––
––
–DR13
DRB1*1366
DR13
DR13(6)
––
––
DR13
DRB1*1367
DR13
––
––
–DR13
DRB1*1368
DR13
––
––
–DR13
DRB1*1369
DR13
––
––
–DR13
DRB1*1370
DR13
––
––
–DR13
DRB1*1371
DR13
––
––
–DR13
DRB1*1372
DR13
––
––
–DR13
DRB1*1373
DR13
––
––
–DR13
DRB1*1374
DR13
––
––
–DR13
DRB1*1375
Undefined
––
––
–Notassignedc
NN:DR11,DR13,
DR6
DRB1*1376
DR13
––
––
–DR13
DRB1*1378
DR13
––
––
–DR13
DRB1*1379
DR13
––
––
–DR13
DRB1*1401
DR14
DR14(6)
DR14[91–100],
DR6[0–7]a
18
DR14[74],DR6
[14],DR13[3]
1942
Training–DR6DR14
DRB1*1402
DR14
DR14(6)
DR14[50–83],
DR6[12–17],
DR17[8–15],
DR13[0–19]
9DR14[61],DR6
[13],DR13[9]
204
Training–DR6DR14
DRB1*1403
DR1403/DR14
DR1403
––
DR14[72],DR6
[12]
37
DR14
DRB1*1404
DR1404/DR14
DR1404
DR14[84–89],
DR1404[5–8],
DR6[3–7],DR8
[0–10]
8DR14[79],DR6
[8],DR1404[3]
80
DR14
DRB1*1405
DR14
DR14(6)
DR14[74–85],
DR6[11–15],
DR3[0–13]
2DR14[86],DR6
[10]
58
DR14
160 ª 2009 John Wiley & Sons A/S � Tissue Antigens 73, 95–170
HLA alleles and serologic types R. Holdsworth et al.
Table
4Continued
HLAallele
Expertassigned
WHO
assigned
InternationalC
ellExchange,UCLA
NMDP
NN
Comments
Assignedtype[%
]Cells
tested
Assignedtype[%
]Cells
tested
Assignedtype>0.55
DRB1*1406
DR14
DR14(6)
DR13[28],DR14
[26],DR6[19],
DR3[11]
1DR14[37],DR13
[22],DR6[15]
117
Training–DR6DR14
DRB1*1407
DR14
DR14(6)
DR14[87–96],
DR6[0–4]a
2DR14[94]b
16
DR14
DRB1*1408
DR14
DR14(6)d
DR14[94]
1DR14[50],DR6
[25]b
4DR14
DRB1*1409
DR14
––
––
–DR14
DRB1*1410
DR14
DR14(6)
DR14[76–83],
DR6[4–10]
2DR14[100]b
4Notassignedc
NN:DR4,DR14,
DR6
DRB1*1411
DR14
DR14(6)
DR14[59],DR6
[12],DR11[12],
DR‘14x11’[9]
1DR14[100]b
1Notassignedc
DR14x11;NN:
DR14
DRB1*1412
DR14
DR14(6)
––
––
DR14
NN:DR6
DRB1*1413
DR14
DR14(6)
DR14[59–86],
DR6[4–17],
DR13[0–10]
3DR6[100]b
1DR14
DRB1*1414
DR14
DR14(6)
DR14[88–89],
DR13[0–5]
2–
–DR14
DRB1*1415
DR8
DR8
DR8[50],DR14
[26],DR13[8]
1DR8[100]b
1DR8
DR81
DR52
DRB1*1416
DR6
DR6
––
DR14[100]b
1DR13
DR14x13
DRB1*1417
DR6
DR6
––
DR13[100]b
1DR6
DR14x13;DR13
weak,DR14
negative
DRB1*1418
DR14
DR6
––
DR14[100]b
1DR14
DRB1*1419
DR14
DR14(6)
––
––
DR14
DRB1*1420
DR14
DR14(6)
––
Blank[100]b
1DR14
DRB1*1421
DR14
DR14(6)
DR14[57–84],
DR13[8–29],
DR6[4–14],
DR17[0–6]a
3DR6[100]b
1DR6
Alsotypedas
DR13
DRB1*1422
DR14
DR14(6)d
––
––
DR14
DRB1*1423
DR14
––
–DR14[100]b
1DR14
DRB1*1424
DR14
––
––
–DR14
DRB1*1425
DR6
––
––
–DR6
DRB1*1426
DR14
DR14(6)
––
––
DR14
DRB1*1427
DR14
DR14(6)
––
––
DR6
NN:DR14
DRB1*1428
DR14
––
––
–DR14
ª 2009 John Wiley & Sons A/S � Tissue Antigens 73, 95–170 161
R. Holdsworth et al. HLA alleles and serologic types
Table
4Continued
HLAallele
Expertassigned
WHO
assigned
InternationalC
ellExchange,UCLA
NMDP
NN
Comments
Assignedtype[%
]Cells
tested
Assignedtype[%
]Cells
tested
Assignedtype>0.55
DRB1*1429
DR14
DR14(6)
––
––
DR14
DRB1*1430
DR6
––
––
–DR6
DRB1*1431
DR14
––
––
–DR14
DRB1*1432
DR14
––
––
–DR14
DRB1*1433
DR6
––
––
–DR6
NN:DR14
DRB1*1434
DR14
––
––
–DR14
DRB1*1435
DR14
––
––
–DR14
DRB1*1436
DR14
––
––
–DR14
DRB1*1437
DR14
––
––
–DR14
DRB1*1438
DR14
––
––
–DR14
DRB1*1439
DR14
––
––
–DR14
DRB1*1440
DR14
––
––
–DR14
DRB1*1441
DR14
––
––
–DR14
DRB1*1442
Undefined
––
––
–Notassignedc
NN:DR11
DRB1*1443
DR14
––
––
–DR14
DRB1*1444
DR14
––
––
–DR14
DRB1*1445
DR14
––
––
–DR14
DRB1*1446
DR14
––
––
–DR14
DRB1*1447
DR14
––
––
–DR14
DRB1*1448
DR14
––
––
–DR14
DRB1*1449
DR14
DR14(6)
––
––
DR14
DRB1*1450
DR14
DR14(6)
––
––
Notassignedc
NN:DR14,DR6
DRB1*1451
DR14
––
––
–DR14
DRB1*1452
DR14
––
––
–DR14
DRB1*1453
DR13/14
DR13(6)
––
––
DR11
DRB1*1454
DR14
–DR14[100]a
3DR14[89]b
9DR14
DRB1*1455
DR14
––
––
–DR14
DRB1*1456
DR14
––
––
–DR14
DRB1*1457
DR4/DR6
––
––
–DR4
NN:DR6
DRB1*1458
DR14
––
––
–DR14
DRB1*1459
DR14
––
––
–DR14
DRB1*1460
DR14
DR14(6)
––
––
DR14
DRB1*1461
DR14
––
––
–DR14
DRB1*1462
DR14
––
––
–DR14
DRB1*1463
DR6
––
––
–DR6f
NN:DR14
DRB1*1464
DR14
––
––
–DR14
DRB1*1465
DR6
––
––
–DR6f
NN:DR14
DRB1*1466
DR14
––
––
–DR14
DRB1*1467
DR6
––
––
–DR6f
NN:DR14
162 ª 2009 John Wiley & Sons A/S � Tissue Antigens 73, 95–170
HLA alleles and serologic types R. Holdsworth et al.
Table
4Continued
HLAallele
Expertassigned
WHO
assigned
InternationalC
ellExchange,UCLA
NMDP
NN
Comments
Assignedtype[%
]Cells
tested
Assignedtype[%
]Cells
tested
Assignedtype>0.55
DRB1*1468
DR14
––
––
–DR14
DRB1*1501
DR15
DR15(2)
DR15[75–90],
DR2[0–19],
DR16[0–13]a
31
DR15[76],DR2
[23]
6428
Training–DR2DR15
DRB1*1502
DR15
DR15(2)
DR15[82–100],
DR2[0–14]a
17
DR15[77],DR2
[16]
676
Training–DR2DR15
DRB1*1503
DR15
DR15(2)
DR15[81–94],
DR2[3–13],
DR16[0–6]a
8DR15[81],DR2
[13]
286
Training–DR2DR15
DRB1*1504
DR15
DR15(2)d
DR15[76–91],
DR2[0–18],
DR16[0–6]a
4DR15[100]b
1DR15
DRB1*1505
DR15
DR15(2)
––
DR15[100]b
1DR15
DRB1*1506
DR15
DR15(2)
––
DR15[100]b
2DR15
DRB1*1507
DR15
DR15(2)d
DR15[82–91],
DR2[5–9],
DR16[0–9]a
2–
–DR15
DRB1*1508
DR15
DR2
––
––
DR15
DRB1*1509
DR15
––
––
–DR15
DRB1*1510
DR2
––
––
–DR2
NN:DR15
DRB1*1511
DR15
––
––
–DR15
DRB1*1512
DR15
––
––
–DR15
DRB1*1513
DR2
––
––
–DR2
NN:DR15,DR16
DRB1*1514
DR15
––
–DR15[100]b
1DR15
DRB1*1515
DR15
––
––
–DR15
DRB1*1516
DR15
––
––
–DR15
DRB1*1517N
Notexpressed
Null
––
––
NT
DRB1*1518
DR15
––
––
–DR15
DRB1*1519
DR15
––
––
–DR15
DRB1*1520
DR15
––
––
–DR15
DRB1*1521
DR2
––
––
–DR2f
NN:DR15,DR16
DRB1*1522
DR15
––
––
–DR15
DRB1*1601
DR16
DR16(2)
DR16[31],DR15
[38],DR2[31]
1DR16[41],DR2
[29],DR15[19]
703
Training–DR2DR16
DRB1*1602
DR16
DR16(2)
DR16[56–82],
DR2[12–28],
DR15[6–22]a
13
DR16[47],DR2
[30],DR15[16]
239
Training–DR2DR16
DRB1*1603
DR16
DR2
––
––
DR16
ª 2009 John Wiley & Sons A/S � Tissue Antigens 73, 95–170 163
R. Holdsworth et al. HLA alleles and serologic types
NMDPdatabase; some individuals carried the allele but did
not have associated serologic typing. In some cases, the
number of cells tested is less than the number in the last
dictionary. In these cases, the typing assignment may have
changed or further data suggest that the typing result was
not informative.
Neural network
An artificial NN was used to predict serologic assignments
for alleles lacking this information and to support serologic
assignments from other sources (7). The same set of alleles
used in previous iterations was used to train the NN. The
training alleles and the broad and split serologic assign-
ments used in the training are indicated in the tables. In this
2008 report, 10 NN were run instead of the five previously
run to increase accuracy of the predictions. After training of
10 independent NN for each locus, the NN were used to
predict the serologic types associated with polymorphic
amino acid sequences of the remaining allelic products and
results summarized from the 10 networks. Primary assign-
ments are listed in one column, secondary assignments in the
‘Comments’ column. The criteria used for inclusion are
described in the 2004 dictionary. Some allelic products with
unusual combinations of serologic epitopes did not receive
an assignment from the NN or have received varying
assignments in the different published iterations of the
network analysis. For example, A*0255, an allele evaluated
in all three iterations of the NN received varying assign-
ments from the NN. In the first NN (7), A2 was assigned as
the primary specificity with A28 and A69 as secondary
specificities; in the second NN (4), A28 was primary with
A69 as secondary; and in this iteration summarizing 10NN,
no specificity was assigned (serologic blank) and A2, A69,
and A28 were assigned as secondary specificities.
It should be noted that a few cases were observed where
the NN did not assign the same serologic specificity as
expected based on the validation data set. For example,
B*1529was assigned as B71 by theNNwhen previously this
allele had been assigned as B15 by serology. This
discrepancy could be because of limited serologic typing
data or because of limitations of the NN prediction. The
data from the NN can be viewed at http://bioinformatics.
nmdp.org/neuralnetwork2007.
The use of a NN to predict the serologic assignments of
antigens encoded by theHLA-C and -DQB1 loci is new. The
alleles with well-defined serology used to train the NN and
to validate the network assignments are indicated in
Tables 3 and 6.
Serology allele phenotype component of the 13th
International Histocompatibility Workshop
The data from the 13th IHWG were obtained by serologic
typing of cells with known HLA alleles. The cells wereTable
4Continued
HLAallele
Expertassigned
WHO
assigned
InternationalC
ellExchange,UCLA
NMDP
NN
Comments
Assignedtype[%
]Cells
tested
Assignedtype[%
]Cells
tested
Assignedtype>0.55
DRB1*1604
DR16
DR16(2)
DR16[53–64],
DR15[16–27],
DR2[9–31]a
2DR16[100]b
1DR16
DRB1*1605
DR16
DR16(2)d
––
DR16[100]b
1DR16
DRB1*1607
DR16
––
––
–DR16
DRB1*1608
DR16
––
––
–DR16
DRB1*1609
DR16
DR16(2)
––
––
DR16
DRB1*1610
DR16
––
––
–DR16
DRB1*1611
DR16
––
––
–DR16
NT,nottested;NN,neuraln
etw
ork;HLA,humanleukocyte
antigen;WHO,WorldHealthOrganization;NMDP,NationalM
arrow
DonorProgram.
aUpdatedInternationalC
ellExchange,UCLA.
bUpdatedNMDPdata.Insomecases,theinform
ationreportedinpreviousdictionarieshaschanged.C
ells
havebeenexcludedfrom
thisstudyinsomecasesbecausetheirHLAtypinghaschanged.
cNotassigned;seecommentcolumnforpredictions>0.20.
dWHO
assignmentbasedondictionary
data.
eTheallele
hasbeenidentifiedbutserologynotinform
ative.
fIfaprimary
specificityisprovidedbytheNN,otherspecificities>0.4
are
shownin
thecomments
column.
164 ª 2009 John Wiley & Sons A/S � Tissue Antigens 73, 95–170
HLA alleles and serologic types R. Holdsworth et al.
Table
5HLA-DRB3,DRB4,DRB5allelesandtheirserologicdesignations
HLAallele
Expert
assigned
WHO
assigned
InternationalC
ellExchange,UCLA
Expert
assigned
WHO
assigned
InternationalC
ellExchange,UCLA
Comments
Assignedtype[%
]Cells
tested
Comments
HLAallele
Assignedtype[%
]Cells
tested
DRB3*0101
DR52
DR52
DR52[90–100]a
88
DRB3*0222
Undefined
––
DRB3*0102
DR52
–DR52[99]
1DRB3*0301
DR52
DR52
DR52[90–100]a
41
DRB3*0103
Undefined
––
–DRB3*0302
DR52
DR52
––
DRB3*0104
Undefined
––
–DRB3*0303
DR52
–DR52[100]a
1
DRB3*0105
Undefined
––
–DRB4*0101
DR53
DR53
DR53[94–100]a
44
DRB3*0106
DR52
DR52
––
DRB4*0102
Undefined
––
–
DRB3*0107
DR52
DR52
––
DRB4*0103
DR53
DR53
DR53[88–100]a
73
DRB3*0108
Undefined
––
–DRB4*01030102N
Notexpressed
Null
Referto
comments
23
DR53(20–54),false-
positiveassignments
DRB3*0109
Undefined
––
–DRB4*0104
Undefined
––
–
DRB3*0110
DR52
DR52
––
DRB4*0105
DR53
DR53
––
DRB3*0111
Undefined
–DRB4*0106
Undefined
––
–
DRB3*0201
DR52
DR52
DR52[97–100]a
3DRB4*0107
Undefined
–
DRB3*0202
DR52
DR52
DR52[90–100]
126
DRB4*0201N
Notexpressed
Null
––
DRB3*0203
DR52
DR52
DR52[100]
1DRB4*0301N
Notexpressed
Null
Referto
comments
1DR53(69)false-positive
assignments
DRB3*0204
Undefined
––
–DRB5*0101
DR51
DR51
DR51[82–100]a
41
DRB3*0205
Undefined
––
–DRB5*0102
DR51
DR51
DR51[86–100]a
10
DRB3*0206
DR52
–DR52[91]a
1DRB5*0103
Undefined
––
–
DRB3*0207
DR52
DR52
––
DRB5*0104
Undefined
––
–
DRB3*0208
DR52
DR52
––
DRB5*0105
Undefined
––
–
DRB3*0209
DR52
DR52
––
DRB5*0106
Undefined
––
–
DRB3*0210
DR52
DR52
––
DRB5*0107
DR51
DR51
––
DRB3*0211
DR52
DR52
––
DRB5*0108N
Notexpressed
Null
Referto
comments
a2
DR51(43–60),false-
positiveassignments
DRB3*0212
Undefined
––
–DRB5*0109
Undefined
––
–
DRB3*0213
Undefined
––
–DRB5*0110N
Notexpressed
Null
Referto
comments
a1
DR51(55),false-positive
assignments
DRB3*0214
Undefined
––
–DRB5*0111
Undefined
–
DRB3*0215
Undefined
––
–DRB5*0112
Undefined
–
DRB3*0216
Undefined
––
–DRB5*0113
Undefined
–
DRB3*0217
Undefined
––
–DRB5*0202
DR51
DR51
DR51[86–100]a
15
DRB3*0218
Undefined
––
–DRB5*0203
Undefined
––
–
DRB3*0219
Undefined
––
–DRB5*0204
Undefined
––
–
DRB3*0220
Undefined
––
–DRB5*0205
Undefined
––
–
DRB3*0221
Undefined
––
–
NT,nottested;NN,neuraln
etw
ork;HLA,humanleukocyte
antigen;WHO,WorldHealthOrganization;NMDP,NationalM
arrow
DonorProgram.
aUpdatedInternationalC
ellExchange,UCLA.
ª 2009 John Wiley & Sons A/S � Tissue Antigens 73, 95–170 165
R. Holdsworth et al. HLA alleles and serologic types
Table 6 HLA-DQB1 alleles and their serologic designations
HLA allele
Expert
assigned
WHO
assigned
International Cell Exchange,
UCLA NMDP NN
CommentsAssigned type [%]
Cells
tested Assigned type [%]
Cells
tested
Assigned
type >0.55
DQB1*0201 DQ2 DQ2 DQ2 [87–100]a 30 DQ2 [98] 9175 Training – DQ2
DQB1*0202 DQ2 DQ2 DQ2 [75–100]a 23 DQ2 [87] 656 DQ2
DQB1*0203 DQ2 DQ2 – – DQ2 [67]b 3 DQ2
DQB1*0204 DQ2 – – – – – DQ2
DQB1*0205 DQ2 – – – – – DQ2
DQB1*0301 DQ7 DQ7(3) DQ7 [47–91], DQ3
[9–44], DQ8
[0–12]a
71 DQ7 [85], DQ3
[10], DQ8 [1]
12,220 Training – DQ3 DQ7
DQB1*0302 DQ8 DQ8(3) DQ3 [9–60], DQ8
[24–91], DQ7
[0–20], DQ9
[0–9]a
37 DQ8 [66], DQ3
[25], DQ7 [4]
6687 Training – DQ3 DQ8
DQB1*0303 DQ9 DQ9(3) DQ3 [22–60], DQ9
[20–67], DQ7
[0–11], DQ8
[0–9]a
23 DQ9 [67], DQ3
[12], DQ2 [11],
DQ8 [1], DQ7
[1]
2653 Training – DQ3 DQ9
DQB1*0304 DQ7 DQ7(3) DQ7 [60], DQ3
[34]
1 DQ7 [40], DQ3
[35], DQ8 [8]
111 DQ7
DQB1*0305 DQ8 DQ8(3)c – – DQ8 [34], DQ3
[30]
70 DQ8
DQB1*0306 DQ3 DQ3 – – DQ8 [100]b 1 DQ4
DQB1*0307 DQ8 – – – – – DQ8
DQB1*0308 DQ8 – – – – – DQ8
DQB1*0309 DQ7 – – – – – DQ7
DQB1*0310 DQ3 DQ8(3) – – DQ7 [100]b 1 DQ7
DQB1*0311 DQ8 – – – – – DQ8
DQB1*0312 DQ9 – – – – – DQ9
DQB1*0313 DQ7 – – – – – DQ7
DQB1*0314 DQ3 – – – – – DQ3d NN: DQ7, DQ8
DQB1*0315 DQ9 – – – – – DQ9
DQB1*0316 DQ7 – – – – – DQ7
DQB1*0317 DQ9 – – – – – DQ9
DQB1*0318 DQ8 – – – – – DQ8
DQB1*0319 DQ7 – DQ7 [91], DQ3 [9]a 1 – – DQ7
DQB1*0320 DQ9 – – – – – DQ9
DQB1*0401 DQ4 DQ4 DQ4 [88–89]a 3 DQ4 [71], DQ3
[10]
142 DQ4
DQB1*0402 DQ4 DQ4 DQ4 [77–100]a 22 DQ4 [86], DQ3 [2],
blank [7]
1085 Training – DQ4
DQB1*0501 DQ5 DQ5(1) DQ1 [25–67], DQ5
[20–63], DQ6
[0–13]a
27 DQ5 [69], DQ1
[20], DQ6 [2]
5539 Training – DQ1 DQ5
DQB1*0502 DQ5 DQ5(1) DQ1 [44–70], DQ5
[10–38], DQ6
[9–37]a
20 DQ5 [48], DQ1
[24], DQ6 [15]
919 DQ5
DQB1*0503 DQ5 DQ5(1) DQ1 [64–89], DQ5
[9–18], DQ6
[0–27]a
17 DQ5 [58], DQ1
[22], DQ6 [4]
1327 DQ5
DQB1*0504 DQ5 DQ5(1)c DQ1 [66], DQ5
[23], DQ6 [8]
1 DQ5 [58], DQ1
[17], DQ6 [2]
48 DQ5
DQB1*0505 DQ5 – – – – – DQ5
DQB1*0601 DQ6 DQ6(1) DQ6 [50–56], DQ1
[33–40], DQ5
[10–11]a
6 DQ6 [64], DQ1
[23]
675 DQ6
166 ª 2009 John Wiley & Sons A/S � Tissue Antigens 73, 95–170
HLA alleles and serologic types R. Holdsworth et al.
Table 6 Continued
HLA allele
Expert
assigned
WHO
assigned
International Cell Exchange,
UCLA NMDP NN
CommentsAssigned type [%]
Cells
tested Assigned type [%]
Cells
tested
Assigned
type >0.55
DQB1*0602 DQ6 DQ6(1) DQ1 [38–73], DQ6
[18–64], DQ5
[0–12]a
22 DQ6 [67], DQ1
[30], DQ5 [1]
5151 Training – DQ1 DQ6
DQB1*0603 DQ6 DQ6(1) DQ1 [31–64], DQ6
[22–63], DQ5
[0–10]a
18 DQ6 [62], DQ1
[23], DQ5 [2]
2807 DQ6
DQB1*0604 DQ6 DQ6(1) DQ1 [40–52], DQ6
[40–44], DQ5
[0–20]a
3 DQ6 [59], DQ1
[27], DQ5 [2]
1592 DQ6
DQB1*0605 DQ6 DQ6(1) – – DQ6 [76], DQ1
[13]
358 DQ6
DQB1*0606 DQ5 – – – DQ5 [100]b 1 DQ5
DQB1*0607 DQ6 – – – DQ1 [75], DQ6
[25]b4 DQ6
DQB1*0608 DQ6 DQ6(1)c – – DQ6 [50], DQ1
[25], DQ5 [25]b6 DQ6 DQ6
DQB1*0609 DQ6 DQ6(1) DQ6 [38–67], DQ1
[27–44], DQ5
[0–6]a
6 DQ6 [48], DQ1
[32], DQ5 [3]
149 DQ6
DQB1*0610 DQ1 – – – DQ1 [100]b 1 DQ6
DQB1*0611 DQ1 DQ1 – – – – DQ6
DQB1*0612 DQ1 DQ1 – – – – DQ6
DQB1*0613 DQ6 – – – be 1 DQ6
DQB1*0614 DQ6 DQ6(1) – – – – DQ6
DQB1*0615 DQ6 – – – – – DQ6
DQB1*0616 DQ6 – DQ6 [33–56], DQ1
[32–56], DQ5
[6–11]a
2 – – DQ6
DQB1*0617 DQ6 – – – be 1 DQ6
DQB1*0618 DQ6 – – – – – DQ6
DQB1*0619 DQ6 – – – – – DQ6
DQB1*0620 DQ6 – – – – – DQ6
DQB1*0621 DQ6 – – – – – DQ6
DQB1*0622 DQ6 – – – – – DQ6
DQB1*0623 DQ6 – – – – – DQ6
DQB1*0624 DQ6 – – – – – DQ6
DQB1*0625 DQ6 DQ6(1) – – – – DQ6
DQB1*0626N Not expressed Null – – – – NT
DQB1*0627 DQ6 – – – – – DQ6
DQB1*0628 DQ6 – – – – – DQ6
DQB1*0629 DQ6 – – – – – DQ6
DQB1*0630 DQ6 – – – – – DQ6
DQB1*0631 DQ6 – – – – – DQ6
DQB1*0632 DQ6 – – – – – DQ6
DQB1*0633 DQ6 – – – – – DQ6
NT, not tested; NN, neural network; HLA, human leukocyte antigen; WHO, World Health Organization; NMDP, National Marrow Donor Program.a Updated International Cell Exchange, UCLA.b UpdatedNMDPdata. In somecases, the information reported in previous dictionaries has changed. Cells have been excluded from this study in some
cases because their HLA typing has changed.c WHO assignment based on dictionary data.d If a primary specificity is provided by the NN, other specificities >0.4 are shown in the comments column.e The allele has been identified but serology not informative.
ª 2009 John Wiley & Sons A/S � Tissue Antigens 73, 95–170 167
R. Holdsworth et al. HLA alleles and serologic types
tested with a common set of well-characterized reagents
including mainly monoclonal antibodies (12) and supple-
mentary allosera. Tables 1–3 show the number of panel
cells for each allele included in the analysis, the assigned
specificity and, where appropriate, comments on the sero-
logical expression of that allele, as reported by the 13th
IHWS serology and HLA phenotype component (8, 9).
These data have not been updated from the 2004 edition of
the HLA data dictionary.
Information obtained from other sources
Data on the serological expression of new alleles have been
submitted fromHLA laboratories. However, because many
laboratories no longer perform serological typing or use
commercial monoclonal reagents, there are only a small
number of alleles that have been tested in this way. In this
edition of the dictionary, only 23 HLA class I alleles have
been submitted with serological information. The ‘Com-
ments’ column in the tables refers to information from
publications (listed at end of document) and other sources
that describe serologic expression of new alleles. It must be
noted, however, that some of these data are based on small
sample numbers tested by a single laboratory.
Expert assigned type
The expert assigned type for HLA-A, -B, -C, -DRB1, -DRB
3/4/5, and -DQB1 alleles is the combination of all serologic
equivalents information. This may help identify serologic
equivalents when there are differences with theWHOHLA-
designated serologic assignments (e.g. B*4005), or where
multiple assignments are possible such as hybrid molecules,
or where more antigen assignments are given (e.g. A* 3204,
Table 1 and B*1303, B*1304, Table 2). Occasionally, the
expert assigned type is based on the NN assignment;
however, while this should be considered with caution, the
NN may be the only information available.
Use of the dictionary in a HSC donor search
The HLA dictionary is a valuable tool in the search for
a matched unrelated stem cell source for a patient in need. It
contains the most current data, from multiple sources, on
the frequency of the phenotype detected for a particular
allele. An alternate patient phenotype can be identified to
assist with serologic types that may be potential matches for
a particular allele, for example B*4807 types as B48 (33%)
and B60 (42%). The search report for a patient with B*4807
will include B48-positive donors, but an alternate pheno-
type search using B60 would identify serologically typed
B60 donors with potential to match. In addition, some
alleles routinely type as blank by serology. The dictionary
can help determine whether donors with serologic blanks
(apparent homozygotes) carry the allele of interest.
Some alleles in the tables are listed with more than one
common serological assignment. This indicates that the
serological pattern is not clear, for example B*4416 has both
B47 and B44 reactivity. The ‘Comments’ section may
provide further information for serological reactivity in
some cases. In addition, many laboratories are not able to
identify many of the WHO-designated HLA specificities.
The International Cell Exchange, UCLA data show that
some of the newer specificities are rarely used but are often
designated by their antigen equivalents, for example A2
instead of A203. Although subsequent cell exchanges do
improve the detection rate, these assignments remain
difficult. It is useful to refer to the percentage recogni-
tion information when selecting alternative antigens for
alternative searches.
Searchable links between alleles and serologic
assignments
A searchable form of the dictionary is available through the
IMGT/HLA database (5) at http://www.ebi.ac.uk/imgt/
hla/. This information can then be used byHSC registries to
routinely update their matching algorithms and to support
other search and matching activities.
Acknowledgments
This work was supported in part by the US Office of Naval
Research N00014-05-1-0859 to the NMDP (MS, MM, and
JK) andN00014-06-1-0726 to the C.W. Bill YoungMarrow
Donor Recruitment and Research Program (CKH). The
participants of the International Cell Exchange, UCLA and
the Transplantation and Immunogenetics Laboratory of
the Welsh Transfusion Service are acknowledged for their
contribution.
References
1. HurleyCK,SchreuderGMT,MarshSGE,LauM,MiddletonD,
Noreen H. The search for HLA-matched donors: a summary of
HLA-A*, -B*, -DRB1/3/4/5* alleles and their association with
serologically defined HLA-A,-B,-DR antigens. Tissue Antigens
1997: 50: 401–18.
2. Schreuder GMT, Hurley CK, Marsh SGE et al. The HLA
dictionary 1999: a summary of HLA-A, -B, -C, -DRB1/3/4/5,
-DQB1 alleles and their association with serologically defined
HLA-A, -B, -C, -DR and -DQ antigens. Tissue Antigens 1999:
54: 409–37.
3. Schreuder GMTh, Hurley CK, Marsh SGE et al. The HLA
dictionary 2001: a summary of HLA-A, -B, -C, -DRB1/3/4/5,
-DQB1 alleles and their association with serologically defined
HLA-A, -B, -C, -DR and -DQ antigens. Tissue Antigens 2001:
58: 109–40.
4. Schreuder GM, Hurley CK, Marsh SG et al. The HLA
Dictionary 2004: a summary of HLA-A, -B, -C, -DRB1/3/4/5
and -DQB1 alleles and their association with serologically
168 ª 2009 John Wiley & Sons A/S � Tissue Antigens 73, 95–170
HLA alleles and serologic types R. Holdsworth et al.
defined HLA-A, -B, -C, -DR and -DQ antigens. Tissue
Antigens 2005: 65: 1–55.
5. Robinson J, Malik A, Parham P, Bodmer JG, Marsh SGE.
IMGT/HLA database – sequence database for the human
major histocompatibility complex. Tissue Antigens 2000:
55: 280–7.
6. Marsh SGE, Albert ED, Bodmer WF et al. Nomenclature
for factors of the HLA system, 2004. Tissue Antigens 2005:
65: 301–68.
7. Maiers M, Schreuder GMT, Lau M et al. Use of a neural
network to assign serologic specificities to HLA-A, -B and
-DRB1 allelic products. Tissue Antigens 2003: 62: 21–47.
8. SchreuderGMT,HoldsworthR, TanakaH et al. The serologic
specificity ofHLA-A, -B and -C alleles definedwith reagents of
the 13th International Histocompatibility Workshop. In:
Hansen JA, Dupont B, eds. HLA2002: Immunobiology of the
Human MHC. Proceedings of the 13th International
Histocompatibility Workshop and Congress, Vol. I and II.
Seattle: IHWG Press, 2006.
9. Fernandez-Vina MA, Yunis EJ. Summary report of the
serology-allele phenotype component of the 13th International
Histocompatibility Workshop. In: Hansen JA, Dupont B, eds.
HLA 2002: Immunobiology of the Human MHC. Proceedings
of the 13th International Histocompatibility Workshop and
Congress, Vol. I and II. Seattle: IHWG Press, 2006.
10. Marsh SGE, Albert ED, Bodmer WF et al. Nomenclature
for factors of the HLA system, 2002. Hum Immunol 2002:
63: 1213–68.
11. Marsh SGE, Bodmer JG, Albert ED et al. Nomenclature
for factors of the HLA system, 2000. Tissue Antigens 2001:
57: 236–83.
12. Maiers M, Schreuder GMT, Yunis EJ, Fernandez-Vina MA.
A computational approach to serologic epitope mapping. In:
Hansen JA, Dupont B, eds. HLA 2002: Immunobiology of the
Human MHC. Proceedings of the 13th International
Histocompatibility Workshop and Congress, Vol. I and II.
Seattle: IHWG Press, 2006
13. Street J, Downing J, Hammond L, Thompson J, Darke C.
Immunogenetics of two newHLA alleles: A*0108 and B*4031.
Tissue Antigens 2003: 61: 322–4.
14. Street J, Guttridge MG, Thompson J, Darke C. Genetics,
serology and sequences of six low frequency HLA-class I
alleles (BSHI abstract). Eur J Immunogen 2001: 28: 467–503
(p502).
15. Gutierrez M, Araujo HA, Stoddard JF et al. Serological
assignment of reported novel HLA-A and -B alleles (ASHI
abstract). Hum Immunol 2002: 63: S40.
16. Street J, Hammond L, Thompson J, Darke C. Serological
characterisation of the products of nine rareHLA class I alleles
(abstract BSHI). Eur J Immunogen 2002: 29: 351–70 (p355).
17. Yang KL, Gao X, Lin PY. Recognition of HLA-A*0248 in
a Chinese donor. Eur J Immunogen 2003: 30: 185–6.
18. Voorter CEM, Gervais T, van den Berg-Loonen EM.
Identification of HLA-A*0249 and confirmation of A*2615.
Tissue Antigens 2002: 60: 529–33.
19. Czachurski D, Rausch M, Scherer S, Opelz G, Mytilineos J.
Characterization of a newHLA-A allele, A*0256, identified in
a Caucasian individual. Tissue Antigens 2002: 60: 180–3.
20. Day S, Rawson J, Evans A, Dunn P. Identification and
characterization of a newHLAallele, A*0262 (BSHI abstract).
Eur J Immunogen 2003: 30: 305–23 (p315).
21. Anholts JDH, Drabbels J, Verduijn W, Oudshoorn M,
Schreuder GMTh. Five newly identified HLA alleles: A*0310,
A*2907, B*4435, Cw*0206, Cw*0506, and confirmation of
A*3106, B*3924, Cw*0314, DRB1*0322 and DRB1*1433
alleles. Tissue Antigens 2004: 63: 80–4.
22. Pyo C-W, Choi H-B, Han H, Hong Y-S, Kim T-G.
Identification of HLA-A*11 variant (A*1107) in the Korean
population. Tissue Antigens 2001: 58: 190–2.
23. Palou E, Santos M, Gil J, Campos E, Nogues N, Ribera A.
Identification and sequence characterization of a novel
HLA-A11 serological variant (HLA-A*1108). Tissue Antigens
2001: 57: 543–5.
24. Garino E, Belvedere M, Berrino M et al. New HLA-A*11
allele, A*1112, identified by sequence-based typing. Tissue
Antigens 2002: 60: 84–7.
25. Takahashi D, Miyazaki T, Araseki M et al. Identification of
a novel allele HLA-A*1113 in a Japanese donor. Tissue
Antigens 2004: 64: 81–3.
26. Wu G-G, Cheng L-H, Li Z et al. Identification of a new HLA
allele, A*1114 in a Chinese family. Tissue Antigens 2003:
61: 253–5.
27. Street J, Hammond L, Downing J, Thompson J, Darke C.
Observations on the HLA-A2403 specificity. Tissue Antigens
2003: 61: 330–3.
28. Voorter CEM, Hepkema BG, Lems SPM, van den
Berg-Loonen EM. Molecular and serological identification
of the HLA-A*3404 allele. Tissue Antigens 2002:
60: 328–30.
29. Herbut B, Woodman R, Kowalick L, Malkki M, Petersdorf
EW,McKenna R. Identification of a novel HLA-B*07 allele –
HLA-B*0726. Tissue Antigens 2002: 59: 60–2.
30. Longhi E, Frison S, Poli F et al. Identification of two new
HLA-B alleles, HLA-B*0732 and HLS-B*5809, by
sequence-based typing. Tissue Antigens 2004: 63: 273–8.
31. Longhi E, Frison S, Espaolas de Arias A et al.
Characterization of two newHLA-B alleles by sequence-based
typing: HLA-B*0817 and B*1311. Tissue Antigens 2003:
62: 66–71.
32. Hemmatpour S, Gupta A, Dunn PPJ, Sinnot PJ. The allele
B*1547 is serologically equivalent to the HLA-B48 antigen
(BSHI abstract). Eur J Immunogen 2003: 30: 305–23 (p323).
33. Kervaire B, Tiercy J-M. Additional diversity within the B70
serotype: identification of B*1580 in aCaucasoid blood donor.
Tissue Antigens 2004: 63: 270–2.
34. Street J, Hammond L, Downing J, Thompson J, Rees TJ,
Darke C. A further example of HLA-B*2712 (BSHI abstract).
Eur J Immunogen 2002: 29: 351–70 (p358).
35. Voorter CEM, Swelsen WTN, van den Berg-Loonen EM.
B*27 in molecular diagnostics: impact of new alleles and
polymorphism outside exons 2 and 3. Tissue Antigens 2002:
60: 25–35.
36. Tamouza R, Mansour I, Bouguacha N et al. A new
HLA-B*27 allele (B*2719) identified in a Lebanese patient
affected with ankylosing spondylitis. Tissue Antigens 2001:
58: 30–3.
ª 2009 John Wiley & Sons A/S � Tissue Antigens 73, 95–170 169
R. Holdsworth et al. HLA alleles and serologic types
37. Darke C, Street J, Hammond L, Downing J, Thompson J.
Immunogenetic study of a new HLA allele B*2723. Tissue
Antigens 2002: 60: 400–3.
38. Elsner H-A, Himmel A, Steitz M et al. HLA-B*3531, a hybrid
of B35 and B61, implications for diagnostic approaches to
alleles with complex ancestral compositions. Tissue Antigens
2002: 60: 95–7.
39. Swelsen WTN, Voorter CEM, van den Berg-Loonen EM.
Sequence analysis of exons 1, 2, 3, 4 and 5 of the
HLA-B5/35 cross-reacting group. Tissue Antigens 2002:
60: 224–34.
40. Estefania E, Gomez-Lozano N, de Pablo R, Moreno ME,
Vilches C. Complementary DNA sequence of the novel
HLA-B*3704 allele. Tissue Antigens 2002: 59: 142–4.
41. Pyo C-W, Han H, Kim T-G. Identification of a new HLA-B
allele, B*3705, containing a Bw6 sequence motif. Tissue
Antigens 2002: 59: 335–7.
42. Garcia-Sanchez F, Fernandez-de-Velasco J, Lillo R et al.
Two new HLA class I alleles recognised by PCR-SSP
and SBT: B*3805 and Cw*0408. Tissue Antigens 2002: 59:
47–8.
43. Voorter CEM, van den Berg-Loonen EM. Sequence based
typing of exons 1-5 of a new HLA-B allele, B*3927. Tissue
Antigens 2004: 63: 480–3.
44. Blanco PV, Theile G, Marcos C, et al. Novel HLA allele,
HLA-B*4013, identified from a potential bone marrow
recipient. Tissue Antigens 2001: 57: 380–3.
45. Voorter CEM, Hepkema BG, Lems SPM, van den
Berg-Loonen EM. Identification of a new HLA-B*40 variant
B*4035. Tissue Antigens 2003: 61: 89–91.
46. Perasaari JP, Koskela S, Partanen J. Characterization a novel
HLA-B40 allele with serological Bw4 motif, HLA-B*4047, in
the Finnish population and confirmation of B*270503 allele.
Tissue Antigens 2004: 63: 595–7.
47. Street J, Downing J, Darke C. Immunogenetics of the
rare HLA-B allele B*4408. Eur J Immunogen 2003:
30: 129–31.
48. Darke C, Street J, Downing J. Immunogenetics of two new
HLA-B alleles: B*4414 and B*5708. Tissue Antigens 2003:
62: 436–41.
49. Canossi A, Papola F, Liberatore G et al. Identification of the
novel allele B*4427 and a confirmatory sequence (B*44022).
Tissue Antigens 2002: 59: 331–4.
50. Przemeck M, Elsner H-A, Sel S, Pastucha LT, Blasczyk R.
HLA-B*4431: a new HLA-B variant with a complex ancestral
history involving HLA-B*44, B*40 and B*07 alleles. Tissue
Antigens 2002: 60: 91–4.
51. Poli F, Longhi E, Frison S et al. Identification of a novel
HLA-B allele – HLA-B*4902.Tissue Antigens 2001: 57: 173–4.
52. Darke C, Street J, Guttridge MG. Sequence, genetics and
serology of a newHLA-B allele: B*4903.Tissue Antigens 2001:
57: 478–80.
53. Voorter CEM, Hepkema BG, Mulkers EMT, Lems SPM, van
den Berg-Loonen EM. Identification of two new HLA-B22
variants, HLA-B*5509 and B*5606. Tissue Antigens 2001:
58: 42–6.
54. Park H-S, Choi J-H, Lee KW. Identification of a novel
HLA-B*55 variant (B*5513) from a Korean family. Tissue
Antigens 2004: 64: 96–8.
55. Lyou J-Y, YangKL, Lee A, Lin PY, Lee TD. Confirmation of
a recombinant allele B*5603 and a hypothetical reciprocal
hybrid. Eur J Immunogen 2002: 29: 69–71.
56. Wu G-G, Cheng L-H, Zhou D et al. Identification of a novel
alleleHLA-B*5610 in aChinese potential bonemarrowdonor.
Tissue Antigens 2003: 61: 256–8.
57. Poli F, Crespiatico L, Frison S, Longhi E, Marlianici E,
Scalamogna M. HLA-B*5808, a new HLA-B allele
characterized by sequence based typing. Tissue Antigens 2003:
62: 551–3.
58. Cantwell L, BoyleA,DivineyMet al. Identification of twonew
Cw alleles – implication for epitope recognition (ASHI
abstract). Hum Immunol 2002: 63: S37.
59. Voorter CEM, Fischer GF, van den Berg-Loonen EM.
Identification of a new HLA-C allele, Cw*0316, by SBT.
Tissue Antigens 2004: 63: 484–6.
60. TestaGV, BunceM, SheldonMH,DunnPPJ,Day S,Marques
SBD. Identification of a new allele, HLA-DRB1*1360, on
a DRB5 haplotype in a Brazilian individual. Tissue Antigens
2004: 63: 617–8.
61. Hammond L, Bengtsson M, Street J et al. HLA-A*2312-a
novel allele found in testing for the UK NEQAS H & I DNA
HLA typing scheme. Tissue Antigens 2006: 68: 175–6.
62. Dubois V, Tiercy JM, Labonne MP, Dormay A, Gebuhrer L.
A new HLA-B44 allele (B*4402012S) with a splicing mutation
leading to a complete deletion of exon 5. Tissue Antigens 2004:
63: 173–80.
170 ª 2009 John Wiley & Sons A/S � Tissue Antigens 73, 95–170
HLA alleles and serologic types R. Holdsworth et al.